













This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 





Reductive Coupling of Alkenylazaarenes 
 
 
Thesis Submitted in Accordance with the Requirement of the University of 






Supervisor: Prof. Hon Wai Lam 
 
EaStCHEM School of Chemistry 







I hereby declare that, except where specific reference is made to other sources, the 
work contained within this thesis is the original work of my own research since the 
registration of the PhD degree in September 2011, and any collaboration is clearly 
indicated. This thesis has been composed by myself and has not been submitted, in 
whole or part, for any other degree, diploma or other qualification. 
 
I confirm that the work submitted is my own, except work which has formed part of 
jointly-authored publications. The contributions of myself and other authors to this 
work have been specifically indicated where relevant. I confirm that appropriate 
credit has been given within the thesis where references have been made to the work 
of others. 
 
The following chapters contain results reported in the following publications: 
 
Chapter 2 – Enantioselective Copper-Catalysed Reductive Coupling of 
Alkenylazaarenes with Ketones; Saxena, A.; Choi, B.; Lam, H. W. J. Am. Chem. 
Soc. 2012, 134, 8428-8431. DOI: 10.1021/ja3036916 
 
Chapter 3 – Enantioselective Copper-Catalysed Reductive Coupling of 
Vinylazaarenes with N-Boc Aldimines; Choi, B.; Saxena, A.; Smith, J. J.; Churchill, 






































































First, I would like to thank my supervisor Professor Hon Wai Lam for the 
opportunity to undertake research within his group. Most of all, I thank him for his 
patience in teaching, his support and continuous guidance throughout the course of 
my postgraduate studies. Without him this work would not have been possible, and I 
am grateful for everything he has taught me throughout my PhD and I hope to take 
all that I have learned with me from this chapter, and onto the next chapter of my 
career.  
 
Thank you to AstraZeneca and the University of Edinburgh for providing funding 
and facilities for my PhD research. Thank you to Dr Gwydion Churchill for being my 
CASE supervisor and for everyone who made me feel welcome during my industrial 
placement at Macclesfield.  
 
I would like to thank the staff at the School of Chemistry from the University of 
Edinburgh and from the University of Nottingham for all the help and support they 
have provided over the years.  
 
I would like to thank all past and present members of the Lam group that I have had 
the opportunity and privilege to work with. You have all contributed to providing a 
great and memorable experience for me over the course of my PhD. To the post-
docs; Dr Graham Pattison, Dr Alan Burns, Dr Dan Best, Dr Suresh Chidipudi, Dr 
Yunfei Luo, Dr David Burns, Dr Ben Partridge, Dr Jose Martínez, Dr Lucia Saya and 
Dr Celia Incerti-Pradillos, thank you for being so approachable and helping me with 
any issues that I had. It has been a pleasure to work with and learn from you. Special 
thanks to Dr Alan Burns, Dr Dan Best and Dr Jose Martínez for their time, patience 
and effort in proof-reading this thesis. I am very grateful and your contributions are 
fully appreciated.  
 
To all the students in the Lam group it has been a pleasure getting to know each and 
everyone of you and thank you for creating a fun and friendly working environment. 




for his patience and continuous guidance and all the work that has led to our 
publications on the Enantioselective Copper-Catalysed Reductive Coupling of 
Alkenylazaarenes. Hamish, Jorge, Szymon, Josh, Amael and Imtiaz-Nottingham 
wouldn’t have been half as much fun without you guys. I hold many fond memories 
of “Classic Choi” moments with you guys. Special thanks to Imtiaz for proof-reading 
as well! To Sam, Charlene, Donna, Martin, Alain, Iain, Darryl, Sit, Alison, Boris, Jen 
and Jonathon, it was great getting to know and work with you in Edinburgh. 
 
I would also like to thank all my friends and family, near and far, for all their support 
and encourgament over the years and for always believing in me. Special thanks to 
Ashton, Fran, Jenni, Sam, Hanne, Catherine, Sarah, Sara and Nic for putting up with 
all the time I have spent talking about my thesis!  
 
Most importantly, I would like to thank my parents for their unconditional love and 
continued support. Thank you for always encouraging me to take on new and 
exciting opportunities and to continuously challenge myself, which has allowed me 
to get to where I am today. Thank you also for always standing by me and supporting 

























List of Abbreviations ........................................................................................................ vii 
Abstract ................................................................................................................................. x 
Lay Summary .................................................................................................................... xii 
 
1. Enantioselective Copper-Catalysed Reductive Coupling of 
Alkenylazaarenes ......................................................................................................... 1 
1.1 Introduction ............................................................................................................ 1 
1.1.1 The Significance of Chirality ................................................................................. 1 
1.1.2  Alkenylazaarenes as Activating Groups ................................................................ 3 
1.2  Nucleophilic Conjugate Addition .......................................................................... 5 
1.2.1  Conjugate Reductions .......................................................................................... 12 
1.2.2  Intramolecular Copper-Catalysed Reductive Aldol Reactions ............................ 23 
1.2.3  Intermolecular Copper-Catalysed Reductive Aldol Reactions ............................ 30 
1.3  Reductive Mannich Reactions.............................................................................. 38 
1.4  Conclusion ........................................................................................................... 51 
 
2. Enatioselective Reductive Coupling of Alkenylazaarenes with Ketones .............. 52 
2.1 Preparation of 2-Alkenylazaarenes ...................................................................... 52 
2.2      Enantioselective Copper-Catalysed Reductive Coupling of    
                Alkenylazaarenes with Ketones ........................................................................... 56 
2.3  Application of Methodology ............................................................................... 68 
2.4  Conclusions ......................................................................................................... 70 
2.5  Future Work ........................................................................................................ 71 
 
3. Enantioselective Reductive Couplings of Vinylazaarenes with N-Boc 
Aldimines .................................................................................................................... 73 
3.1  Aims and Objectives ........................................................................................... 73 
3.2  Screening of Various N-Protected Imines ............................................................ 74 
3.3  Preparation of Alkenylazaarenes.......................................................................... 75 
3.4  Preparation of N-Boc Aldimines .......................................................................... 77 
3.5 Ligand Screen and Optimisations ........................................................................ 80 




3.5.2  Larger Scale Reaction and Deprotection.............................................................. 91 
3.6  Exploration of β-Substituted Alkenylazaarenes ................................................... 92 
3.7  Conclusions and Future Work .............................................................................. 95 
 
4.  Experimental ............................................................................................................. 97 
4.1     Enantioselective Copper-Catalysed Reductive Coupling of    
                Alkenylazaarenes with Ketones ........................................................................... 97 
4.1.1 Preparation of Alkenylazaarenes.......................................................................... 99 
4.1.2 Preparation of Alkenylboronic Esters ................................................................ 106 
4.1.3 Preparation of β-Substituted Alkenylazaarenes ................................................. 108 
4.1.4 Preparation of Vinylarenes ................................................................................. 111 
4.1.5 Enantioselective Copper-Catalysed Reductive Coupling Reactions ................. 113 
4.2     Enantioselective Copper-Catalysed Reductive Coupling of Vinylazaarenes    
                with N-Boc Aldimines ....................................................................................... 116 
4.2.1 Preparation of Vinylazaarenes ........................................................................... 117 
4.2.2 Preparation of β-Substituted Alkenylazaarenes ................................................. 119 
4.2.3 Preparation of N-Boc Imines .............................................................................. 121 
4.2.3.1 tert-Butyl N-[(benzenesulfonyl)(phenyl)methyl]carbamates ............................. 122 
4.2.3.2 N-Boc Imines ..................................................................................................... 129 
4.2.4 Enantioselective Copper-Catalysed Reductive Coupling Reactions ................. 135 
4.3   X-Ray Crystallography Data ............................................................................. 160 
 



















LIST OF ABBREVIATIONS 
 
δ   delta 
µw   microwave 
Ac   acetyl 
acac   acetylacetonate 
app   apparent 
aq.   aqueous 
Ar   aryl 
BINAP  2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl 
Bn    benzyl 
Boc   t-butyloxycarbonyl 
br   broad 
c   concentration 
ca.   circa 
cald   calculated 
cat.   catalyst 
cod   1,5-cyclooctadiene 
Cp   cyclopentadienyl 
CuH   copper hydride 
Cy   cyclohexane 
d   doublet  
DBM   dibenzoylmethane 
DCM   dichloromethane 




DEPT   distortionless enchancement by polarisation transfer 
DIBAL  diisobutylaluminium hydride 
DIFLUORPHOS  5,’-bis(diphenylphosphino)-2,2,2’,2’-tetrafluoro-4,4’-bi-1,3-
benzodioxole 
DMAP   4-(dimethylamino)pyridine 
DMF   dimethylformamide 
DMSO   dimethyl sulfoxide 
dppb   1,4-bis(diphenylphosphino)butane 
dppf   1,1’-bis(diphenylphosphino)ferrocene 
dppp   1,3-bis(diphenylphosphino)propane 
dr   diasteriomeric ratio 
ee   enantiomeric excess 
EI   electron impact 
equiv   equivalents 
ES   electrospray  
ESI   electrospray ionisation 
EVK   ethyl vinyl ketone 
EWG   electron withdrawing group 
FT   Fourier transform  
Het   heterocycle 
HPLC    high performance liquid chromatography 
HRMS   high resolution mass spectroscopy 
IR   infrared spectroscopy 
IPA   iso-propyl alcohol 




Ln   ligand 
m   multiplet 
m.p.   melting point 
MTBE   methyl tert-butyl ether 
MVK   methyl vinyl ketone 
NHC   N-heterocyclic carbene 
NMR   Nuclear magnetic resonance 
Nu   nucleophile 
pin   pinacol 
PMHS   polymethylhydrosiloxane 
PMP   p-methoxyphenyl 
Ph   phenyl 
q   quartet 
rac   racemic 
rt   room temperature 
s   singlet 
t   triplet 
tert   tertiary 
TLC    thin layer chromatrography 
THF   tetrahydrofuran 
TMDS   1,1,3,3-tetramethyldisiloxane  
Ts   p-toluenesulfonyl 





Chiral azaarene-containing molecules, tertiary alcohols and α-stereogenic amines are 
ubiquitous structures in pharmaceuticals, agrochemicals and natural products. The 
development of new catalytic enantioselective methods to construct molecules 
containing these chemotypes is of significant utility. Recent efforts within the Lam 
group have targeted the development of processes that exploit the embedded imine 
functionality within an azaarene to activate adjacent alkenes towards nucleophilic 
additions. Chapter 1 reviews the current state of the art with respect to nucleophilic 
additions of alkenylazaarenes and catalytic conjugate reduction reactions. 
 
Chapter 2 describes a catalytic, enantioselective reductive coupling of 2-
alkenylazaarenes with ketones using chiral CuH-bisphosphine complex in the 
presence of PhSiH3 as a hydride source. The scope of this process is broad, with 
eleven different types of azaarenes and a range of acyclic and cyclic ketones 
demonstrated as effective coupling partners. β-Substitution on the alkene is tolerated, 
and the reactions proceed under mild conditions to deliver products with good to 














Chapter 3 describes, further investigation of the scope of enantioselective reductive 
coupling, using N-Boc aldimines as electrophiles. This process is tolerant of a variety 
of vinylazaarenes and N-Boc aldimines, and provides aromatic heterocycles bearing 
α-stereogenic amines with good to moderate yields and good to excellent levels of 





























A catalyst is defined as a substance that can lower the energy barrier for a chemical 
reaction to proceed whilst remaining unchanged at the end of the reactions. Metal 
catalysts is a useful tool to enable chemical reactions to occur that would not take 
place under normal reaction conditions.  
 
The use of a catalyst derived from the metal copper is a common theme throughout 
this thesis. Copper is cheap, and earth abundant metal developing new chemical 
transformations employing such a metal has economical and environmental 
advantages.  
 
In this regard, a new chemical transformation has been developed employing a 
copper catalyst and is described in this thesis, which results in the creation of novel 
chemical compounds with motifs that are prevalent in many natural products. The 
development of such methodology have potential to provide easier access to building 






1. ENANTIOSELECTIVE COPPER-CATALYSED 
REDUCTIVE COUPLING OF ALKENYLAZAARENES  
1.1 Introduction 
 
1.1.1 The Significance of Chirality 
 
Chirality describes the symmetry property of a molecule that cannot be superimposed 
onto its mirror image. Derived from the Greek word for ‘hand’, the iconic conceptual 
illustration of chirality is the difference between our left and right hands. Despite 
having the same composition, hands are related as non-superimposable mirror 
images and are non-identical. This concept is of great importance at the molecular 
level where, just as a right hand will not fit a left glove or operate a pair of left 
handed scissors, the handedness of a chiral molecule can greatly affect its 
interactions with asymmetric biological environments.   
 
Chirality has a very significant role in living organisms as numerous biological 
compounds are inherently chiral. Compounds such as DNA, proteins and 
carbohydrates are all chiral. To function properly they require highly precise 
interactions in which the host molecule interacts with two enantiomeric molecules in 
different ways. Enantiomers of a compound such as a drug can have vastly different 
effects on the body. For example, the non-steroidal anti-inflammatory drug Naproxen 
(1) is marketed as the (S)-enantiomer as it is 28 times more effective than the (R)-
enantiomer.1 For the drug Ibruprofen (2), the (S)-enantiomer is biologically active, 
however the inactive (R)-enantiomer racemises in vivo allowing the racemic drug to 





Figure 1.01: Chiral Drug Molecules 
In certain cases one enantiomer produces a beneficial effect, while the other is 
associated with detrimental side-effects or lacks efficacy. Such was the case of the 
drug Thalidomide (3), prescribed in the 1960s to alleviate morning sickness in 
pregnant women. Tragically, women who were administered this drug bore children 
with limb deformities. Thalidomide was marketed as a racemate, where the (R)-
enantiomer had desirable sedative properties while its (S)-enantiomer is teratogenic 
and induces fetal malformations.3 However, dosing with optically pure (R)-
Thalidomide would still lead to (S)-Thalidomide in the body as the drug racemises in 
vivo. After the devastating effects of Thalidomide, in 1987 the U.S. Food and Drug 
Administration (FDA) published a set of guidelines, followed by a policy statement 
in 1992 discouraging the development of racemic drugs.4 The FDA now requires 
substantial analysis of both enantiomers of any new chiral drug.  
 
In 2013, 8 out of the top 10 selling small molecule drugs worldwide were chiral, and 
4 out of the top 10 selling drugs contained at least one nitrogen-containing aromatic 
heterocycle (azaarene); exemplifying azaarenes as key building blocks for drug 
discovery  (Figure 1.02).5  
 





Additionally, azaarene motifs are prevalent in numerous natural products, 
agrochemicals and dyes; an example of each is illustrated in Figure 1.03.  
 
 
Figure 1.03: Examples of Azaarene-Containing Compounds 
 
This highlights the importance of developing enantiopure materials, and that research 
into the functionalisation of chiral azaarenes and their derivatives is a valuable 
endeavor for the development of new pharmaceuticals and other synthetically useful 
compounds.  
 
1.1.2  Alkenylazaarenes as Activating Groups 
 
Currently, the principal methods for functionalisation of azaarenes are SNAr 
reactions6 and metal-catalysed cross-coupling reactions.7 C-H bond activation has 
also become increasingly popular in recent years.8 However, these methods do not 
generally furnish chiral products. With azaarenes featuring prominently in chiral 
pharmaceuticals, natural products and agrochemicals, there is a huge drive to develop 
catalytic enantioselective methods to synthesise compounds incorporating this 




containing substrates where the azaarene acts as a non-participating by-stander; 
however, the development of methodology which takes advantage of the inherent 
chemical properties of the azaarene itself to promote the reaction should prove to be 
a potent and complementary tool for their synthesis.  
 
An existing and well established class of reaction which fulfils this criterion is the 
catalytic enantioselective Friedel-Craft additions of π-excessive azaarenes to a π-
electrophile (Scheme 1.01).9 
 
 
Scheme 1.01: Friedel-Crafts Additions of π-Excessive Azaarenes to π-Electrophiles 
 
This methodology relies on an embedded enamine within π-excessive azaarenes such 
as indoles or pyrroles which renders the azaarene nucleophilic. However, many 
classes of azaarenes do not contain an embedded enamine but rather an embedded 
imine (Figure 1.04).  
 
  
Figure 1.04: Azaarenes Containing an Embedded Imine  
 
The embedded imine exhibits electron-withdrawing properties akin to those of 
carbonyl groups. This similarity raised questions as to whether the electron-




associated with carbonyl functionality. For example, could a prochiral 
alkenylazaarene such as 2-alkenylpyridine 20 be a feasible substrate for catalytic 
enantioselective 1,4 nucleophilic additions, where the embedded imine activates the 
adjacent olefin (Scheme 1.02). 
 
 
Scheme 1.02: 1,4-Addition to Alkenylpyridine 
 
Thus, investigations into the potential of C=N containing azaarenes as activating 
groups for new catalytic enantioselective processes began to feature prominently in 
the Lam research group.10 
 
Prior to detailing our efforts on C=N containing azaarenes as activating groups in 
enantioselective catalysis, the literature precedence for nucleophilic additions to 
alkenylazaarenes is warranted. 
 
1.2  Nucleophilic Conjugate Addition 
 
One of the most powerful synthetic methods in modern day organic chemistry is the 
1,4-addition of nucleophiles to electron deficient olefins. The mechanism of a typical 
1,4-addition involves the attack of a nucleophile to a C=C double bond conjugated to 






Scheme 1.03: 1,4-Nucleophilic Conjugate Addition 
 
This methodology is commonly associated with alkenes activated by electron-
withdrawing groups such as carbonyl, nitrile, nitro, sulfonyl or phosphonyl groups. 
Although less common, imines have also been successfully applied for this 
purpose.11  
 
The electron-withdrawing nature of the C=N moiety within an azaarene has long 
been recognised, dating back to 1933 when Hoffman demonstrated the addition of 
Grignard reagents to 2-alkenylquinolines (Scheme 1.04).12 
 
Scheme 1.04:1,4-Addition of Grignard Reagents to Alkenylquinonine12 
 
Levine and Wilt published one of the earliest successful nucleophilic additions of a 
carbonyl compound to alkenylazaarenes in 1953.13 They reported an alkylation of 
vinylpyridine (23) using a ketone enolate in the presence of sub-stoichiometric 





Scheme 1.05: Addition of Enolate to Vinylpyridine13a 
 
Mono-alkylated products 25a-25e were obtained in low yields. They observed that 
when the starting material contained several α-hydrogens, multiple alkylations on 
vinylpyridine would occur. Experiments revealed that the extent of alkylation 
depended on the limiting reagent, as the product can be enolised and react with 
another molecule of vinylpyridine to furnish multi-alkylated azaarene products as 
side products. This side reaction can be suppressed by using excess ketone. 
Employing acetone in the reaction, they found almost negligible alkylation on the 
vinylpyridine (product 25c). Alkylation of 4-vinylpyridine with acetophenone gave 
phenyl γ-(4-pyridyl)-propyl ketone (25e), demonstrating that the reaction does not 
depend on a nitrogen atom at the 2-position. There is only a small difference in 
yields obtained with the two different orientations of the pyridine substituent.  
 
In 1956, Magnus and Levine published an extension of previous methodology from 
their laboratory to include the additions of amides, amines and nitriles to 4-







 Scheme 1.06: Addition of Amines to Vinylpyridines14   
 
For 4-vinylpyridine, glacial acetic acid catalysed the amine addition reaction, 
however, for amine additions to 2-methyl-5-vinylpyridine the use of sodium 
methoxide gave superior results (products 29a-29c). The same paper also reported 
the formation of 2-(aminoethyl)pyridine (32) using two separate routes; the first 
involving the direct pyridethylation of ammonia with 2-vinylpyridine (30), and the 
second involving the synthesis of N-pyridylethylated amide (31) followed by 
hydrolysis to give 2-(aminoethyl)pyridine (32) (Scheme 1.07).  
 
 




Investigations by Boy and Guernon into thiazole 5-carboxylic acid derivatives 
demonstrated that vinylthiazoles could undergo Michael-like additions (Scheme 
1.08).15 In the absence of a catalyst, ethyl-4-(trifluoromethyl)-2-vinylthiazole-5-
carboxylate precursor 33 underwent Michael-like additions with various secondary 
amines to give 2-aminoethyl-5-carbethoxythiazoles (34a-34d). 
 
 
Scheme 1.08: Syntheses of 2-Aminoethyl-5-Carbethoxythiazoles15 
 
Acyclic amines and diamines were the most effective addition partners giving 
products in good yields (products 34a-34b) followed by cyclic amines with slightly 
diminished yields (product 34c). Sterically hindered amines were also tolerated 
giving products in modest yields (product 34d).  
 
In 1983, Dryanska and Ivanov reported the conjugate addition of various 
nucleophiles to 2-styrylbenzothiazole (35) and 2-styryloxazole (36) in the presence 





Scheme 1.09: 2-Styrylbenzothiazoles and 2-Styrylbenzoxazoles as Michael-Acceptors16 
 
Pronucleophiles including ketones, nitriles, esters and 2-benzyloxazole and 2-
benzylthiazole were applied in these conjugate additions. Substitution at the -
position of the electrophile with a bulky phenyl group was also tolerated. The report 
showed that alkenyl benzoxazoles and benzothiazoles could effectively participate in 
1,4-nucleophilic conjugate additions. 
 
In 1998, Houpis and co-workers presented the first catalytic addition of 
organometallic reagents to unactivated olefins 39 using nickel-catalysis to give 





Scheme 1.10: Nickel-Catalysed 1,4-Addition to 4-Alkenylpyridines using Grignard Reagent17 
 
Efforts towards an asymmetric variant of this reaction were met with limited success 
(0-15% ee), despite screening a broad range of chiral ligands (bisphosphines, 
diamines, aminoalcohols, bisulphonamides and diols). However, this work suggests 
that highly enantioselective, nucleophilic 1,4-addition to alkenylpyridines may be 
possible.  
 
A recent review by Klump18 summarizes extensive examples of the addition of 
nitrogen, oxygen, sulphur and carbon nucleophiles to a range of vinylazaarenes 
which all gives rise to achiral or racemic products. For those examples, 
enantioselective variants could not be developed due to the lack of β-substitution in 
the azaarene moiety. In comparison to vinylazaarenes, 1,4-addition to β-substituted 







1.2.1  Conjugate Reductions 
 
Under the umbrella of conjugate additions is a specific class of reactions called 
conjugate reductions. Catalytic reactions that reduce carbon-carbon double bonds to 
generate products with stereocenters beta to a carbonyl group with high 
enantioselectivities are of high value. Asymmetric conjugate reductions of α,β-
unsaturated carbonyl compounds by organosilanes, mediated by complexes of 
rhodium, platinum, palladium and molybdenum have the ability to  facilitate such 
reactions.19 However, the use of copper, a cheaper and more earth abundant metal, 
for the analogous transformation is a comparatively recent development.20 
 
Carbonyls, nitriles, sulfones, phosphonates, and nitro groups have all been shown to 
provide sufficient activation of the adjacent olefin towards conjugate reduction.21 
Taking advantage of the carbophilic nature of copper, and through proper choice of 




Scheme 1.11: Catalytic 1,4-Reduction of Alkenes  
 
Copper(I) hydride is amongst the oldest metal hydride to be properly documented, 
dating back to 1844, first characterized by Wurtz as a red brown solid.23 The most 
extensively studied copper hydride (CuH) is the hexameric phosphine stabilised 
complex, [(Ph3P)CuH]6, first described by Osborn et al.
24 However, it was not until 
the late 1980s that use of CuH reagents gained notoriety as a highly reliable method 
of effecting conjugate reductions of unsaturated carbonyl derivatives though a 
seminal publication by Stryker et al.25 In 1988, Stryker and co-workers reported the 
remarkable ability of the Osborn complex [(Ph3P)CuH]6, to effect 1,4-conjugate 





Scheme 1.12: Catalytic 1,4-Reduction Using Stryker’s Reagent25 
 
The properties of this hexameric CuH complex include very mild reaction 
conditions, excellent functional group compatibility and overall efficiencies. All of 
this contributed to propelling [(Ph3P)CuH]6, a beautiful crystalline red solid, to the 
status of “Reagent of the Year” in 1991. It is now commonly referred to as Stryker’s 
reagent. It can be prepared in multi-gram quantities from four readily available and 
inexpensive precursor compounds (CuCl, NaOt-Bu, PPh3 and H2)
26 forming 
“environmentally friendly” sodium chloride and tert-butanol as by-products.27  
 
Exchanging PPh3 for chiral non-racemic ligands generates chiral CuH species 
capable of catalysing conjugate reductions in an asymmetric manner.  The synthesis 
of ligated CuH species relies on treatment of CuCl (43) with NaOt-Bu (44) to give 
CuOt-Bu (45). Addition of hydride source 46 (such as hydrosilane) to pre-formed 45 
in the presence of a ligand leads to the generation of ligated CuH species 47 (Scheme 
1.13). CuOt-Bu 45 is highly susceptible to oxidation therefore oxygen-free 
conditions are required when preparing CuH species 47. Air-stable and commercially 
available Cu(OAc)2H2O was found to be a suitable substitute for CuOt-Bu (45). 
Cu(OAc)2H2O (where Cu has an oxidation state of +2) is efficiently reduced to the 
CuH species 47 (where Cu has an oxidation state of +1) in the presence of a 
hydrosilane reductant and a ligand. Hydrosilanes are generally inexpensive and 
environmentally friendly and they have become a frequent source of stoichiometric 




1,1,3,3-tetramethyldisiloxane (TMDS), Fleming’s silane (PhMe2SiH), and 
phenylsilane (PhSiH3) are examples of such reagents. 
 
 
Scheme 1.13: Preparation of Ligated Copper Hydrides 
 
Chiral bisphosphines have rapidly become the optimal ligands to form ligated CuH 
complexes. To date, virtually all success has come from a relatively small subset of 
either biaryl or ferrocenyl bisphosphine ligands. Advantageously, these ligands are 
available commercially both in quantity and in enantiomerically pure form; examples 
are illustrated in Figure 1.05. 
 
 
Figure 1.05: Bisphosphines used for enantioselective CuH Reactions 
 
N-Heterocyclic carbenes (NHCs) have increased in popularity as an alternative to 
using bisphosphine ligands.20a They are usually generated from the starting 
imidazolium salt 49 by treatment with base and CuCl, to give copper-carbene 
complex 50 followed by in situ conversion to the NHC-stabilized copper hydride 51 
in the presence of a silane (Scheme 1.14). The use of air-stable and isolatable copper-
carbene complex 50 in particular has made this an attractive alternative.28 However, 
the use of chiral non-racemic carbene-based copper hydrides has not been applied in 





Scheme 1.14: Preparation of CuH-NHC Complexes20a 
 
Enantioselective conjugate reductions catalysed by chiral bisphosphine-ligated CuH 
complexes and their application towards the synthesis of natural products and 
pharmaceutical drugs are well documented.20, 29 Detailed discussion on each report 
will not be covered in this thesis, rather only important breakthroughs and reports 
relevant to our study will be presented below. 
 
Buchwald and co-workers were the first to report an enantioselective conjugate 
reduction of α,β-unsaturated esters catalysed by the in situ formation of a 
bisphosphine-stabilised chiral CuH species (Scheme 1.15).30  
 
 
Scheme 1.15: Catalytic Enantioselective 1,4-Reduction of α,β-Unsaturated Esters30d 
 
Using CuCl as the copper source, NaOt-Bu as the base, and (S)-p-tol-BINAP as the 
chiral ligand; α,β-unsaturated esters 52 underwent smooth 1,4-conjugate reduction 
furnishing the corresponding saturated products (53a-53d) with high chemo- and 




reacted to give predominantly opposite enantiomers 53b and 53c respectively both 
with high levels of enantioselection. 
 
The catalytic cycle proposed by Buchwald for the conjugate reduction of enoate 52a 
is illustrated in Scheme 1.16.30d Treatment of CuCl with NaOt-Bu in the presence of 
a p-tol-BINAP forms (p-tol-BINAP)CuOt-Bu 54. Addition of PMHS results in σ-
bond metathesis between (p-tol-BINAP)CuOt-Bu 54 and PMHS to generate (p-tol-
BINAP)CuH species 55. Asymmetric conjugate reduction of enoate 52a then occurs, 
resulting in formation of a copper enolate intermediate 56, subsequent σ-bond 
metathesis with PMHS forms silylketene acetal 57 thus regenerating copper hydride 
55. The isolable product 57, when quenched with a proton source such as EtOH, 
affords the enantioenriched ester 53a. 
 
 







The Buchwald group subsequently extended this methodology, applying it to enones 




Scheme 1.17: Catalytic Enantioselective 1,4-Reduction of Enones, Lactones and 
Lactams30b, 30c 
 
High yields and excellent ee’s were again observed in the corresponding saturated 
products 59 and 60. In the cases of lactones and lactams, they found air-stable 
CuCl2·H2O to be a suitable replacement for CuCl. Included in this publication was 
the utilisation of their methodology in the synthesis of the antidepressant drug (-)- 
Paroxetine (64).30b The key reduction step of compound 62 in the synthetic route to 





Scheme 1.18: Synthesis of (-)-Paroxetine by CuH-catalysed 1,4-Reduction30b 
 
Buchwald and co-workers also observed that the rate of conjugate reduction 
dramatically increased upon addition of alcohol addictives.30b In fact, several 
methods actually rely on the presence of bulky alcohol (e.g., t-BuOH) to enhance 
reaction rates.20a The role of this additive is rapid protonation of the intermediate 
copper enolate 65 to give a copper alkoxide 69, which readily undergoes σ-
metathesis in the presence of excess silane regenerating copper hydride 70, 
bypassing the slow σ-metathesis step between Cu-O (65) and Si-H (66) bonds, thus 
vastly improving the rate of reduction (Scheme 1.19).  
 
 




This proposed mechanism was supported in deuterium studies using t-BuOD by the 
group of Lipshutz (Scheme 1.20).31 Asymmetric 1,4-hydrosilyation of unsaturated 
lactone 71 using t-BuOD revealed the majority of the deuterium was incorporated at 
the α-position, and only small quantities were incorporated at the β-position. As no 
exchange occurs between PMHS and t-BuOD, it appears that the rate enhancement 
results from the rapid protonation of the copper enolate by the alcohol rather than by 
the silane.  
 
 
Scheme 1.20: Deuterium Experiment: Effect of Alcohol in CuH-Catalysed Reductions31 
 
In a series of publications, Lipshutz and co-workers reported the CuH-catalysed 
conjugate reduction of acyclic and cyclic enones with high yields and 
enantioselectivities.31-32 Extensive ligand screening revealed that chiral biaryl 
bisphosphine ligands such as Segphos- and Josiphos-derived CuH species lead to 
higher levels of chiral induction than those obtained with the corresponding BINAP-
CuH derivatives. Josiphos-type bisphosphines gave excellent results for acyclic 
enones 73, whilst Segphos ligands were extremely efficient at reducing sterically 





Scheme 1.21: Catalytic Enantioselective 1,4-Reductions32c, 32d  
 
Examples of CuH-catalysed conjugate reductions involving the 1,4-reduction of 
polarized alkenes are present in literature and have been discussed so far. Lam and 
co-workers embarked on extending this methodology to include other important, yet 
underexploited electron-withdrawing groups on the acceptor, specifically, nitrogen-
containing aromatic heterocycles. The importance of these structures has been 
previously discussed. Processes that exploit the ability of a suitably positioned C=N 
moiety within an azaarene to activate an adjacent alkene towards a catalytic 
enantioselective addition reaction were subsequently developed.10g, 10h The first of 
these reports describes a highly enantioselective copper-catalysed reductions of β,β-







Scheme 1.22: Catalytic Enantioselective Reduction of β,β-Disubstituted Alkenylazaarenes10h 
 
In the presence of catalytic Cu(OAc)2·H2O, a Josiphos bisphosphine ligand and 
stoichiometric quantities of t-BuOH, a series of β,β-disubstituted 2-alkenylazaarenes 
77 were reduced using PhSiH3 in high yields and with excellent enantioselectivities. 
A range of azaarenes were found to be compatible substrates including pyridine 
(78a), pyrazine (78b), benzoxazole (78c) and benzothiazole (78d). Additionally, the 
reaction tolerated functionalities including esters (78a) and silyl ethers (78b). 
 
The catalytic cycle postulated for this reaction is relatively similar to the accepted 
mechanism for CuH-catalysed 1,4-reduction (Scheme 1.23). Since this reaction is 
likely to proceed via the intermediacy of organocopper species 80 that undergoes 
protonation with t-BuOH, it was questioned whether these intermediates could be 






Scheme 1.23: Postulated Catalytic Cycle of CuH-Catalysed 1,4-Reduction of β,β-
Disubstituted Alkenylazaarenes10h 
 
Conjugate reduction-alkylation, conjugate reduction cyclisation and conjugate 
reduction allylic substitution reactions were some of the avenues considered. Efforts 
ultimately focused on the conjugate reduction-aldol reaction and the Mannich 
reaction as the development of efficient catalytic asymmetric methods for the 
construction of chiral tertiary alcohols and chiral amines are highly desirable 
(Scheme 1.24).  
 





The aldol reaction is a classical method that has been routinely used for over 150 
years. First reported by Borodin in 1869, it has become one of the most powerful and 
versatile methods in organic synthetic chemistry for the construction of carbon-
carbon bonds. Conjugate reduction followed by an aldol reaction of the resulting 
enolate constitutes a reductive aldol reaction, which, when promoted by catalytic 
amounts of various transition-metal complexes and a hydride source, is a powerful 
tool for the creation of C-C bonds in a regio-, stereo- and enantioselective fashion. 
To date the catalysts for reductive aldol coupling based on rhodium,34 cobalt,35 
iridium,36 ruthenium,37 palladium,38 nickel,39 indium,40 and copper41 have been 
devised. Notably, rhodium and copper complexes play a dominant role in this field of 
organic chemistry.21a The use of copper hydride also has inherent advantages of 
lower costs and higher selectivity. For the purpose of this report only copper-
catalysed reductive aldol reactions will be discussed.  
 
1.2.2  Intramolecular Copper-Catalysed Reductive Aldol Reactions 
 
Chiu and co-workers applied the use of Stryker’s reagent stoichiometrically and 
catalytically in CuH-catalysed reductive intramolecular aldol reactions.42 In 2001, 
they demonstrated that the copper enolates formed in situ by conjugate reduction of 
α,β-unsaturated carbonyl compounds with stoichiometric quantities of Stryker’s 
reagent participate in an intramolecular aldol cyclisation furnishing five or six 









Scheme 1.25: Diastereoselective CuH-Mediated Reductive Aldol Cyclisation Using Stryker’s 
Reagent42b 
 
The process is tolerant of a number of electron-withdrawing groups conjugated to the 
alkene including ketones, esters and nitriles (products 84a-84d). The reaction 
proceeded to form new 5- or 6-membered carbocycles with high diastereoselectivity 
and with exclusively cis-stereochemistry. The report also noted E- and Z- isomereric 
substrates delivered products with the same stereochemistry; however the trans-
isomer reacted at a faster rate than its cis-isomeric counterpart.  
 
Subsequently in 2004, the same group reported a catalytic use of Stryker’s reagent in 
a reductive aldol cyclisation of alkynediones 85 (Scheme 1.26).42a  
 
 






Using sub-stoichiometric quantities of Strkyer’s reagent and PMHS as the hydride 
source, the cyclisation of alkynediones proceeded efficiently to furnish β-
hydroxycycloalkenone (products 86a-86d) in modest yields. The products were 
formed with predominately cis-stereochemisty in all cases examined. The β-
hydroxycycloalkenones products are complementary to those formed from the 
intramolecular Baylis-Hillman reaction. β-Substituted enones and ketones are poor 
Michael-acceptors and electrophiles respectively for the Baylis-Hillman reaction, 
conversely the reductive aldol cyclisations of related alkynones 86 mediated by 
Stryker’s reagent occurred at low temperatures and mild conditions.  
 
In 2005, Lam and co-workers described the first diastereo- and enantioselective 
CuH-catalysed reductive aldol cyclisation mediated by bisphosphine ligands.43 The 
cycloreduction gave β-hydroxylactones 88a-88d with excellent diastereoselectivity 
(>95:5 in all cases) and modest to good enantioselectivities (Scheme 1.27). 
 
 






During this investigation they detected small quantities of the uncyclised side 
product that had undergone reduction at the enoate and in some cases at the ketone 
resulting in moderate yields. This observation indicates that the rate of σ-bond 
metathesis of the intermediate copper enolate with the siloxane is competitive with 
the rate of aldol cyclisation. A plausible catalytic cycle for the process was included 
in the communication (Scheme 1.28). 
 
 
Scheme 1.28: Proposed Catalytic Cycle of CuH-Catalysed Aldol Cycloreduction43 
 
Cu(OAc)2 in the presence of bisphosphine and TMDS is reduced to generate a CuH-
bisphosphine complex 89, which then engages in hydrometalation with substrate 87 
to generate the copper enolate 90. Carbonyl  addition results in the copper aldolate 
91, which then undergoes σ-bond metathesis with the siloxane to liberate the 
silylated product 92 (silyl deprotection occurs upon work-up to give the product 88), 
regenerating the CuH-bisphosphine complex 89. The observed stereochemistry is 
postulated to arise from preferential formation of the Z-copper enolate, coupled with 
chelation in the carbonyl addition step (as in 91). 
 
This methodology was extended for the synthesis of 4-hydroxypiperdin-2-ones, 




N-Alkyl-N-arylamides bearing no stereocenters such as substrate 94a (where R2 and 
R3 = H) cyclised efficiently to give products 95a in a good yield and excellent 
diastereoselectivity. Enantioenriched acrylamide containing pre-existing 
stereocenters cyclised to give the corresponding piperidinones 95b-95d respectively, 
in moderate to excellent levels of 1,2- and 1,3-asymmetric induction.  
 
 
Scheme 1.29: Intramolecular Reductive Aldol Reaction of α,β-Unsaturated Amides44  
 
Further transformations of the β-hydroxy piperidinones were performed to 
demonstrate the synthetic utility of this methodology (Scheme 1.30). Reductive 
removal of the carbonyl group of 95a by treatment with borane at reflux allows entry 
into the piperidine ring system 96a, which is a structural feature of many natural 
products and biologically active compounds.45 Oxidative removal of the PMP group 
on 96a followed by in situ treatment of the resulting amine with Boc2O furnished 








In 2008, Lipshutz and co-workers reported the first CuH-catalysed intramolecular 
reductive aldol reactions of acyclic β,β-disubstituted keto enones 98, generating 




Scheme 1.31: CuH-Catalysed Reductive Aldol Reactions of β,β-Disubstituted Keto Enones46 
 
An alternative copper-catalysed cycloreduction method furnished cyclised product 
99a, employing heterogeneous Cu/C in the presence of NaOPh and stoichiometric 
hydride DEMS in toluene (Scheme 1.32). 
 
 
Scheme 1.32: Heterogeneous Reductive Aldol Reactions46 
 
They also reported that the asymmetric reductive aldol reaction could be run entirely 




surfactant; a nanomicelle-forming PTS (a non-ionic, vitamin E based surfactant; 2% 
by weight) (Scheme 1.33). In the presence of stoichiometric PhSiH3 1,4-reduction/ 
cyclisation led to adduct ent-99a with excellent yields and enantioselectivity.  
 
 
 Scheme 1.33: Aqueous Asymmetric Reductive Aldol Reactions46 
 
In 2009, Riant et al. described a CuH-catalysed reductive aldol cyclisation of 
diketoesters (Scheme 1.34).47 The domino process catalysed by a CuH-Taniaphos 
complex, in the presence of PhSiH3 furnished highly diastereoselective and 






Scheme 1.34: Enantioselective CuH-Catalysed Reductive Aldol Cyclisation of Diketo-
Esters47 
 
In literature there are abundant examples of CuH-catalysed intramolecular reductive 
aldol cyclisations, but there are comparatively fewer reports on intermolecular 
reductive aldol reactions. The formation of five or six- membered rings in 
intramolecular cyclisations serves as a strong kinetic driving force for the reaction to 
occur. However, in analogous intermolecular couplings, the reaction is entropically 
less favourable due to the absence of this driving force. Nevertheless, 
enantioselective CuH-catalysed reductive aldol couplings using organosilanes as the 
hydride source have been reported previously.  
 
1.2.3  Intermolecular Copper-Catalysed Reductive Aldol Reactions 
 
In 2006, Shibasaki and co-workers reported an enantioselective intermolecular 
reductive aldol reaction to ketones using a chiral CuH-bisphosphine complex 
(Scheme 1.35).48 Initial experiments using methyl acrylate and acetophenone did not 
produce meaningful enantio- and diastereoselectivity; therefore efforts were focused 
on asymmetric induction at the α-position using symmetrical ketones 103. Modest 




(products 104a-104c). The use of a cyclic ketone afforded the coupled product 104d 
with significantly diminished enantioselectivity and lower yields. Nevertheless, the 
report successfully demonstrated the intermolecular CuH-catalysed reductive 
coupling of α,β-unsaturated esters with ketones. 
 
 
Scheme 1.35:  Asymmetric Induction at α-Position in Reductive Aldol Reaction to Symmetric 
Ketones48 
 
A subsequent publication by the same group reported the reductive coupling of 
allenic esters 105 to ketones 106 to furnish  enantiomerically enriched tertiary 
alcohols (Scheme 1.36).49 This publication highlighted a dramatic ligand effect that 
allowed the selective synthesis of two constitutional isomers (α- and γ-aldol) 
depending on the ligand employed. In the presence of CuOAc, (R)-DTBM-Segphos, 
PCy3 and pinacolborane in THF, allenic esters 105 reacted with various ketones to 
selectively produce γ-cis-tertiary alcohols 107a-107d. Changing the reaction 
conditions to CuF(PPh3)3·2EtOH, Taniphos ligand and pincolborane in THF led to 
the selective production of α-products 108a-108d in excellent yields and modest to 
high enantioselectivity. They demonstrated that the product distribution (α- and γ-
aldol) could be switched depending on the structure of the chiral bisphosphine 
ligand, though no explanation of the reaction mechanism and how the choice of 




Scheme 1.36: CuH-Catalysed Reductive Aldol Reaction of Allenic Esters to Ketones49 
 
The terminal alkene in 108 provides a functional handle for further derivatisation. 
For example, alcohol 108e was converted to 109 in a chain extension sequence 
involving cross-metathesis without any epimerisation at the α-position or 
racemisation (Scheme 1.37).   
 
 






In 2006, Riant et al. also published a report on copper-catalysed asymmetric 
reductive aldol coupling of α,β-unsaturated esters with ketones. In the presence of 
CuF(PPh3)3·2MeOH as the precatalyst, (R,S)-Cy-Taniaphos as the chiral ligand and 
PhSiH3 as the stoichiometric reductant, various aromatic ketones 111 participated  in 
a reductive aldol reaction with methyl acrylate (110) affording products 112a-112d 
with high diastereo- and enantiocontrol (Scheme 1.38).41b The major isomer formed 
under these reaction conditions was the erythro isomer.  
 
 
Scheme 1.38: Cu-Catalysed Asymmetric Reaction of Aryl Methyl Ketones and Methyl 
Acrylate50 
 
Riant et al. subsequently applied the catalytic system described above to the syn-
selective reductive coupling of aldehydes 113 with methyl acrylate (110) (Scheme 
1.39).47 Substrate scope include acyclic aliphatic aldehydes (product 113a), cyclic 
aliphatic aldehydes (product 113b), aromatic aldehydes (product 113c) and 
heteroaromatic aldehydes (product 113d); all participated successfully in the reaction 
with conversion >99%. Isolated yields were reported to be in the range of 74-99% for 
products 113a-113d. Diastereoselectivity for this reaction was poor, but good 
enantioselectivities were observed. The ability to selectively reduce α,β-unsaturated 
esters and then couple with an aldehyde is notable given the high reactivity of 





Scheme 1.39: CuH-Catalysed Reductive Coupling of Methyl Acrylate with Aldehydes47 
 
Having established an efficient catalytic system for the CuH-catalysed reductive 
aldol coupling of methyl acrylates with aldehydes and ketones using various chiral 
bisphosphine ligands, Riant et al. turned their attention to the performance of NHC 
ligands in such catalytic reactions. Using substoichiometric quantities of achiral 
NHC-ligated copper catalyst (IMes)Cu(DBM) the reductive coupling of α,β-
unsaturated esters and aldehydes were realised (Scheme 1.40).52  
 
 




Good yields were observed with various aliphatic and (hetero)aromatic aldehydes, 
with the anti-isomer being the dominant product in all cases examined (products 
117a-117d). Diastereoselectivities were modest (up to 73:27 dr), but the reaction was 
highly chemoselective. They also examined other electron-withdrawing functional 
groups on the Michael acceptor (Scheme 1.41). Using unsaturated ketone 118 with 
cyclohexane carboxaldehyde (119) gave the corresponding product in good yield and 
promising diastereoselectivity (product 120). Nitrile 121 coupled with cyclohexane 




Scheme 1.41: NHC Cu-Catalysed Reductive Aldol Reaction with Various Electrophilic 
Alkenes52 
 
In 2013, Li and co-workers described a CuH-catalysed domino reaction of tert-butyl 
acrylate with ketones in the presence of hydrosilane PMHS and CuH-Xantphos 
complex (Scheme 1.42).53 The reaction was tolerant of electron-donating groups 
furnishing products with good diastereoselectivities (product 125a-125b). Substrates 
with electron-withdrawing groups on the ketone furnished products with excellent 




 Scheme 1.42: NHC Cu-Catalysed Reductive Aldol Reaction with Various Electrophilic 
Alkenes53 
 
In a more recent publication, Li and co-workers described a CuH-catalysed reductive 
aldol addition of α,β-unsaturated diesters to furnish lactones.54  Using substituted 
acetophenones 126 and dimethyl itaconate (127) in the presence of 
CuF(PPh3)3·2MeOH-Xantphos derived catalyst and stoichiometric PMHS furnished 
separable lactones (products 128a-128d) in excellent yields (Scheme 1.43). The 
reaction was tolerant of electron-withdrawing groups and electron-donating groups 





Scheme 1.43: Conjugate Aldol Lactonization Domino Reaction of Dimethyl Itaconate54 
 
Although diastereoselectivities were poor, it is a useful methodology for preparing 
lactones with an exo-ester moiety. Symmetrical ketones gave products with a single 
stereocentre in high yields (Scheme 1.44). 
 
 






1.3  Reductive Mannich Reactions 
 
Compared with the Cu(I)-catalysed intermolecular reductive aldol reactions of α,β-
unsaturated carbonyl compounds previously discussed, the corresponding reductive 
Mannich reactions are less well studied. Mannich-type reactions of an aldimine with 
an enolate component are some of the most important and versatile tools to construct 
β-amino carbonyl compounds.55 The products of the Mannich reaction have been 
used for the enantioselective synthesis of several important nitrogen containing 
products such as amino acids, amino sugars, imino sugars and amino alcohols.56 
 
In 2002, Matsuda and co-workers reported a rhodium-catalysed method for the 
synthesis of β-amino esters from aldimines, methyl acrylate and diethylmethylsilane 
(Scheme 1.45).55  
 
 
Scheme 1.45: Rh-Catalysed Mannich-type Reaction of Aldimine with Methyl Acrylate55  
 
In the presence of rhodium catalyst [Rh(cod)(P(OPh)3)2]OTf, diethylmethylsilane as 
reductant in CH2Cl2 furnished Mannich-type products 133a-133c, in high yields and 
moderate diastereoselectivities. The reaction was intolerant of N-alkyl aldimines, 
such as N-cyclohexyl aldimine 132d, which did not react to give β-ester 133d under 
the given reaction conditions. Though a general highly diastereoselective method 
was not established, the report demonstrated a new route to design certain types of β-





In the same year, Morken and co-workers reported a highly diastereoselective 
iridium-catalysed reductive coupling of acrylates 134 and imines 135 in the synthesis 
of trans β-lactams 136a-136d (Scheme 1.46).57 β-Lactams are prevalent substructures 
in biologically active compounds such as effective antibiotic agents, protease 
inhibitors and cholesterol absorption inhibitors, therefore their synthesis is of 
significant value.58  
 
 
Scheme 1.46: Iridium-Catalysed Synthesis of β-Lactams57 
  
C-aryl imines furnished the corresponding β-lactams 136a in good yields and high 
diastereoselectivities. Allylic and proparyglic imines reacted without competitive 
hydrosilation of the C-C π-bond affording products 136b and 136c respectively. 
They also demonstrated that furans do not interfere with the reaction (product 136d). 
 
A postulated reaction mechanism was included in the communication (Scheme 1.47). 
The first step involves the in situ generation of an iridium hyride 137 which reacts 
with the acrylate 134 to provide an iridium enolate 138. Iridium enolate 138 couples 
with aldimine 135 to provide a β-amido ester 139. Subsequent cyclisation furnishes 





Scheme 1.47: Postulated Reaction Mechanism of Iridium-Catalysed Synthesis of β-
Lactams57 
 
A report by Nishiyama and co-workers in 2007, demonstrated the conjugate 
reduction of α,β-unsaturated esters followed by a Mannich-type coupling towards 
aldimines using a rhodium-bis(oxazolinyl)phenyl Rh(Phebox) catalyst and 
alkoxyhydrosilanes to give β-amino esters 143a-143d (Scheme 1.48).59 Good yields 
and high anti-selectivity were observed in all cases and electron-withdrawing and 
electron-donating substituents were tolerated on both aryl groups.  





Scheme 1.48: Reductive Mannich-Type Coupling of Aldimines and t-Butyl Acrylate59  
 
Crotonates and cinnamates were also explored as enolate sources giving products 
with good yields and diastereoselectivities (Scheme 1.49). Interestingly, it was found 







Scheme 1.49: Reductive Mannich-type Coupling of Aldimines with Crotonates and 
Cinnamates59 
 
An attempt at asymmetric induction was unsuccessful. Employing a chiral 
Rh(Phebox) catalyst, the reaction of p-methoxyimine 148 with tert-butyl acrylate 
(147) gave Mannich adduct 149 in high yield and diastereoselectivity; however, no 
enantioselectivity was observed (Scheme 1.50).  
 





In 2007, Krische and co-workers reported a rhodium-catalysed reductive Mannich 
coupling of vinyl ketones to N-sulfonylimines mediated by hydrogen. Initial studies 
focused on the hydrogenative coupling of methyl vinyl ketone (MVK) to N-
arylaldimines (Scheme 1.51).60  
 
Scheme 1.51: Hydrogen Mediated Reductive Mannich Coupling of MVK to N-Arylaldimines60 
 
They reported that the coupling of MVK to imine 151a derived from aniline gave the 
desired reductive Mannich product 152a in excellent yield but poor 
diastereoselectivity. They postulated aldimines which incorporated more sterically 
demanding groups may couple with higher levels of diastereoselection. Accordingly, 
sterically hindered imines were examined which incorporated o-isopropylphenyl and 
o,p-dimethylphenyl N-aryl residues. Increased steric demands did not result in 
heightened levels of diastereoselection and affected conversion adversely (products 
152c and 152d). It was reasoned that the poor levels of diastereoselection in 
additions to N-arylaldimines were due to facile geometrical isomerism in the 
presence of the metal catalyst.61 Hydrogenative Mannich coupling proceeded more 
efficiently with highly electrophilic N-(o-nitrobenzenesulfonyl)aldimines 153 to 
afford the coupling products 154a-154d in good to excellent yields and superior 
diastereoselectivities compared with aniline derived imines 151 (Scheme 1.52).  





Scheme 1.52: Diastereoselective Hydrogen-Mediated Reductive Mannich Coupling of MVK 
to N-(o-Nitrophenyl)sulfonylaldimines60 
 
Deuterium experiments were conducted to investigate the mechanism of the reaction 
(Scheme 1.53). Performing the reductive coupling reaction using MVK 150, p-
nitrobenzaldimine (153a) and elemental deuterium, they found the Mannich coupling 
product deuterio-154a incorporates a single deuterium atom at the former enone β-
position and incorporation at the α-position is not observed. The sole incorporation 
of a deuterium atom is consistent with a mechanism involving irreversible enone 
hydrometalation. However, enone-imine oxidative coupling followed by 
hydrogenolytic cleavage of the resulting oxarhodacycle cannot be excluded.  
 
  
Scheme 1.53: Reductive Mannich Coupling under a Deuterium Atmosphere60 
 
Lam and co-workers reported a new variant of the reductive Mannich reaction 
involving the coupling of commercially available 4-acryloylmorpholine (155) with a 
range of aromatic N-tosyl aldimines 156 using diethylzinc as the stoichiometric 





 Scheme 1.54: Cobalt-Catalysed Reductive Mannich Reaction of 4-Acrylmorpholine with N-
Tosyl Aldimines62 
 
N-Tosyl aldimines were found to undergo reductive coupling with 4-acrylmorpholine 
(155) in moderate to good yields and with good levels of diastereoselection. 
Aldimines with electron-donating substituents such as methyl and methoxy (products 
157a-157b) provided superior results compared with those containing electron-
withdrawing substituents (product 157c). 
 
Cordova and Zhao reported an amine-catalysed direct asymmetric reductive Mannich 
reaction of β,β-disubstituted α,β-unsaturated aldehydes 158 furnishing amino acid 




 Scheme 1.55: Direct Catalytic Enantioselective Reductive Mannich-type Reaction56 
 
In the presence of chiral pyrrolidine A with Hantzsch ester (159) as hydride source, 
the reaction proceeded smoothly to furnish the corresponding chiral aldehydes 160 in 
good to high yields and excellent ee’s (up to 97%).  Employing N-PMP-protected α-
iminoglycoxylate (161) as the electrophile the reductive Mannich-type reaction 
provided the corresponding amino acid derivatives 162a-162d in good yields and 
with good to excellent diastereo- and enantioselectivity. 
 
An organocatalytic enantioselective reductive Mannich protocol was also developed 
which led to the other diastereomer of 162d. A catalytic amount of (R)-Proline was 
added to the reaction mixture together with N-PMP-protected α-imino-glyoxylate 
(161) and a syn-selective Mannich addition (product 162d) was achieved with high 






Scheme 1.56: Syn-Selective Reductive Mannich-type Reaction using (R)-Proline56  
 
In 2008, Shibasaki et al. developed the first CuH-catalysed asymmetric reductive 
Mannich reaction employing N-phosphinoyl ketimines. This methodology was the 
first example of the catalytic asymmetric synthesis of β-amino acid derivatives 
(Scheme 1.57).63 
 
Scheme 1.57:  Catalytic Asymmetric Reductive Mannich Reaction of Ketimines63 
 
Exchanging the stoichiometric reducing agent from pinacolborane for hydrosilanes 
improved the enantioselectivity significantly. Lower reaction temperatures and 
employing sterically less hindered bis-arylphosphines as ligands saw an 
improvement in the product yield. Using a CuOAc-DIFLUORPHOS complex 
catalyst and (EtO)3SiH as a reducing agent at −30
oC or lower, α,β-unsaturated esters 




Mannich fashion. The substrate scope covers both aromatic and α,β-unsaturated 
ketimines as acceptors, affording α-methyl, ethyl-, and ethoxy-carbonylmethyl-
substituted products (products 165a-165d respectively) with high enantio- and 
diastereoselectivities. The products were converted to enantiomerically enriched β-
amino acid derivatives 166a in high yield without any racemisation or epimerisation 




Scheme 1.58:  Conversion to β-Amino Acid Derivative63 
 
Recently, Buchwald and co-workers reported a CuH-catalysed method for the 
preparation of highly functionalised indolines (Scheme 1.59).64  
 
 





The reaction displayed good functional group tolerance and gave exclusively cis-
indolines in high yields and good to excellent enantioselectivities (products 168a-
168c). The reasons for the observed diastereoselectivity were not disclosed in the 
communication. 2-Alkenylimine precursor 167d which possesses a vinyl group, 
proved to be the only exception providing indoline 168d with diminished 
diastereoselectivity (11:1 dr). Interestingly, the choice of alcohol was important for 
the yield. When t-BuOD was used in lieu of t-BuOH the reduced styrene side product 
was reduced (from 3% to <1%) and a slight increase in yield was obtained (from 
92% to 96%). Extension of this method to β-substituted styrenes furnished indoline 
168c with good yield and high enantioselectivity; however, a higher catalyst loading 
was required (8 mol%) and the best result was obtained in the absence of 
triphenylphosphine. 
 
To the best of our knowledge, the only report of catalytic reductive coupling 
reactions of alkenylazarenes is that from the Krische group, describing a racemic 
rhodium-catalysed hydrogenative coupling65 of vinylazines with N-arylsulfonyl 
imines (Scheme 1.60).66  
 
 





Catalytic hydrogenation of alkenylazines 169 and N-arylsulfonyl imines 170 in the 
presence of a cationic rhodium catalyst ligated by (2-Fur)3P and molecular hydrogen 
results in the reductive coupling to furnish branched products of imine addition 
171a-171d with modest levels of syn-diastereoselectivity. The reaction proceeds 
efficiently at ambient temperatures and pressures. In evaluating the scope of the vinyl 
azine partner, they noted that the parent 2-vinylpyridine did not participate in the 
coupling, most likely due to strong coordination at nitrogen to the rhodium catalyst 
rendering it ineffective. Accordingly, 6-substituted vinylpyridines were selected as 
coupling substrates and participated efficiently to (hetero)aromatic (products 171a 
and 171d)and aliphatic imines (products 171b and 171c). Fused bicyclic vinyl azines 
were also effective coupling partners (product 171d). 
 
The results in Krische’s paper are impressive; however, there are some limitations 
within their work. We envisaged that a related enantioselective variant employing 




















1.4  Conclusion 
 
To summarise, it has been shown that azaarenes are important moieties in natural 
products, pharmaceuticals and other biologically active molecules. The use of 
azaarenes as activating groups has been successfully employed in enantioselective 
catalysis with a number of reports in literature. It has been demonstrated that 2-
alkenylazaarenes can act as activators of an adjacent olefin in the electrophilic 
component of the reaction and provide Michael addition products with excellent 
diastereo- and enantioselectivities. With this knowledge in hand, the aim of our 
research was to extend current methodologies and to develop other complementary 
novel methods for the asymmetric functionalisation of azaarenes. 
 
In the following results and discussion sections, studies exploiting the electron-
withdrawing ability of a C=N embedded within an azaarene to couple with ketones 
and imines in the construction of chiral tertiary alcohol and chiral amines are 
discussed (Scheme 1.24).  
 
 










2. ENATIOSELECTIVE REDUCTIVE COUPLING OF 
ALKENYLAZAARENES WITH KETONES  
 
2.1 Preparation of 2-Alkenylazaarenes  
 
For the preparation of 2-vinylazaarenes and β-substituted alkenylazaarenes, the most 
simple and efficient method involves a Suzuki-Miyaura coupling between a 
halogenated azaarene 172 and potassium vinyltrifluoroborate (173) or an 
alkenylboronic ester 178 (Scheme 2.01).  
 
 
Scheme 2.01: Preparation of Alkenylazaarenes via Suzuki-Miyaura Cross-Coupling 
Chemistry 
 
Although potassium vinyltrifluoroborate (173) is commercially available, it was 
prepared in a one-step procedure through addition of vinyl magnesium bromide (174) 
to trimethyl borate and in situ treatment of the resulting boronic ester with KHF2 
(Scheme 2.02).   
 
 




2-Vinylazaarenes 175 were synthesised using Suzuki-Miyaura cross-coupling 
reactions conditions developed by Molander and co-workers.67 Halogenated 
azaarenes 172 were coupled with potassium vinyltrifluoroborate (173) in the 
presence of Et3N and catalytic PdCl2(dppf)·CH2Cl2 to give a range of 2-
vinylazaarenes 175b-175l in good to high yields  (Scheme 2.03). 
 
  
Scheme 2.03: Preparation of Alkenylazaarenes via Suzuki-Miyaura Cross-Coupling 
Chemistry 
 
Attempts to synthesise sterically hindered 2-vinylazaarenes containing phenyl groups 
were unsuccessful; bulky halo-azaarenes 172m and 172n did not undergo cross-
coupling efficiently with potassium vinyltrifluoroborate under the standard 
conditions (Scheme 2.04). Analysis of the 1H NMR spectra of the crude reaction 
mixtures showed <5% conversion to the coupled product and the starting material 






Scheme 2.04: Unsuccessful Substrate Preparation 
 
Additionally, various 2-vinylarenes containing electron-withdrawing substituents 
were prepared in high yields (190a-190c) using the general Suzuki-Miyaura cross-
coupling procedure (Scheme 2.06).67 Drawing on knowledge from a previous study 
within the Lam group on rhodium-catalysed 1,4-arylations,10f it was hoped that 
electron-deficient vinylarenes may also participate in a copper-catalysed reductive 
coupling reaction.  
 
 
Scheme 2.05: Synthesis of Vinylarenes 
 
The preparation of β-substituted alkenylazaarenes involved a two-step strategy. First, 
alkenylboronic esters 179 were synthesised following a procedure previously 
developed by Wang and co-workers.68 This reaction involves the zirconium-
mediated hydroboration of terminal alkynes 177 leading to the stereoselective 







Scheme 2.06: Synthesis of Alkenylboronic Esters 
 
The newly synthesised alkenylboronic esters 178 were then subjected to the Suzuki-
Miyaura cross-coupling procedure with halogenated azaarenes 172 (Scheme 2.07). 
The reactions proceeded efficiently and β-substituted alkenylazaarenes 179a-179c 
were isolated in good yields.  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
 





An alternative method to prepare β-substituted alkenylazaarenes involved direct 
formation of the azaarene moiety. The reaction of benzoin (182) with crotonic acid 
(183) in the presence of DMAP and DCC afforded intermediate 184, which upon 
treatment with ammonium acetate in glacial acetic acid cyclised to give 
alkenyloxazole 179d in high yields (Scheme 2.08). 
 
 Scheme 2.08: Synthesis of β-Substituted 2-Alkenyloxazole 
 
2.2  Enantioselective Copper-Catalysed Reductive Coupling of 
Alkenylazaarenes with Ketones 
  
The project began with a screening of chiral bisphosphines in order to obtain the 
optimum ligand for this enantioselective copper-catalysed reductive coupling 
process. For the ligand evaluation, 2-vinylquinoline (175b) was selected as the 
azaarene substrate and commercially available acetophenone (185) was selected as 
the ketone coupling partner. Drawing on knowledge from a related study on copper-
catalysed reduction of β,β-disubstituted alkenylazaarenes,10h PhSiH3 was selected as 
the hydride source, Cu(OAc)2·H2O as the source of copper and toluene as the 
solvent. Under these conditions, various chiral bisphosphine ligands were screened 









Table 2.01: Ligand Optimisation for Cu-Catalysed Reductive Coupling Reactionsa 
 
 
Entry Ligand 186b:187b drb eec (%) 
1 L1 11:1 1:1 43, 50 
2 L2 24:1 1:1 27, 17 
3 L3 13:1 1:1 67, 67 
4 L4 7:1 5:1 93, 60 
5 L5 17:1 1:1 −60, 92 
6 L6 12:1 1:1 92, 93 
aReactions were conducted using 0.1 mmol of 175b. bDetermined by 1H NMR analysis of the unpurified reaction 
mixtures. cDetermined by chiral HPLC analysis. 
 
Proof of concept was quickly established, and all ligands evaluated led to complete 
consumption of 2-vinylquinoline to provide the coupling product 186b as a mixture 
of diastereomers, along with traces of the reduction product 187. Enantioselectivities 
were low with (R)-BINAP (L1) and (R)-MeO-DuPhos (L2). However, improved 
results were observed using (R)-MeO-Biphep (L3) with a modest enantioselectivity 
(67% ee). Superior enantioselectivities were obtained employing the Taniaphos 
ligand (L4), (R,R)-Quinox-P* L5, and the Josiphos ligand L6, and all provided ee’s 




employing L4, which provided 186b in 5:1 dr and 93% ee for the major isomer while 
also displaying good chemoselectivity between the coupling product and the 
reduction product (ratio 186b:187). The excellent selectivity provided by L4 
prompted the selection of this ligand for further experimentation. 
 
A screening of hydrosilanes revealed PhSiH3 to be the optimum stoichiometric 
hydride for this reaction. Comparable enantioselectivities were observed with 
TMDS, PMHS and Ph2MeSiH but reaction rates were slower. 
 
In regard to the solvent choice, a range of polar and non-polar solvents including 
acetone, diethyl ether, dichloromethane and dioxane afforded reductive coupling 
product 186b with decreased diastereoselectivity compared with toluene. 
Accordingly, toluene was selected as the preferred solvent for this process.  
 
With a generalised procedure in hand, the scope of the reaction was investigated 
utilising the previously prepared 2-alkenylazaarenes. First, the scope of various 2-





Scheme 2.09: Cu-Catalysed Reductive Aldol Coupling of Vinylazaarenes with Acyclic 
Ketones 
 
2-Vinylpyridine coupled efficiently with acetophenone affording diastereomeric 
products 186aa and 186ab in high yields. These were obtained with high 
enantioselectivities (>99% and 92% ee respectively). Other compatible substrates 
included 2-vinylquinoline (products 186b and 186c) and 1-vinylisoquinoline 
(products 186d-186g). The relative and absolute stereochemistries of quinoline-
containing products 186b and 186c were determined by single crystal X-ray 















Figure 2.01: Stereochemical Determination of 2-Vinlyquinoline-Containing Products 
 
In regards to the reaction employing acyclic ketones, the diastereoselectivities of the 
reaction appeared to be dependent on the steric properties of the azaarene. Increasing 
diastereoselectivities were observed going from pyridine to quinoline to isoquinoline 
(compare diastereomeric ratios for products 186a, 186b and 186d). The scope of the 
electrophile included acyclic ketones containing various alkyl, aryl or heteroaryl 
substituents (products 186a-186g). Ketones with electron-withdrawing (product 
186e) and electron-donating (186f) groups on the aryl ring also coupled efficiently 
and with high enantioselectivities (up to >99% ee).   
 
2-Vinylbenzothiazole (175k) and 2-vinylbenzoxazole (175l) did not undergo 
reductive coupling with acetophenone. 1H NMR analysis of the unpurified reaction 
mixtures revealed a complex mixture of products and no peaks corresponding to 
either starting product or the desired product (Scheme 2.10). 2-Vinylbenzothiazole 
(175k) and 2-vinylbenzoxazole (175l) are not bench-stable and has a tendency to 
degrade at room temperature; therefore it is presumed that the rate of starting 
material decomposition is greater than the rate of reductive coupling under the 





Scheme 2.10: Cu-Catalysed Reductive Aldol Coupling of Vinylazaarenes with Acyclic 
Ketones 
 
Deviating from acyclic ketones, five- and six-membered cyclic ketones were 
investigated by my co-worker Aakarsh Saxena. Cyclic ketones were also found to be 
effective substrates for the reductive coupling process (Scheme 2.11). This was 
demonstrated with two indanones (products 186h and 186i), 4-chromanone (product 
186j), 4-thiochromanone (product 186k) and tetralone (product 186l). Within these 
results, the scope of the azaarene was broadened to include two isomeric forms of 
pyrimidine (products 186h and 186i), a thiazole (186j), a 5-substituted pyridine 















Next, the scope of this reaction was extended to include β-substituted 
alkenylazaarenes (Scheme 2.12). 
 
 
Scheme 2.12: Reductive Coupling of β-Substituted Alkenylazaarenes with Ketones 
 
These reactions demonstrate alkenylazaarenes containing β-phenylethyl, 
methoxymethyl or ethyl groups smoothly underwent reductive coupling to deliver 
products 189a-189c with good to high diastereoselectivities and excellent 
enantioselectivities. These products also encompassed additional examples of 
different azaarenes, such as a dimethoxytriazine (product 189a), 1,3-pyrimidine 
(product 189b) and diphenyloxazole (product 189c).  
 
In accordance with the accepted catalytic cycle of conjugate reduction of enoates,30d 
a possible mechanism for the present copper-catalysed reductive coupling of 
alkenylazaarenes with ketones is described in Scheme 2.13 using 2-vinylquinoline 
(175b) for illustrative purposes. Cu(OAc)2 in the presence of bisphosphine L4 and 
PhSiH3 is reduced to generate ligated CuH species 190, which undergoes a 1,4-




occurs via a six-membered transition state 192 to give copper alkoxide 193 which 
then undergoes σ-bond metathesis with PhSiH3 to liberate the silylated product 194 
(silyl deprotection occurs upon work-up to give product 186b), regenerating the 
ligated CuH species 190 (Scheme 2.13). 
 
 
 Scheme 2.13: Postulated Catalytic System 
 
Interestingly, the stereochemical outcome of the reaction exhibits a strong substrate 
dependence. For example, 2-vinylquinoline-containing products 186b-186c were 
formed with the opposite sense of enantioinduction compared with 1-
vinylisoquinoline-containing products 186d-186g despite the same enantiomer of L4 
being employed throughout. In addition, different diastereochemical outcomes were 
obtained with cyclic as opposed to acyclic ketones. A six-membered Zimmerman-
Traxler-type transition state is assumed to be adopted where the larger aryl group of 
the ketone occupies the pseudoequatorial position.70 Figure 2.02 depicts 





Figure 2.02: Rationalization of Stereochemical Outcomes TS 1 and TS 2 
 
TS 1 and TS 2 depicts the conformations which are consistent with the participation 
of Z-azaallylcopper species for the reactions producing products 186b, 186c and 
186d-186g. The enantioinduction observed in TS 1 is opposite to that in TS 2 and 
the reasons for this are not clear at this present time. The preference for the Z- 
azaallylcopper species in TS 2 can be explained by the severe A1,3-strain
71 that would 
disfavour the corresponding E-azaallylcopper species. However, a similar argument 
cannot be used to explain the same preference for TS 1. For reactions involving 
cyclic ketones (products 186h-186l), reaction through the E-azaallylcopper species 
(or the Z-azaallyl copper species in the case of 186j) appears to be favoured, as in TS 
3 for the formation of 186i (Figure 2.07).  
 
 
Figure 2.03: Rationalization of Stereochemical Outcomes TS 3 
 
The discussion so far has been based upon the assumption that chair-like transition 




excluded. Further studies are required to investigate the interplay between sterics 
and/or electronic properties of the alkenylazaarene and ligand in order to determine 
the reasons for the observed stereochemical outcomes.  
 
3-Vinylpyridine and 4-vinylpyridine (substrates 195 and 196, respectively) did not 
participate in the reductive coupling reaction with acetophenone (185) (Scheme 
2.14). From these observations, it suggests that coordination of the copper to the 
nitrogen atom on the azaarene is required in order to form the six-membered 
Zimmerman-Traxler-type transition state for the reaction to proceed. However, the 
possibility that these substrates are simply insufficiently activated under these 
reaction conditions cannot be excluded.   
 
 
Scheme 2.14: Reductive Aldol Coupling of 3- and 4-Vinylpyridine 
 
The use of aldehydes as electrophiles for this reaction was briefly explored. 2-
Vinylquinoline 175b and benzaldehyde (197) failed to undergo reductive coupling 
under the standard reaction conditions (Scheme 2.15). Analysis of the 1H NMR 
spectrum of the crude reaction mixture showed peaks corresponding to unreacted 
175b and benzyl alcohol (product of reduction of benzaldehyde). As aldehydes are 
more reactive than ketones, it was postulated under our reaction conditions that the 
reduction of benzaldehyde to benzyl alcohol is preferential to the reduction of the 






Scheme 2.15: Cu-Catalysed Reductive Coupling of 2-Vinlylquinoline with Benzaldehyde 
 
To test the scope of this process further, electron deficient vinylarenes were also 
synthesised as previously discussed. Attempts to couple electron deficent vinylarenes 
with acetophenone (185) were unsuccessful. These results indicates that the C=N 
moiety in azaarenes is crucial in activating the adajecent alkene and that combined 
with the ability to coordinate to the copper to form the six-membered transition state 











2.3  Application of Methodology  
 
Ravuconazole72 and Voriconazole73 are potent antifungal agents containing the key 
structural features embodied by the reductive coupling products in the methodology 
described in this chapter (Figure 2.04).  
 
 
Figure 2.04: Structurally Relevant Pharmaceuticals 
 
Voriconazole (199) was selected as an ideal target molecule for the copper-catalysed 
reductive coupling chemistry. Retrosynthetic analysis revealed a short two-step 
sequence towards the enantioselective synthesis of Voriconazole (Scheme 2.17). 
 
 





As an initial test, the Cu-catalysed reductive coupling of 2-vinylquinoline 175b with 
commercially available ketone 201 was attempted (Scheme 2.18). None of the 
coupled product was observed in the 1H NMR spectrum of the crude reaction 
mixture. It is possible that the nitrogen atoms on the triazole ring of the ketone may 
be poisoning the system by strongly binding to the copper catalyst; however, the 
exact reasons are currently unclear. Further experimentation is needed to address this 




Scheme 2.18: Synthesis of Voriconazole Analogue 
 
This was exemplified in a patent from Pfizer in 2014, relating to an improved process 
for the preparation of Voriconazole (199) citing our paper utilising the generation of 
copper nucleophiles from vinylazaarenes in an enantioselective addition to ketones 
(Scheme 2.19).74 
 





2.4  Conclusions 
 
In summary, an enantioselective copper-catalysed reductive coupling of 
alkenylazaarenes with ketones has been developed.10c The scope of the process is 
broad, and the enantioselectivities of the products were uniformly high. In addition to 
pyridine, other effective nitrogen containing heteroarenes included quinoline, 
isoquinoline, pyrimidines, quinoxaline and thiazole. A range of acyclic and cyclic 
ketones have also been shown to be effective coupling partners. The process is not 
limited to vinylazaarenes; -substituted alkenylazaarenes are also effective coupling 
partners and the reactions proceed under mild conditions to deliver products in good 
to high levels of diastereo- and enantioselectivities. Functionality tolerated at the -
position of the alkene included ethyl, phenethyl and allylic ether group. This report 
has demonstrated the first examples of catalytic asymmetric reductive coupling of 
alkenylazaarenes with features that should be advantageous for application of this 
process in the preparation of novel enantioenriched chiral azaarene-containing 
building blocks.  
 
Essential structural requirements of the alkenylazaarenes were revealed when 3- and 
4-vinylpyridine failed to undergo reductive coupling under the developed set of 
conditions. For the reaction to proceed the nitrogen atom must be at the 2-position 
within the azaarene so that it is in conjugation with the olefin and also so that it is in 
close proximity with the ligated-copper species to form the six-membered 
Zimmerman-Traxler-type transition state. 
 
Finally, the synthesis of anti-fungal drug Voriconazole (199) was attempted. Despite 
our unsuccessful attempts, the synthesis was achieved through slight modification of 
our reaction conditions. We expect that the methodology developed should be 
applicable to the preparation of other novel enantioenriched chiral azaarene-







2.5  Future Work 
 
The enantioselective copper-catalysed reductive coupling chemistry developed opens 
up two obvious avenues for future work in this area. It is anticipated that by changing 
from a hydride nucleophile to a carbon or heteratom nucleophile this process would 
become more divergent, granting access to a variety of chiral compounds starting 
from a single substrate (Scheme 2.20). In this regard, the copper-catalysed 1,4-
addition of Grignard reagents51b, 75 and boron reagents76 is well precedented and 
development of such reactions to incorporate an azaarene moiety would be a 
valuable endeavour.  
 
 





Alternatively, another avenue to explore is by changing the electrophile, resulting in 
the trapping of the organocopper intermediate by a different functional group (e.g. 
imines or allyl species) resulting in a diverse range of products (Scheme 2.21). In 




Scheme 2.21:  Domino Conjugate Addition/Mannich Reaction or Conjugate Addition/Allylic 
Substitution Reaction of Alkenylazaarenes 
 
Finally, although attempts were made, it would be still be useful if the practicality of 
this methodology was displayed through its application towards synthesising a 
biologically active molecule. Such an application would demonstrate the utility of 
this methodology as an efficient tool for the generation of enantioenriched azaarene-
containing motifs which, as discussed in chapter 1 are, commonly used building 





3. ENANTIOSELECTIVE REDUCTIVE COUPLINGS OF 
VINYLAZAARENES WITH N-BOC ALDIMINES  
 
3.1  Aims and Objectives 
 
Chapter 2 detailed the copper-catalysed reductive coupling of alkenylazaarenes with 
ketones; a process which enables the synthesis of azaarene-containing products with 
two contiguous stereocenters, including a tertiary alcohol.10c The ability to employ 
other types of electrophiles would be beneficial to increasing the substrate scope and 
the utility of the reaction. As discussed in Chapter 1, Krische and co-workers 
described the racemic rhodium-catalysed hydrogenative coupling of vinylazines with 
N-sulfonylaldimines (Scheme 3.01A).66 It was anticipated that a related 
enantioselective variant employing chiral copper hydride chemistry could be 
developed (Scheme 3.01B). 
 
Scheme 3.01: Coupling of Vinylazaarenes with Imines 
 
This would give rise to β-amino heterocycles with up to three stereocenters. It was 
hoped that control over both the relative and absolute stereochemistry could be 
achieved and subsequent deprotection of the protected amine could be realised to 





3.2  Screening of Various N-Protected Imines 
 
The project began with a screening of chiral bisphosphines in order to obtain the 
optimum ligand for this enantioselective copper-catalysed reductive coupling 
process. For the ligand evaluation, 2-vinylquinoline (175b) was selected as the 
azaarene substrate and a range of N-protected aldimines (203-208) was selected as 
coupling partner. Drawing on knowledge from a related study on copper-catalysed 
reductive couplings of alkenylazaarenes,10c PhSiH3 was selected as the hydride 
source, Cu(OAc)2·H2O as the source of copper and toluene as the solvent. Under 
these conditions, various chiral bisphosphine ligands were screened (Table 3.01).   
 
Table 3.01: Cu-Catalysed Reductive Coupling of 2-Vinylquinoline with Aldimines 
 



























aConversions were determined by 1H NMR analysis of the unpurified reaction mixture, bSubstrate prepared by Dr 
Daniel Best, , cSubstate prepared by Joshua Smith,  dReaction performed by Joshua Smith, eSubstrate prepared by 
Nawasit Chotsaeng 
 
Pleasingly, the reductive coupled product was observed in all acyclic imines 
evaluated (entries 1-4). However, N-tosyl imine 203 and N-diphenylphoshinoyl 
imine 204 both gave poor conversions with significant quantities of starting material 
2-vinylquinoline (175b) recovered (entries 1 and 2). With cyclic sulfamidate imines 
(entries 5 and 6), only starting material was recovered. Promisingly, Cbz imine 205 
and N-Boc imine 206a both underwent the coupling efficiently with complete 
conversion to products. As the proof of concept had been established, the next step 
was to probe whether the reaction could proceed in a diastereo- and enantioselective 
manner. The reaction employing N-Boc imine 206a (entry 4) was selected for further 
asymmetric development. Advantageously, N-Boc deprotection is normally facile. 
Employing imines that have an easily cleavable protecting group such as a Boc-
group is synthetically beneficial as it should allow access to the free amine 
compounds and for sensitive functionality to be tolerated in the deprotection step. 
 
3.3  Preparation of Alkenylazaarenes 
 
For the preparation of the azaarene coupling partner, the same synthetic strategy was 
utilised as seen in Chapter 2; preparation of 2-vinylazaarenes though Suzuki-Miyaura 
coupling between halogenated azaarenes 172 and potassium vinyltrifluoroborate 
(173). A range of 2-vinylazaarenes were synthesised using previously reported 






Scheme 3.05: Preparation of 2-Vinylazaarene 175o 
 
An alternative two step synthetic route was employed for the synthesis of 2-bromo-6-
vinylpyridine (175p) (Scheme 3.06).66 Treatment of 2,6-dibromopyridine (215) with 
n-BuLi provided the 2-lithiated pyridine species, which, in the presence of 
acetaldehyde, forms alcohol 216. Dehydration of alcohol 216 by H2SO4 provides 2-
bromo-6-vinylpyridine (175p) in moderate yield.  
 
 Scheme 3.06: Synthesis of 2-Bromo-6-Vinylpyridine 
 
 
β-Substituted 2-alkenylazaarenes were prepared by coupling alkenylboronic acid 
pinacol esters, prepared from the previous study (Chapter 2), with halogenated 
azaarenes 172 using standard Suzuki-Miyaura cross-coupling procedures (Scheme 
3.07). The reactions proceeded efficiently and β-substituted alkenylazaarenes 179e-
179g were isolated in good yields.  
 





3.4  Preparation of N-Boc Aldimines 
 
Various N-Boc aldimines were synthesised following the general procedure as 
illustrated in Scheme 3.02. 
 
Scheme 3.02: Strategy for the Synthesis of N-Boc Aldimines 
 
Despite being commercially available, tert-butyl carbamate (218) was conveniently 
prepared in a one-step procedure from Boc-anhydride (217). tert-Butyl carbamate 
(218) was isolated in excellent yields after recrystallisation (Scheme 3.02).  
 
Next, the required sulfonylcarbamates 219, a synthetic precursor of N-Boc aldimines 
were readily prepared following a modified literature procedure77 using tert-butyl 
carbamate (218), various commercially available aromatic and aliphatic aldehydes 
and sodium benzenesulfinate or sodium 4-methylbenzenesulfinate suspended in a 

















With the sulfonylcarbamates in hand, the corresponding N-Boc aldimines (206a-
206n) were synthesised in excellent yields through the elimination of ArSO2H under 












3.5 Ligand Screen and Optimisations 
  
With both sets of substrates in hand, investigations began into the enantioselective 
CuH-catalysed reductive coupling of 2-alkenylazaarenes with N-Boc aldimines. 
First, an evaluation of various chiral bisphosphines was performed in order to 
determine the optimum ligand for this process. For ligand evaluation, 2-
vinylquinoline (175b) was selected as the azaarene substrate and phenyl N-boc imine 
(206a) was selected as imine coupling partner. The initial ligand screen was 
performed under similar reaction conditions to those used in the previous study of 
enantioselective copper-catalysed reductive coupling of alkenylazaarenes with 

























Table 3.02: Evaluation of Chiral Bisphosphines for the Cu-Catalysed Reductive Coupling of 
2-Vinylquinoline with N-Boc Iminea 
 
Entry Ligand 212a:220b drb ee (%)c 
1 L7 9:1 5:1 51 
2 L8 19:1 6:1 56 
3 L9 5:1 13:1 33 
4 L10 6:1 19:1 25 
5 L11 13:1 19:1 45 
6 L12 19:1 19:1 1 
7 L13 19:1 19:1 79 
8 L14 18:1 19:1 69 
9 L15 19:1 19:1 82 
aReactions were conducted using 0.1 mmol of 175b. bDetermined by 1H NMR analysis of the unpurified reaction 




Pleasingly, most ligands evaluated showed promising chemoselectivity (in terms of 
the ratio of product to reduced starting material), diastereo- and enantioselectivity. 
With (S)-PhanePhos (L7), a Taniaphos ligand (L8) and a Josiphos ligand (L9) both 
enantioselectivity and diastereoselectivity were moderate. High diastereoselectivities 
were obtained with L10-L15 (entries 4 to 9); however, only good enantioselection 
were observed with (R,R)-Ph-BPE (L13), the Josiphos ligand (L14) and (S)-DTBM-
Segphos (L15). (S)-DTBM-Segphos (L15) was identified as the most effective chiral 
ligand for this reaction as it also displayed high chemoselectivity (ratio of 212a:220) 
combined with high enantio- and diastereoselectivities.  
 
Reaction optimisation studies were conducted by my co-worker Aakarsh Saxena. 
With regards to the hydride source, all those evaluated gave excellent 
diastereoselectivities (Table 3.03). Modest enantioselectivities were observed using 
poly(methylhydrosiloxane) (PMHS) and Ph2SiH2. PhSiH3 and pinacolborane both 
provided products with good enantioselectivities; however enantioselectivity was 
superior when employing 1,1,3,3-tetramethyldisiloxane (TMDS). The use of 
(EtO)3SiH as hydride showed significant quantities of the 2-vinylquinoline in the 
1H 
NMR spectrum of the unpurified reaction mixture and no identifiable peaks 
corresponding to the coupled product were observed.  
 








Entryb Hydride drc ee (%)d 
1 PhSiH3 19:1 81 
2 TMDS 19:1 87 
3 PMHS 19:1 75 
4 (EtO)3SiH -- -- 
5 Ph2SiH2 19:1 68 
6 (pin)BH 19:1 81 
aReactions were conducted using 0.1 mmol of 175b. b Reaction performed by Aakarsh Saxena. cDetermined by 1H 
NMR analysis of the unpurified reaction mixtures. dDetermined by chiral HPLC analysis. 
 
With respect to the solvent; THF, Et2O, toluene and 1,4-dioxane all afforded product 
212a with high diastereoselectivities and good enantioselectivities (Table 3.04). 
However, THF was the only solvent which gave complete dissolution of all the 
reagents at the start of the reaction; therefore, THF was chosen as the preferred 
solvent for this process. 
 
Table 3.04: Evaluation of Solventa 
 
Entryb Solvent drc ee (%)d 
1 Et2O 19:1 76 
2 THF 19:1 85 
3 toluene 19:1 87 
4 CH2Cl2 -- -- 
5 1,4-dioxane 19:1 88 
aReactions were conducted using 0.1 mmol of 175b. . b Reaction performed by Aakarsh Saxena. cDetermined by 1H 




3.5.1  Substrate Scope 
 
Application of the optimised conditions to the reaction of various 2-vinylazaarenes 
with phenyl N-Boc-protected imine 206a gave the reductive coupled products in 
good yields and good to high enantio- and diastereoselectivities (Scheme 3.08).  
 
 
Scheme 3.08: Reductive Coupling of Vinylazaarenes with N-Boc imine 206a 
 
In the presence of Cu(OAc)2·H2O (5 mol%), L15 (5 mol%) and TMDS (1.2 equiv), 
the reaction proceeded smoothly in THF at room temperature to give the reductive 
coupling product 212a as the anti-diastereomer in 63% yield, excellent 
diastereoselectivity (>19:1 dr) and good enantioselectivity (85% ee). Other effective 




(212d), benzoxazole (212e) and benzothiazole (212f). Vinylazaarenes containing 
benzannulation gave products with notably higher diastereoselectivities (products 
212a, 212b, 212e and 212f), while 6-bromopyridine and 3-phenyl-6-vinylpyridazine 
resulted in more modest diastereoselectivities (212c and 212d). In the case of 6-
bromo-2-vinylpyridine the diastereomers were difficult to separate completely and 
the minor isomer was formed in a much lower enantiomeric excess (20% ee) 
compared with the major isomer (80% ee). 
 
The relative and absolute stereochemistry of benzothiazole-containing product 212f 
was determined by single crystal X-ray crystallography using a copper radiation 
source (Figure 3.01). The absolute and relative configurations of 212a-212e were 
assigned by analogy with that observed in 212f. 
 
 














Subsequently, the focus shifted to broadening the scope of the reaction to include 
various (hetero)aromatic N-Boc aldimines 206b-206l (Scheme 3.09 and Scheme 
3.10). Aromatic imines with substituents at the ortho-, meta- and para-positions on 
the phenyl ring (such as methyl, chloro, trifluoromethyl or methoxy) underwent the 
addition reaction successfully with a range of different 2-vinylazaarenes in modest 
yields and moderate to high enantio- and diastereoselectivities. Furthermore, 
reactions of imines containing 1-naphthyl, 2-naphthyl, 2-thienyl, dioxolane or 
boronate esters were also successful.  For 2-vinylquinoline-containing products 
(221a-221c), all imines evaluated gave modest yields, high diastereoselectivities and 
good enantioselectivities. Quinoxaline-containing products (221d-221e) 
demonstrated the reaction tolerated N-Boc imines with electron-withdrawing groups 
(221d) and electron-donating groups (221e) on the aryl ring. However, a noticeable 
decrease in diastereoselectivity was observed when an imine encompassing an 
electron-withdrawing group is employed (e.g. adduct 221d vs. 221e and 221f). 
Diastereoselectivities were generally lower for benzoxazole-containing products 
(221g-221i) compared with quinoline-containing and quinoxaline-containing 
products.  Excellent enantioselectivities were observed for benzothiazoles-containing 
products when coupled with a para- substituent on the imine (product 221k) or 1-








As observed previously (Scheme 3.08), the reactions of non-benzannulated 
azaarenes; 2-bromo-6-vinylpyridine and 3-phenyl-6-vinylpyridazine generally gave 
lower diastereoselectivities (products 221n-221s) as shown in Scheme 3.10. Lower 
diastereoselectivities were also obtained with an imine containing a p-pinacol 
boronic ester (221m and 221p). Interestingly, the minor diastereomers obtained for 
products 221n and 221p were obtained in low or non-existent enantiomeric excesses.  
 
Scheme 3.10: Reductive Coupling of Vinyl-Pyridines and Pyridazines 175 with Various N-
Boc Imines 
 
Compared with the results shown in Scheme 3.07 and with similar reactions using 
ketones as electrophiles,10c these reactions often provided lower yields of the 
reductive coupling products due to more prevalent side reactions, such as reduction 
of both reaction partners without C-C bond formation. Although no definitive trends 




highest enantioselectivities, values of 85% enantiomeric excess or higher were 
observed in several cases (221a, 221c, 221d, 221k-221m, 221p 221r).  
 
The relative and absolute stereochemistry of quinoxaline-containing product 221d 
and pyridazine-containing product 221r was determined by single crystal X-ray 
crystallography using a copper radiation source (Figure 3.02). The relative and 
absolute configurations of 221a-221c, 221e-221p and 221s were assigned by analogy 
to that observed in 221d and 221r which was also consistent with the observed sense 









The reductive coupling of 4-phenyl-2-vinylthiazole (175j) with imines 206a and 206l 
proceeded with low enantioselectivity using ligand L15. Fortunately, (R,R)-Ph-BPE 
(L13) provided improved results and gave 221t in 88% yield, >19:1 dr, and 87% ee 
and 221u with 83% yield, >19:1 dr and 78% ee (Scheme 3.11).  
 
 
Scheme 3.11: Reductive coupling of 175j with Various N-Boc Imines using L13 
 
Again, X-ray crystallography confirmed the relative and absolute stereochemistry of 








The reaction of 2-vinylbenzothiazole (175k) with an imine 206m (2.0 equiv) 
containing an aliphatic substituent (cyclohexyl) was also studied (Scheme 3.12). 
Although low enantioselectivities were obtained using ligands L13 or L15, the 
Josiphos ligand SL-J006-1 (L14) gave improved results and provided the two 
diastereomers of 221v  in 73% and 16% yields, in 82% and 74% enantiomeric excess 
for the major and minor isomers, respectively.  
 
 
Scheme 3.12: Reductive coupling of 175k with 206m using L12 
 
3.5.2  Larger Scale Reaction and Deprotection 
 
It is also possible to conduct this process on a larger scale. For example, reductive 
coupling of 2-vinylquinoxaline (175d) on a 3.00 mmol scale using N-Boc imine 206a 
(1.1 equiv) in the presence of CuO(Ac)2·H2O (5 mol%), (S)-DTBM-SEGPHOS (5 
mol%) and TMDS (1.2 equiv) provided  212b in 69% yield (750 mg) and 75% ee 
(Scheme 3.13) (cf 69% yield and 92% ee on a 0.3 mmol scale see Scheme 3.07). The 
significant drop in enantioselectivity could be attributed to the uneven cooling of the 
reaction vessel. Rapid addition of the organosilane may have also resulted in an 
exotherm thereby raising the temperature of the reaction mixture, which could result 









Scheme 3.13: Larger Scale Enantioselective Cu-Catalysed Reductive Coupling of 175d with 
Phenyl N-Boc Imine 206a 
 
Finally the removal of the Boc group from 221a was achieved under acidic 
conditions (using HCl generated by the reaction of TMSCl with MeOH), which 
provided the amine 222 in 90% yield with no loss of enantiopurity (Scheme 3.14).  
 
 
Scheme 3.14: Deprotection of 221a 
 
3.6  Exploration of β-Substituted Alkenylazaarenes 
 
Initial investigations into β-substituted alkenylazaarenes were briefly explored as 
reductive coupling partners using conditions established for vinylazaarenes in the 
preceding discussions (Scheme 3.15). Initial reactions were promising; with the 
desired coupled product obtained with various β-substituted alkenylazaarenes and N-
Boc imines. However, chemoselectivity between the desired coupled product 223 
and the reduction product 224 was very poor. The diastereoselectivities and 





Scheme 3.15: Reductive Coupling of β-Substituted Alkenylazaarenes with N-Boc Imine 206 
 
Using the reaction between β-substituted alkenylazaarene 179f and N-Boc imine 
206a, attempts were made to improve the chemoselectivity of the reaction (Table 
3.04). Increasing the equivalents of the hydride source TMDS did not result in any 
significant improvements in terms of chemoselectivity. Changing the hydride source 
to PhSiH3 saw a slight increase in the ratio of reduction product 224a to coupled 
product 223a.  Increasing the equivalents of imine 206a to 2.5 equivalents saw an 
improvement in the chemoselectivity (entries 7 to 9) towards the coupled product; 
however, conversion was also adversely affected. Further investigations are required 
















223a: 224ab drb of 223a ee of 223a (%)c 
1 TMDS 1.2 1.1 >95 2.2:1 19:1 82 
2 TMDS 1.4 1.1 >95 2.1:1 19:1 83 
3 TMDS 1.6 1.1 >95 1.7:1 19:1 82 
4 PhSiH3 1.2 1.1 >95 1.7:1 19:1 82 
5 PhSiH3 1.4 1.1 >95 1.9:1 19:1 84 
6 PhSiH3 1.6 1.1 >95 1.8:1 19:1 79 
7 PhSiH3 1.4 1.5 >95 2.4:1 19:1 86 
8 PhSiH3 1.4 2.0 80 2.5:1 19:1 87 
9 PhSiH3 1.4 2.5 70 5: 1 19:1 84 
aReactions were conducted using 0.1 mmol of 179f. bDetermined by 1H NMR analysis of the unpurified reaction 















3.7  Conclusions and Future Work 
 
In summary, an enantioselective copper-catalysed reductive coupling of 
vinylazaarenes with N-Boc aldimines has been developed.33 The results demonstrate 
the ability of chiral copper-bisphosphine complexes to catalyse the enantioselective 
reductive coupling of vinylazaarenes with hetero(aryl) N-Boc imines. The reactions 
provide reductive coupling products with moderate to high enantioselectivities. 
Compatible azaarenes included quinoline, quinoxaline, bromo-pyridine, pyridazine, 
benzoxazole, benzothiazole and thiazole. A range of aromatic imines were shown to 
be effective coupling partners with substituents at the ortho-, meta- and para-
positions on the phenyl ring (such as methyl, chloro, trifluoromethyl or methoxy) 
(Scheme 3.16). Reactions of imines containing 1-naphthyl, 2-naphthyl, 2-thienyl, 
dioxolane or boronate esters were also successful. The reaction is also compatible 
with aliphatic imines. In addition, successful deprotection of the Boc-group enabled 
rapid synthesis of the corresponding chiral free amine with no loss of enantiopurity. 
 
 
Scheme 3.16: Reductive Coupling of Vinylazaarenes with N-Boc Imines 
 
The use of β-substituted alkenylazaarenes were briefly explored and showed 
promising results (high enantioselectivies and diastereoselectivities obtained for 
some substrates). However, further screening and reaction optimisations are required 
to develop it into an efficient reaction.  
 
In both projects; the enantioselective copper-catalysed reductive coupling of 
alkenylazaarenes with ketones and the enantioselective copper-catalysed reductive 




organosilanes were employed which creates a stoichiometric amount of silyl waste at 
the end of the reaction. On an industrial scale the removal of stoichiometric waste 
can be difficult and costly. Future work in this area could be to explore the use of 
molecular hydrogen (cheap, non-toxic and no stoichiometric waste formed) as the 
hydride source whilst still employing a cheap and earth abundant metal such as 




















































4.  EXPERIMENTAL 
 
4.1 Enantioselective Copper-Catalysed Reductive Coupling of 




THF and toluene were dried and purified by passage through activated alumina 
columns using a solvent purification system. All commercially available reagents 
were used as received. Thin layer chromatography (TLC) was performed on Merck 
DF-Alufoilien 60F254 0.2 mm precoated plates. Product spots were visualized by UV 
light at 254 nm, and subsequently developed using vanillin, potassium permanganate, 
or ceric ammonium molybdate solution as appropriate. Flash column 
chromatography was carried out using silica gel (Fisher Scientific 60Å particle size 
35-70 micron) employing the method of Still and co-workers.78 Melting points were 
recorded on a Gallenkamp melting point apparatus and are uncorrected. Infra-red 
spectra were recorded on a Jasco FT/IR-460 Plus instrument as a thin film on sodium 
chloride plates or as a dilute solution in CHCl3. 
1H NMR spectra were recorded on a 
Bruker AV500 (500 MHz), a Bruker AVA400 (400 MHz) spectrometer, or a Bruker 
OPEN400 (400 MHz) spectrometer. Chemical shifts () are quoted in parts per 
million (ppm) downfield of tetramethylsilane, using residual protonated solvent as 
internal standard (CDCl3 at 7.27 ppm). Abbreviations used in the description of 
resonances are: s (singlet), d (doublet), t (triplet), q, (quartet), app (apparent), br 
(broad). Coupling constants (J) are quoted to the nearest 0.1 Hz. Proton-decoupled 
13C NMR spectra were recorded on a Bruker AV500 (125.8 MHz) spectrometer or a 
Bruker AVA400 (100.6 MHz) spectrometer. Chemical shifts () are quoted in parts 
per million (ppm) downfield of tetramethylsilane, using deuterated solvent as internal 
standard (CDCl3 at 77.0 ppm). Assignments were made using the DEPT sequence 
with secondary pulses at 90° and 135°. Proton-decoupled 19F NMR spectra were 




reported in parts per million (ppm) downfield of CFCl3, using fluorobenzene as 
internal standard (C6H5F at –113.2 ppm). High resolution mass spectra were recorded 
on a Finnigan MAT 900 XLT spectrometer or a Finnigan MAT 95XP spectrometer 
at the EPSRC National Mass Spectrometry Service Centre, University of Wales, 
Swansea, or on a Finnigan MAT 900 XLT spectrometer at the School of Chemistry, 
University of Edinburgh. Optical rotations were performed on an Optical Activity 
POLAAR 20 polarimeter. Chiral HPLC analysis was performed on an Agilent 1100 
instrument using 4.6 x 250 mm columns. Authentic racemic samples of products for 
chiral HPLC assay determinations were obtained using rac-BINAP as the ligand. 
 
Preparation of Potassium Vinyltrifluoroborate (173)  
 
To a solution of trimethyl borate (6.90 mL, 62.0 mmol) in THF (45 mL) was added 
dropwise vinylmagnesium bromide 174 (1.0 M THF solution, 50 mL, 50 mmol) at –
78 °C. The resulting suspension was stirred for 20 min at –78 °C and then allowed to 
warm to room temperature for 1 h. The mixture was then cooled to 0 °C and KHF2 
(19.0 g, 248 mmol) was added followed by the addition of water (35 mL) over 30 
min. After stirring at room temperature for 20 min, the solution was concentrated and 
the crude material was dissolved in acetone, filtered and concentrated. The resulting 
white solid was purified by dissolving in hot acetone and precipitating with Et2O, to 
give potassium trifluoroboroate (173) (6.35 g, 95%) as a white solid. 1H NMR (400 
MHz, (CD3)2OC) )  5.83 (1H, ddq, JHH = 19.7, 13.5 and JHB = 3.7 Hz, CH=CH2), 
5.30-5.18 (1H, m, CH=CH2), 5.16-5.04 (1H, m, CH=CH2); 
13C NMR (100.6 MHz, 
(CD3)2OC))  120.6 (q, JCB = 4.6 Hz); 
19F NMR (377 MHz, (CD3)2OC))  −142.8 
(dd, J = 104.5, 46.0 Hz). 1H NMR, 13C NMR and 19F NMR data were consistent with 









4.1.1 Preparation of Alkenylazaarenes 
 






2-Vinylquinoline (175b)  
 
A solution of 2-chloroquinoline (1.64 g, 10.0 mmol), potassium vinyltrifluoroborate 
(1.61 g, 12.0 mmol), PdCl2(dppf)·CH2Cl2 (163 mg, 0.200 mmol), and Et3N (1.4 mL, 
10 mmol) in i-PrOH (156 mL) was heated to reflux for 16 h. The mixture was cooled 
to room temperature and partitioned between CH2Cl2 (100 mL) and H2O (40 mL). 
The aqueous layer was separated and extracted with CH2Cl2 (2 × 50 mL) and the 
combined organic layers were washed with brine (100 mL), dried (MgSO4), filtered, 
and concentrated in vacuo. Purification of the residue by column chromatography 
(5% EtOAc/hexane) gave vinylquinoline 175b (1.26 g, 81%) as a pale yellow oil. 1H 
NMR (500 MHz, CDCl3)  8.13 (1H, d, J = 8.6 Hz, ArH), 8.08 (1H, d, J = 8.5 Hz, 
ArH), 7.79 (1H, d, J = 8.1 Hz, ArH), 7.71 (1H, ddd, J = 8.4, 6.9, 1.4 Hz, ArH), 7.62 
(1H, d, J = 8.6 Hz, ArH), 7.54-7.48 (1H, m, ArH), 7.05 (1H, dd, J = 17.4, 10.9 Hz, 
CH=CH2), 6.29 (1H, dd, J = 17.4, 0.6 Hz, CH=CH2), 5.68 (1H, dd, J = 10.9, 0.7 Hz, 
CH=CH2); 
13C NMR (125.8 MHz, CDCl3)  156.1 (C), 148.0 (C), 138.0 (CH), 136.4 
(CH), 129.6 (CH), 129.4 (CH), 127.48 (CH), 127.45 (C), 126.3 (CH), 119.8 (CH2), 







1-Vinylisoquinoline (175c)  
 
 A solution of 1-chloroisoquinoline (1.31 g, 8.00 mmol), potassium 
vinyltrifluoroborate (1.29 g, 9.60 mmol), PdCl2(dppf)·CH2Cl2 (131 mg, 0.160 
mmol), and Et3N (1.1 mL, 8.0 mmol) in i-PrOH (110 mL) was heated to reflux for 16 
h. The mixture was cooled to room temperature and partitioned between CH2Cl2 (50 
mL) and H2O (40 mL). The aqueous layer was separated and extracted with CH2Cl2 
(2 × 50 mL) and the combined organic layers were washed with brine (50 mL), dried 
(MgSO4), filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (5%→20% EtOAc/hexane) gave vinylisoquinoline 175c (812 mg, 
65%) as a dark brown oil. 1H NMR (500 MHz, CDCl3) δ 8.54 (1H, d, J = 5.6 Hz, 
ArH), 8.27 (1H, dd, J = 8.5, 0.7 Hz, ArH), 7.82 (1H, d, J = 8.2 Hz, ArH), 7.72 – 
7.56 (4H, m, ArH & CH=CH2), 6.53 (1H, dd, J = 17.0, 1.9 Hz, CH=CH2), 5.73 (1H, 
dd, J = 10.8, 1.9 Hz, CH=CH2); 
13C NMR (125.8 MHz, CDCl3) δ 154.9 (C), 142.3 
(CH), 136.6 (C), 132.1 (CH), 129.9 (CH), 127.2 (CH), 127.2 (CH), 126.4 (C), 124.7 
(CH), 121.8 (CH2), 120.3 (CH). 
1H NMR and 13C NMR data were consistent with 
those reported previously.80  
 
2-Vinylquinoxaline (175d)  
 
A solution of 2-chloroquinoxaline (1.32 g, 8.00 mmol), potassium 
vinyltrifluoroborate (1.29 g, 9.60 mmol), PdCl2(dppf)·CH2Cl2 (131 mg, 0.160 
mmol), and Et3N (1.1 mL, 8.0 mmol) in i-PrOH (125 mL) was heated to reflux for 16 
h. The mixture was cooled to room temperature and partitioned between CH2Cl2 (50 
mL) and H2O (40 mL). The aqueous layer was separated and extracted with CH2Cl2 
(2 × 50 mL) and the combined organic layers were washed with brine (50 mL), dried 
(MgSO4), filtered, and concentrated in vacuo. Purification of the residue by column 




as an orange oil. 1H NMR (500 MHz, CDCl3)  9.01 (1H, s, ArH), 8.12-8.01 (2H, m, 
ArH), 7.77 (1H, dd, J = 8.4, 6.9, 1.6 Hz, ArH), 7.73 (1H, dd, J = 8.4, 6.9, 1.8 Hz, 
ArH), 7.05 (1H, dd, J = 17.0, 11.1 Hz, CH=CH2), 6.49 (1H, dd, J = 17.0, 0.5 Hz, 
CH=CH2), 5.80 (1H, dd, J = 11.1, 0.5 Hz, CH=CH2); 
13C NMR (125.8 MHz, CDCl3) 
 150.5 (C), 143.6 (CH), 142.2 (C), 141.8 (C), 134.8 (CH), 130.3 (CH), 129.5 (CH), 
129.4 (CH), 129.1 (CH), 122.1 (CH2). 
1H NMR and 13C NMR data were consistent 




A solution ethyl-2-chloronicotinate (928 mg, 5.00 mmol), potassium 
vinyltrifluoroborate (804 mg, 6.00 mmol), PdCl2(dppf)·CH2Cl2 (82 mg, 0.10 mmol), 
and Et3N (0.5 mL, 5.0 mmol) in i-PrOH (80 mL) was heated to reflux for 16 h. The 
mixture was cooled to room temperature and partitioned between CH2Cl2 (100 mL) 
and H2O (40 mL). The aqueous layer was separated and extracted with CH2Cl2 (2 × 
50 mL) and the combined organic layers were washed with brine (100 mL), dried 
(MgSO4), filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (5% EtOAc/hexane) gave the vinylnicotinate 175e (804 mg, 91%) 
as a dark yellow oil. IR (film) 2982, 1722 (C=O), 1581, 1557, 1437, 1263, 1140, 
1073, 990, 940, 797, 743 cm‒1; 1H NMR (500 MHz, CDCl3)  8.69 (1H, dd, J = 4.7, 
1.8 Hz, ArH), 8.15 (1H, dd, J = 7.9, 1.8 Hz, ArH), 7.62 (1H, dd, J = 17.0, 10.7 Hz, 
CH=H), 7.23 (1H, dd, J = 7.9, 4.7 Hz, ArH), 6.49 (1H, dd, J = 17.0, 2.2 Hz, 
CH=CH2), 5.59 (1H, dd, J = 10.7, 2.2 Hz, CH=CH2), 4.39 (2H, q, J = 7.1 Hz, 
OCH2CH3), 1.4 (3H, t, J = 7.1 Hz, OCH2CH3); 
13C NMR (125.8 MHz, CDCl3)  
166.4 (C), 155.0 (C), 151.9 (CH), 138.4 (CH), 133.8 (CH), 124.6 (C), 121.8 (CH), 
121.4 (CH2), 61.5 (CH2), 14.2 (CH3);  m/z (EI) 177.1 ([M+H]
+, 100). 1H and 13C 







Ethyl 6-vinylpyridine-3-carboxylate (175f) 
 
 A solution of ethyl-6-chloronicotinate (1.48 g, 8.00 mmol), potassium 
vinyltrifluoroborate (1.29 g, 9.60 mmol), PdCl2(dppf)·CH2Cl2 (131 mg, 0.160 
mmol), and Et3N (1.1 mL, 8.0 mmol) in i-PrOH (125 mL) was heated to reflux for 16 
h. The mixture was cooled to room temperature and partitioned between CH2Cl2 (100 
mL) and H2O (40 mL). The aqueous layer was separated and extracted with CH2Cl2 
(2 × 50 mL) and the combined organic layers were washed with brine (100 mL), 
dried (MgSO4), filtered, and concentrated in vacuo. Purification of the residue by 
column chromatography (5% EtOAc/hexane) gave vinylpyridine 175f (1.30 g, 92%) 
as a pale orange oil. IR (film) 2938, 1722 (C=O), 1595, 1368, 1287, 1115, 1025, 856, 
800, 741 cm‒1; 1H NMR (500 MHz, CDCl3)  9.17 (1H, d, J = 1.8 Hz, ArH), 8.25 
(1H, dd, J = 8.2, 2.2 Hz, ArH), 7.40 (1H, d, J = 8.2 Hz, ArH), 6.87 (1H, dd, J = 
17.5, 10.8 Hz, CH=CH2), 6.34 (1H, dd, J = 17.5, 1.0 Hz, CH=CH2), 5.62 (1H, dd, J 
= 10.8, 1.0 Hz, CH=CH2), 4.41 (2H, q, J = 7.1 Hz, OCH2CH3), 1.41 (3H, t, J = 7.1 
Hz, OCH2CH3); 
13C NMR (125.8 MHz, CDCl3)  165.2 (C), 159.1 (C), 150.8 (CH), 
137.6 (CH), 136.2 (CH), 124.8 (C), 120.9 (CH2), 120.6 (CH), 61.3 (CH2), 14.3 






A solution of 2-chloro-4,6-methoxypyrimidine (1.40 g, 8.00 mmol), potassium 
vinyltrifluoroborate (1.29 g, 9.60 mmol), PdCl2(dppf)·CH2Cl2 (131 mg, 0.160 
mmol), and Et3N (1.1 mL, 8.0 mmol) in i-PrOH (125 mL) was heated to reflux for 16 
h. The mixture was cooled to room temperature and partitioned between CH2Cl2 (100 
mL) and H2O (40 mL). The aqueous layer was separated and extracted with CH2Cl2 




dried (MgSO4), filtered, and concentrated in vacuo. Purification of the residue by 
column chromatography (5% EtOAc/hexane) gave the vinylpyrimidine 175g (1.00 g, 
75%) as a pale yellow oil. IR (film) 2953, 1583, 1396, 1378, 1261, 1191, 1164, 1043, 
987, 830 cm‒1; 1H NMR (500 MHz, CDCl3)  6.70 (1H, dd, J = 17.3, 10.2 Hz, 
CH=CH2), 6.60 (1H, dd, J = 17.3, 2.2 Hz, CH=CH2), 5.92 (1H, s, ArH), 5.68 (1H, 
dd, J = 10.2, 2.2 Hz, CH=CH2), 3.97 (6H, s, 2 × OCH3); 
13C NMR (125.8 MHz, 
CDCl3)  171.3 (2 × C), 163.3 (C), 136.5 (CH), 123.6 (CH2), 88.0 (CH), 53.9 (2 × 
CH3); HRMS (ESI) Exact mass calcd for C8H11N2O2 [M+H]







 A solution of 6-chloro-2,4-methoxypyrimidine (1.40 g, 8.00 mmol), potassium 
vinyltrifluoroborate (1.29 g, 9.60 mmol), PdCl2(dppf)·CH2Cl2 (131 mg, 0.160 
mmol), and Et3N (1.1 mL, 8.0 mmol) in  i-PrOH (125 mL) was heated to reflux for 
16 h. The mixture was cooled to room temperature and partitioned between CH2Cl2 
(100 mL) and H2O (40 mL). The aqueous layer was separated and extracted with 
CH2Cl2 (2 × 50 mL) and the combined organic layers were washed with brine (100 
mL), dried (MgSO4), filtered, and concentrated in vacuo. Purification of the residue 
by column chromatography (5% EtOAc/hexane) gave vinylpyrimidine 175h (1.07 g, 
80%) as a pale yellow oil. IR (film) 2954, 1557, 1456, 1337, 1204, 1106, 1031, 840, 
791, 598 cm‒1; 1H NMR (500 MHz, CDCl3)  6.60 (1H, dd, J =17.2, 10.4 Hz, 
CH=CH2), 6.46 (1H, dd, J = 17.2, 1.7 Hz, CH=CH2), 6.29 (1H, s, ArH), 5.58 (1H, 
dd, J = 10.4, 1.7 Hz, CH=CH2), 4.02 (3H, s, OCH3), 3.98 (3H, s, OCH3); 
13C NMR 
(125.8 MHz, CDCl3)  172.4 (C), 165.3 (C), 164.1 (C), 134.7 (CH), 121.9 (CH2), 
99.3 (CH), 54.6 (CH3), 53.9 (CH3); HRMS (ESI) Exact mass calcd for C8H11N2O2 





2-Vinyl-nicotinitrile (175i)   
 
A solution 2-chloro-3-pyridine carbon nitrile (1.11 g, 8.00 mmol), potassium 
vinyltrifluoroborate (1.29 g, 9.60 mmol), PdCl2(dppf)·CH2Cl2 (131 mg, 0.160 
mmol), and Et3N (1.1 mL, 8.0 mmol) in i-PrOH (125 mL) was heated to reflux for 16 
h. The mixture was cooled to room temperature and partitioned between CH2Cl2 (100 
mL) and H2O (40 mL). The aqueous layer was separated and extracted with CH2Cl2 
(2 × 50 mL) and the combined organic layers were washed with brine (100 mL), 
dried (MgSO4), filtered, and concentrated in vacuo. Purification of the residue by 
column chromatography (5% EtOAc/hexane) gave vinylnicotinitrile 175i as pink 
solid (847 mg, 81%). IR (film) 3048 (=CH), 2227 (C≡N), 1577, 1553, 1442, 1393, 
1098, 982, 947, 795 cm‒1; 1H NMR (500 MHz, CDCl3)  8.77 (1H, dd, J = 4.8, 1.7 
Hz, ArH), 7.93 (1H, dd, J =7.9, 1.8 Hz, ArH), 7.29 (1H, dd, J =7.9, 4.8 Hz, ArH), 
7.20 (1H, dd, J =16.9, 10.7 Hz, CH=CH), 6.67 (1H, dd, J =16.9, 1.9 Hz, CH=CH2), 
5.76 (1H, dd, J =10.7, 1.5 Hz, CH=CH2); 
13C NMR (125.8 MHz, CDCl3)  157.1 
(C), 152.7 (CH), 140.4 (CH), 132.0 (CH), 123.9 (CH2), 122.0 (CH), 116.4 (C), 107.6 
(C); m/z (EI) 130.1 ([M+H]+, 100). 
 
2-Vinyl-4-phenyl-1,3-thiazole (175j)  
 
A solution of 2-bromo-4-phenylthiazole (1.92 g, 8.00 mmol), potassium 
vinyltrifluoroborate (1.29 g, 9.60 mmol), PdCl2(dppf)·CH2Cl2 (131 mg, 0.160 
mmol), and Et3N (1.1 mL, 8.0 mmol) in i-PrOH (125 mL) was heated to reflux for 16 
h. The mixture was cooled to room temperature and partitioned between CH2Cl2 (100 
mL) and H2O (40 mL). The aqueous layer was separated and extracted with CH2Cl2 
(2 × 50 mL) and the combined organic layers were washed with brine (100 mL), 
dried (MgSO4), filtered, and concentrated in vacuo. Purification of the residue by 




as a green solid. m.p. 28-30 C; IR (film) 3111, 1602, 1485, 1443, 1079, 978, 919, 
852, 737, 705 cm‒1; 1H NMR (500 MHz, CDCl3)  7.91 (2H, dt, J = 8.2, 1.6 Hz, 
ArH), 7.46-7.41 (2H, m, ArH), 7.40 (1H, s, ArH), 7.37-7.33 (1H, m, ArH), 7.00 (1H, 
ddd, J = 17.5, 10.9, 0.5 Hz, CH=CH2), 6.11 (1H, d, J =17.5 Hz, CH=CH2), 5.59 
(1H, d, J = 10.9 Hz, CH=CH2); 
13C NMR (125.8 MHz, CDCl3)  166.9 (C), 156.0 
(C), 134.3 (C), 130.6 (CH), 128.7 (2 × CH), 128.2 (CH), 126.4 (2 × CH), 119.9 





A solution 2-bromobenzothiazole (1.00 g, 4.67 mmol), potassium 
vinyltrifluoroborate (0.75 g, 5.61 mmol), PdCl2(dppf)·CH2Cl2 (76 mg, 0.09 mmol), 
and Et3N (0.65 mL, 4.67 mmol) in i-PrOH (60 mL) was heated to reflux for 16 h. 
The mixture was cooled to room temperature and partitioned between CH2Cl2 (50 
mL) and H2O (20 mL). The aqueous layer was separated and extracted with CH2Cl2 
(2 × 50 mL) and the combined organic layers were washed with brine (50 mL), dried 
(MgSO4), filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (5% EtOAc/hexane) gave vinylbenzothiazole 175k (530 mg, 70%) 
as a pale yellow amorphous solid. Rf 0.43 (10% EtOAc/ petroleum ether); IR (film) 
3060 (CH=CH2), 2359, 1489, 1437, 1312, 1108, 984, 927, 758, 728 cm
‒1; 1H NMR 
(500 MHz, CDCl3)  8.01 (1H, dd, J = 7.7, 0.5 Hz, ArH), 7.86 (1H, ddd, J = 7.9, 1.1, 
0.6 Hz, ArH), 7.48 (1H, ddd, J = 8.3, 7.3, 1.2 Hz, ArH), 7.39 (1H, ddd, J = 8.3, 7.3, 
1.2 Hz, ArH), 7.06 (1H, dd, J = 17.5, 10.9 Hz, CH=CH2), 6.20 (1H, d, J =17.5 Hz, 
CH=CH2), 5.78 (1H, d, J =10.9 Hz, CH=CH2); 
13C NMR (125.8 MHz, CDCl3)  
167.2 (C), 153.6 (C), 134.3 (C), 131.4 (CH), 126.3 (CH), 125.6 (CH), 123.3 (CH), 
123.2 (CH2), 121.6 (CH); HRMS (ESI) Exact mass calcd for C9H8NS [M+H]+ : 







2-Vinyl-1,3-benzoxazole (175l)  
 
A solution 2-chlorobenzoxazole (768 mg, 5.00 mmol), potassium 
vinyltrifluoroborate (800 mg, 6.00 mmol), PdCl2(dppf)·CH2Cl2 (82 mg, 0.08 mmol), 
and Et3N (0.7 mL, 5.0 mmol) in i-PrOH (80 mL) was heated to reflux for 16 h. The 
mixture was cooled to room temperature and partitioned between CH2Cl2 (50 mL) 
and H2O (20 mL). The aqueous layer was separated and extracted with CH2Cl2 (2 × 
50 mL) and the combined organic layers were washed with brine (50 mL), dried 
(MgSO4), filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (5% EtOAc/hexane) gave vinylbenzoxazole 175l (726 mg, 67%) as a 
colourless oil. 1H NMR (500 MHz, CDCl3)  7.77-7.67 (1H, m, ArH), 7.56-7.47 
(1H, m, ArH), 7.40-7.29 (2H, m, ArH), 6.77 (1H, dd, J = 17.6, 11.1 Hz, CH=CH2), 
6.48 (1H, dd, J = 17.6, 1.0 Hz, CH=CH2), 5.86 (1H, dd, J = 11.1, 1.0 Hz, CH=CH2); 
13C NMR (125.8 MHz, CDCl3)  162.0 (C), 150.3 (C), 141.8 (C), 125.4 (CH), 125.3 
(CH2), 124.5 (CH), 123.9 (CH), 120.2 (CH), 110.5 (CH). 
1H and 13C NMR data were 
consistent with those reported previously.83  
 
4.1.2 Preparation of Alkenylboronic Esters 
 
4,4,5,5-Tetramethyl-2-[(E)-4-phenylbut-1-enyl]-[1,3,2]dioxaborolane (178a)  
 
To a mixture of 4-phenylbut-1-yne (5.62 mL, 40.0 mmol), Cp2ZrHCl (292 mg, 1.00 
mmol), and Et3N (0.56 mL, 4.00 mmol) at room temperature was added 
pinacolborane (5.80 mL, 40.0 mmol) over 2 min, and the mixture was stirred for 16 
h. The reaction was quenched carefully with H2O (75 mL) and after effervescence 
had ceased, the mixture was extracted with Et2O (2 × 100 mL). The combined 
organic extracts were dried (MgSO4), filtered, and concentrated in vacuo. 




alkenylboronic ester 178a (7.86 g, 76%) as a colourless oil. 1H NMR (500 MHz, 
CDCl3)  7.39-7.35 (2H, m, ArH), 7.30-7.26 (3H, m, ArH) 6.81 (1H, dt, J = 18.0, 
6.2 Hz, CH=CHCH2), 5.61 (1H, dt, J = 18.0, 1.3 Hz, CH=CHCH2), 2.86-2.83 (2H, 
m, CH2), 2.60-2.56 (2H, m, CH2), 1.37 (12H, s, 2 × C(CH3)2); 
13C NMR (125.8 
MHz, CDCl3)  153.4 (CH), 141.7 (C), 128.4 (4 × CH), 125.8 (CH), 83.1 (2 × C), 
37.4 (CH2), 34.5 (CH2), 24.7 (4 × CH3), the CH adjacent to boron was not observed 
due to the quadrupolar coupling effect of 11B. 1H and 13C NMR data were consistent 




To a mixture of 3-methoxy-propyne (2.5 mL, 30 mmol), Cp2ZrHCl (193 mg, 0.700 
mmol), and Et3N (0.4 mL, 3.0 mmol) at room temperature was added pinacolborane 
(4.35 mL, 30.0 mmol) over 2 min, and the mixture was stirred for 16 h. The reaction 
was quenched carefully with H2O (40 mL) and after effervescence had ceased, the 
mixture was extracted with Et2O (2 × 50 mL). The combined organic extracts were 
dried (MgSO4), filtered, and concentrated in vacuo. Purification of the residue by 
column chromatography (5% EtOAc/hexane) gave the alkenylboronic ester 178b 
(2.44 g, 41%) as a colourless oil. 1H NMR (500 MHz, CDCl3)  6.68-6.57 (1H, m, 
CH=CH), 5.69 (1H, dm, J = 18.2 Hz, CH=CH), 4.00-3.99 (2H, m, CH2), 3.34 (3H, s, 
OCH3), 1.26 (12H, s, 2 × C(CH3)2); 
13C NMR (125.8 MHz, CDCl3)  149.0 (CH), 
83.2 (2 × C), 74.1 (CH2), 58.3 (CH3), 24.7 (4 × CH3), the CH adjacent to boron was 
not observed due to the quadrupolar coupling effect of 11B. 1H and 13C NMR data 












To a mixture of 1-hexyne (7.30 mL, 80.0 mmol), Cp2ZrHCl (516 mg, 2.00 mmol), 
and Et3N (1.12 mL, 8.00 mmol) at room temperature was added pinacolborane (11.6 
mL, 80.0 mmol) over 2 min, and the mixture was stirred for 16 h. The reaction was 
quenched carefully with H2O (150 mL) and after effervescence had ceased, the 
mixture was extracted with Et2O (2 × 100 mL). The combined organic extracts were 
dried (MgSO4), filtered, and concentrated in vacuo. Purification of the residue by 
column chromatography (5% EtOAc/hexane) gave the alkenylboronic ester 178c 
(7.90 g, 47%) as a colourless oil. 1H NMR (500 MHz, CDCl3)  6.64 (1H, dt, J = 
17.9. 6.4 Hz, CH=CHCH2), 5.43 (1H, dt, J = 17.9, 1.6 Hz, CH=CHCH2), 2.20-2.11 
(2H, m, CH2), 1.45-1.30 (4H, m, 2 × CH2), 1.27 (12H, s, 2 × C(CH3)2), 0.90 (3H, t, J 
= 7.1 Hz, CH3). 
13C NMR (125.8 MHz, CDCl3)  154.7 (CH), 82.9 (2 × C), 35.5 
(CH2), 30.3 (CH2), 24.7 (4 × CH3), 22.2 (CH2), 13.9 (CH3). 
1H and 13C NMR data 
were consistent with those observed previously.85 
 
4.1.3 Preparation of β-Substituted Alkenylazaarenes 
 
2,4-Dimethoxy-6-[(E)-3-methoxyprop-1-en-1-yl]-1,3,5-triazine (179a)  
 
A solution of 2-chloro-4,6-dimethyl-1,3,5-triazine (1.40 g, 8.00 mmol), boronic ester 
178a84 (2.27 g, 8.80 mmol), Pd(OAc)2 (269 mg, 1.20 mmol), PPh3 (630 mg, 2.40 
mmol), and NaOH (960 mg, 24.0 mmol) in THF (80 mL) was heated to reflux for 2 
h. The mixture was cooled to room temperature, diluted with H2O (60 mL), and 
extracted with CH2Cl2 (2 × 50 mL). The combined organic layers were washed with 
brine (50 mL), dried (MgSO4), filtered, and concentrated in vacuo. Purification of the 




alkenyltriazine 179a (1.41 g, 65%) as a pale brown solid. m.p. 52-54 C; IR (film) 
1654, 1559, 1498, 1458, 1352, 1201, 1111, 1082, 979, 816 cm‒1; 1H NMR (500 
MHz, CDCl3)  7.48 (1H, dt, J = 15.6, 6.9 Hz, CH=CHCH2), 7.33-7.28 (2H, m, 
ArH), 7.24-7.18 (3H, m, ArCH), 6.39 (1H, d, J = 15.6 Hz, CH=CHCH2), 4.05 (6H, 
s, 2 × OCH3), 2.88-2.81 (2H, m, CH2Ph), 2.68-2.60 (2H, m, CH2CH2Ph); 
13C NMR 
(125.8 MHz, CDCl3)  174.6 (C), 172.5 (C), 146.3 (CH), 141.0 (C), 128.5 (2 × CH), 
128.3 (2 × CH), 126.1 (CH), 55.0 (2 × CH3), 34.6 (CH2), 34.4 (CH2); HRMS (ES) 
Exact mass calcd for C15H18N3O2 [M+H]




A solution of 2-bromopyrimidine (477 mg, 3.00 mmol), alkenylboronic ester 85e 
(588 μL, 2.77 mmol), Pd(OAc)2 (34 mg, 0.15 mmol), PPh3 (157 mg, 0.600 mmol), 
and Cs2CO3 (1.95 g, 6.00 mmol) in MeCN (30 mL) and H2O (8 mL) was heated to 
reflux for 16 h. The mixture was cooled to room temperature, diluted with H2O (30 
mL), and extracted with CH2Cl2 (2 × 50 mL). The combined organic layers were 
washed with saturated aqueous NH4Cl solution (50 mL), dried (MgSO4), filtered and 
concentrated in vacuo. Purification of the residue by column chromatography 
(5%→40% EtOAc/hexane) gave the alkenylpyrimidine 179b (303 mg, 75%) as a 
yellow oil. IR (film) 1723, 1659, 1557, 1420, 1383, 1319, 1192, 1122, 977, 749 cm‒
1; 1H NMR (500 MHz, CDCl3)  8.69 (2H, d, J = 4.7 Hz, ArH), 7.19 (1H, dt, J = 
15.7, 5.7 Hz, CH=CHCH2), 7.12 (1H, t, J = 4.9 Hz, ArH), 6.83-6.76 (1H, m, 
CH=CHCH2), 4.21 (2H, dd, J = 5.2, 1.7 Hz, CH2), 3.44 (3H, s, OCH3); 
13C NMR 
(125.8 MHz, CDCl3)  164.2 (C), 157.0 (2 × CH), 137.1 (CH), 130.4 (CH), 118.8 
(CH), 72.1 (CH2), 58.4 (CH3); HRMS (EI) Exact mass calcd for C8H10N2O1 [M]
+: 







Benzoin (2.12 g, 10.0 mmol), 4-dimethylaminopyridine (122 mg, 1.00 mmol) and 
(E)-but-2-enoic acid (0.95 g, 11.0 mmol) were dissolved in CH2Cl2 (25 mL), and 
dicyclohexylcarbodiimide (2.06 g, 10.0 mmol) was subsequently added. The reaction 
was stirred at room temperature for 16 h. The reaction was diluted with EtOAc (25 
mL) and vacuum filtered through a silica plug. The resulting eluent was washed with 
5% HCl (50 mL), saturated NaHCO3 (50 mL), brine (50 mL), dried (MgSO4), filtered 
and concentrated in vacuo. Purification of the residue by column chromatography 
(10%→20% EtOAc/hexane) gave the enoate 184 (1.52 g, 54%). 
Enoate 184 (1.49 g, 5.31 mmol), ammonium acetate (2.05 g, 26.6 mmol) and acetic 
acid (8 mL) were heated to reflux at 120 °C for 2 h. The reaction mixture was cooled 
to room temperature, diluted with EtOAc (20 mL) and washed with H2O (2 × 20 
mL). The combined organic layers were washed with saturated NaHCO3 (50 mL), 
brine (50 mL), dried (MgSO4), filtered and concentrated in vacuo. Purification of the 
residue by column chromatography (5% EtOAc/hexane) gave the alkenyloxazole 
179d (600 mg, 43%) as a while solid. 1H NMR (500 MHz, CDCl3)  7.75-7.76 (2H, 
m, ArH), 7.67-7.68 (2H, m, ArH), 7.32-7.43 (6H, m, ArH), 6.89 (1H, dq, J = 15.9, 
6.9 Hz, CH=CHCH3), 6.45 (1H, app dd, J = 15.9, 1.7 Hz, CH=CHCH3), 2.02 (3H, 
dd, J = 6.9, 1.7 Hz, CH3); 
13C NMR (125.8 MHz, CDCl3)  159.7 (C), 144.5 (C), 
136.1 (C), 135.3 (CH), 132.5 (CH), 128.9 (CH), 128.55 (CH), 128.46 (CH), 128.3 
(CH), 128.0 (2 × CH), 127.9 (2 × CH), 126.4 (CH), 117.7 (CH), 18.5 (CH3);  HRMS 
(ES+): Exact mass calcd for C18H15NO [M+H]
+: 216.1232, found: 262.1230. 1H and 









4.1.4 Preparation of Vinylarenes 
 
2-Vinylacetophenone (181a)  
 
A solution of 2-bromoacetophenone (0.40 mL, 3.00 mmol), potassium 
vinyltrifluoroborate (482 mg, 3.60 mmol), PdCl2(dppf)·CH2Cl2 (49 mg, 0.06 mmol), 
and Et3N (0.42 mL, 3.00 mmol) in i-PrOH (50 mL) were heated to reflux for 16 h. 
The mixture was cooled to room temperature and partitioned between CH2Cl2 (50 
mL) and H2O (20 mL). The aqueous layer was separated and extracted with CH2Cl2 
(2 × 20 mL) and the combined organic layers were washed with brine (50 mL), dried 
(MgSO4), filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (5% EtOAc/hexane) gave vinylacetophenone 181a (847 mg, 81%) 
as a colourless oil. 1H NMR (400 MHz, CDCl3)  7.64-7.56 (2H, m, ArH), 7.48-7.43  
(1H, m,  ArH), 7.33 (1H, dd, J = 7.5, 1.3 Hz, ArH), 7.21 (1H, dd, J = 17.4, 10.9 Hz, 
CH=CH2), 5.65 (1H, dd, J = 17.4, 1.3 Hz, CH=CH2), 5.36 (1H, dd, J = 10.9, 1.3 Hz, 
CH=CH2),2.59 (3H, s, CH3). 
1H NMR data was consistent with those reported 
previously.87 
 
Ethyl 4-ethenylbenzoate (181b)   
 
A solution of ethyl 4-bromobenzoate (1.3 mL, 8.0 mmol), potassium 
vinyltrifluoroborate (1.29 g, 9.60 mmol), PdCl2(dppf)·CH2Cl2 (131 mg, 0.160 
mmol), and Et3N (1.1 mL, 8.0 mmol) in i-PrOH (125 mL) was heated to reflux for 16 
h. The mixture was cooled to room temperature and partitioned between CH2Cl2 (100 
mL) and H2O (40 mL). The aqueous layer was separated and extracted with CH2Cl2 
(2 × 50 mL) and the combined organic layers were washed with brine (100 mL), 
dried (MgSO4), filtered, and concentrated in vacuo. Purification of the residue by 




80%) as a clear colourless oil. 1H NMR (500 MHz, CDCl3) δ 8.05-7.99 (2H, m, 
ArH), 7.49-7.44 (2H, m, ArH), 6.76 (1H, dd, J = 17.6, 10.9 Hz, CH=CH2), 5.87 (1H, 
dd, J = 17.6, 0.5 Hz, CH=CH2), 5.39 (1H, dd, J = 10.9, 0.5 Hz, CH=CH2), 4.38 (2H, 
q, J = 7.1 Hz, CH2CH3), 1.41 (3H, t, J = 7.1 Hz, CH2CH3); 
13C NMR (125.8 MHz, 
CDCl3)  166.4 (C), 141.8 (C), 136.1 (2 × CH), 129.8 (2 × CH), 129.6 (C), 126.1 
(CH), 116.4 (CH2), 60.9 (CH2), 14.3 (CH3). 
1H NMR and 13C NMR data were 
consistent with those reported previously.88   
 
Methyl 2-vinylbenzoate (181c)  
 
A solution of methyl-2-bromobenzoate (1.1 mL, 8.0 mmol), potassium 
vinyltrifluoroborate (1.29 g, 9.60 mmol), PdCl2(dppf)·CH2Cl2 (131 mg, 0.160 
mmol), and Et3N (1.1 mL, 8.0 mmol) in i-PrOH (125 mL) was heated to reflux for 16 
h. The mixture was cooled to room temperature and partitioned between CH2Cl2 (100 
mL) and H2O (40 mL). The aqueous layer was separated and extracted with CH2Cl2 
(2 × 50 mL) and the combined organic layers were washed with brine (100 mL), 
dried (MgSO4), filtered, and concentrated in vacuo. Purification of the residue by 
column chromatography (5% EtOAc/hexane) gave methyl benzoate 181c (1.10 g, 
85%) as a clear colourless oil. 1H NMR (500 MHz, CDCl3) δ 7.89 (1H, dd, J = 7.8, 
1.4 Hz, ArH), 7.59 (1H, dd, J = 7.8, 0.6 Hz, ArH), 7.52-7.44 (2H, m, ArH and 
CH=CH2), 7.35-7.31 (1H, m, ArH), 5.66 (1H, dd, J = 17.5, 1.3 Hz, CH=CH2), 5.37 
(1H, dd, J = 11.0, 1.3 Hz, CH=CH2), 3.92 (3H, s, CH3);
 13C NMR (125.8 MHz, 
CDCl3)  167.8 (C), 139.6 (C), 135.9 (CH), 132.1 (CH), 130.3 (CH), 128.6 (C), 
127.4 (CH), 127.2 (CH), 116.5 (CH2), 52.1 (CH3). 
1H NMR and 13C NMR data were 







4.1.5 Enantioselective Copper-Catalysed Reductive Coupling 
Reactions 
 
General Procedure: Reductive Coupling of Vinylazaarenes Using Ligand L13 
(0.40 mmol Scale) 
 
A solution of the appropriate vinylazaarene (0.40 mmol), Cu(OAc)2·H2O (4.0 mg, 
0.02 mmol), ligand SL-T001-1 (L4) (13.8 mg, 0.02 mmol), and the appropriate 
ketone (0.44 mmol) in toluene (2 mL) was stirred at 0 °C for 15 min. PhSiH3 (59 μL, 
0.48 mmol) was then added dropwise over 1 min. The mixture was stirred at 0 °C for 
30 min, then at room temperature for 15 h. The reaction was quenched carefully with 
silica gel (ca. 250 mg), and the resulting suspension was stirred for 15 min before 
being filtered through a short plug of silica gel using EtOAc (50 mL) as eluent. The 
filtrate was concentrated in vacuo and the residue was purified by column 
chromatography to give the reductive coupling product. 
 
 (2S,3R)-2-Phenyl-3-(quinolin-2-yl)butan-2-ol (186b). The title 
compound was prepared according to General Procedure from 2-
vinylquinoline 175b (62 mg, 0.40 mmol) and acetophenone (51 
μL, 0.44 mmol) and purified by column chromatography (5% EtOAc/hexane) to give 
a white solid (66 mg, 60%). m.p. 108-110 C; [α] 24D  +14.2 (c 0.84, CHCl3); IR (film) 
3312 (OH), 1598, 1558, 1504, 1456, 1412, 1065, 843, 762, 697 cm‒1; 1H NMR (500 
MHz, CDCl3)  8.17 (1H, d, J = 8.4 Hz, ArH), 8.08 (1H, d, J = 8.5 Hz, ArH), 7.84 
(1H, d, J = 8.0 Hz, ArH), 7.77-7.73 (1H, m, ArH), 7.62 (2H, d, J = 7.4 Hz, ArH), 
7.58-7.53 (1H, m, ArH), 7.41 (2H, t, J = 7.8 Hz, ArH), 7.36 (1H, d, J = 8.4 Hz, 
ArH), 7.30-7.26 (1H, m, ArH), 7.06 (1H, br s, OH), 3.36 (1H, q, J = 7.1 Hz, 
CHCH3), 1.41 (3H, s, CH3COH), 1.13 (3H, d, J = 7.1 Hz, CHCH3); 
13C NMR 




128.8 (CH), 128.0 (2 × CH), 127.6 (CH), 126.9 (C), 126.22 (CH), 126.18 (CH), 
125.0 (2 × CH), 122.5 (CH), 76.4 (C), 50.7 (CH), 30.8 (CH3), 17.1 (CH3); HRMS 
(ESI) Exact mass calcd for C19H20N1O1 [M+H]
+: 278.1539, found: 278.1541. 
Enantiomeric excess was determined by HPLC with a Chiralcel OD-H column (98:2 
hexane:i-PrOH, 0.8 mL/min, 230 nm, 25 °C); tr (minor) = 12.6 min, tr (major) = 20.3 
min; 93% ee.  
 
(2S,3R)-1,2-Diphenyl-3-(quinolin-2-yl)butan-2-ol (186c). The 
title compound was prepared according to General Procedure 
from 2-vinylquinoline 175b (62 mg, 0.40 mmol) and 2-phenylacetophenone (86 mg, 
0.44 mmol) and purified by column chromatography (5% EtOAc/hexane) to give a 
white solid (85 mg, 60%). m.p. 108-110 C; [α] 24D  +55.2 (c 1.05, CHCl3);  IR (film) 
3302 (OH), 1599, 1504, 1452, 1424, 1327, 1074, 832, 754, 700 cm‒1; 1H NMR (500 
MHz, CDCl3)  8.22 (1H, d, J = 8.4 Hz, ArH), 8.13 (1H, d, J = 8.5 Hz, ArH), 7.87 
(1H, d, J = 8.1 Hz, ArH), 7.78 (1H, ddd, J = 8.4, 6.9, 1.3 Hz, ArH), 7.61-7.56 (1H, 
m, ArH), 7.47-7.40 (3H, m, ArH), 7.36-7.27 (3H, m, ArH and OH), 7.25-7.20 (1H, 
m, ArH), 7.02-6.98 (3H, m, ArH), 6.70 (2H, dd, J = 6.4, 3.1 Hz, ArH), 3.60 (1H, q, J 
= 7.1 Hz, CHCH3), 3.10 (1H, d, J = 13.4 Hz, CH2Ph), 2.90 (1H, d, J = 13.4 Hz, 
CH2Ph), 1.17 (3H, d, J = 7.1 Hz, CHCH3); 
13C NMR (125.8 MHz, CDCl3)  166.2 
(C), 146.8 (C), 144.5 (C), 137.5 (C), 137.3 (CH), 130.5 (2 × CH), 130.0 (CH), 128.7 
(CH), 127.6 (4 × CH), 127.1 (2 × CH), 126.8 (C), 126.3 (CH), 126.1 (CH), 125.9 
(CH), 125.6 (CH), 122.7 (CH), 79.6 (C), 49.0 (CH), 48.9 (CH2), 17.5 (CH3); HRMS 
(ESI) Exact mass calcd for C25H24N1O1 [M+H]
+: 354.1852, found: 354.1856. 
Enantiomeric excess was determined by HPLC with a Chiralcel OD-H column (99:1 
hexane:i-PrOH, 0.8 mL/min, 230 nm, 25 °C); tr (major) = 10.9 min, tr (minor) = 12.4 
min; 97% ee. 
 
(2R,3S)-3-(Isoquinolin-1-yl)-2-phenylbutan-2-ol (186d). The title 
compound was prepared according to General Procedure from 2-
vinylisoquinoline 175c (62 mg, 0.40 mmol) and acetophenone (51 μL, 
0.44 mmol) and purified by column chromatography (5% 




0.97, CHCl3); IR (film) 3290 (OH), 1561, 1502, 1457, 1385, 1065, 1002, 824, 768, 
744 cm‒1; 1H NMR (500 MHz, CDCl3)  8.48 (1H, d, J = 5.7 Hz, ArH), 8.29 (1H, d, 
J =8.5 Hz, ArH), 7.89 (1H, d, J = 8.1 Hz, ArH), 7.77-7.65 (4H, m, ArH), 7.61 (1H, 
d, J = 5.7 Hz, ArH), 7.49 (1H, br s, OH), 7.44 (2H, t, J = 7.8 Hz, ArH), 7.33-7.28 
(1H, m, ArH), 4.12 (1H, q, J = 7.0 Hz, CHCH3), 1.38 (3H, s, CH3COH), 1.13 (3H, d, 
J = 7.0 Hz, CHCH3); 
13C NMR (125.8 MHz, CDCl3)  165.8 (C), 147.8 (C), 140.4 
(CH), 136.6 (C), 130.3 (CH), 128.0 (2 × CH), 127.8 (CH), 127.6 (CH), 127.1 (C), 
126.2 (CH), 125.1 (2 × CH), 124.5 (CH), 119.5 (CH), 76.4 (C), 43.8 (CH), 30.5 
(CH3), 16.9 (CH3); HRMS (ESI) Exact mass calcd for C19H20N1O1 [M+H]
+: 
278.1539, found: 278.1542. Enantiomeric excess was determined by HPLC with a 
Chiralcel OD-H column (98:2 hexane:i-PrOH, 0.8 mL/min, 280 nm, 25 °C); tr 





A solution of alkenylazaarene 179a (77 mg, 0.30 mmol), Cu(OAc)2·H2O (3.0 mg, 
0.015 mmol), ligand SL-T001-1 (L4) (10.3 mg, 0.015 mmol), and and 4-chromanone 
(62 mg, 0.42 mmol) in toluene (1.5 mL) was stirred at 0 °C for 15 min. PhSiH3 (56 
μL, 0.45 mmol) was then added dropwise over 1 min. The mixture was stirred at 0 
°C for 30 min, then at room temperature for 4 h. The reaction was quenched carefully 
with silica gel (ca. 250 mg), and the resulting suspension was stirred for 15 min 
before being filtered through a short plug of silica gel using EtOAc (50 mL) as 
eluent. The filtrate was concentrated in vacuo and the residue was purified by 
column chromatography (10%→40% EtOAc/hexane) to give a yellow gum (95 mg, 
75%). [] 24D  +8.6 (c 0.93, CHCl3); IR (film) 3383 (OH), 2966, 1559, 1502, 1452, 




7.9, 1.4 Hz, ArH), 7.25-7.10 (4H, m, ArH), 7.05 (2H, d, J = 7.0 Hz, ArH), 6.93-6.88 
(1H, m, ArH), 6.86 (1H, dd, J = 8.2, 1.1 Hz, ArH), 4.39 (1H, br s, OH), 4.26-4.15 
(2H, m, OCH2), 4.02 (6H, s, 2 x OCH3), 3.53 (1H, dd, J = 11.3, 2.1 Hz, CHCH2), 
2.55 (1H, ddd, J = 14.8, 9.1, 6.2 Hz, PhCHAHB), 2.50-2.40 (1H, m, PhCHAHB), 2.32 
(1H, ddd, J = 14.5, 10.2, 4.4 Hz, OCH2CHXHY), 2.18-2.05 (1H, m, OCH2CHXHY), 
1.83 (1H, ddd, J = 14.3, 4.9, 2.9 Hz, PhCH2CH2CH2), 1.59-1.40 (2H, m, 
PhCH2CH2CH2), 1.35-1.24 (1H, m, PhCH2CH2CH2); 
13C NMR (125.8 MHz, CDCl3) 
δ 182.7 (C), 171.8 (C), 155.1 (C), 141.8 (C), 129.0 (CH), 128.1 (4 x CH), 126.5 (C), 
125.8 (CH), 125.6 (CH), 120.8 (CH), 117.4 (CH), 70.7 (C), 62.6 (CH2), 55.9 (CH), 
55.2 (2 × CH3), 35.4 (CH2), 32.0 (CH2), 29.8 (CH2), 28.0 (CH2); HRMS (ESI) Exact 
mass calcd for C24H27N3O4Na [M+Na]
+: 444.1894, found: 444.1895. Enantiomeric 
excess was determined by HPLC with a Chiralcel OD-H column (95:5 hexane:i-
PrOH, 0.8 mL/min, 280 nm, 25 °C); tr (minor) = 27.4 min, tr (major) = 30.8 min; 
96% ee. 
 
4.2 Enantioselective Copper-Catalysed Reductive Coupling of 




THF used in reactions were dried and purified by passage through activated alumina 
columns using a solvent purification system. “Petroleum ether” refers to Sigma 
Aldrich product 24587 (petroleum ether boiling point 40-60 °C). All commercially 
available reagents were used as received. Thin layer chromatography (TLC) was 
performed on Merck DF-Alufoilien 60F254 0.2 mm precoated plates. Product spots 
were visualized by UV light at 254 nm, and subsequently developed using vanillin, 
potassium permanganate, or ninhydrin solution as appropriate. Flash column 
chromatography was carried out using silica gel (Fisher Scientific 60Å particle size 
35-70 micron). Melting points were recorded on a Gallenkamp melting point 
apparatus and are uncorrected. Infra-red spectra were recorded on a Jasco FT/IR-460 
Plus instrument as a thin film on sodium chloride plates or as a dilute solution in 
CHCl3. 




AVA400 (400 MHz) spectrometer, or a Bruker OPEN400 (400 MHz) spectrometer. 
For 1H NMR spectra, chemical shifts () are quoted in parts per million (ppm) 
downfield of tetramethylsilane, using residual protonated solvent as internal standard 
(CDCl3 at 7.27 ppm, (CD3)2CO at 2.05 ppm, CD3OD at 3.31 ppm). Abbreviations 
used in the description of resonances are: s (singlet), d (doublet), t (triplet), q, 
(quartet), quin (quartet), app (apparent), br (broad). Coupling constants (J) are quoted 
to the nearest 0.1 Hz. For 13C NMR spectra, chemical shifts () are quoted in parts 
per million (ppm) downfield of tetramethylsilane, using deuterated solvent as internal 
standard (CDCl3 at 77.0 ppm, (CD3)2CO at 29.84 ppm, CD3OD at 49.00 ppm). 
Assignments were made using the DEPT sequence with secondary pulses at 90° and 
135°. Proton-decoupled 19F NMR spectra were recorded on a Bruker AVA400 (377 
MHz) spectrometer. High-resolution mass spectra were recorded using electrospray 
ionization (ESI) or electron impact ionization (EI) techniques. Optical rotations were 
performed on a Bellingham and Stanley ADP410 polarimeter. HPLC analysis was 
performed on Agilent 1100 or Agilent 1200 series instruments using 4.6 x 250 mm 
columns. Authentic racemic samples of products for chiral HPLC assay 
determinations were obtained using rac-BINAP as the ligand. 
 
4.2.1 Preparation of Vinylazaarenes 
 
3-Phenyl-6-vinylpyridazine (175o)  
 
A solution of 3-chloro-6-phenylpyradazine (1.53 g, 8.03 mmol), potassium 
vinyltrifluoroborate (1.29 g, 9.63 mmol), PdCl2(dppf)·CH2Cl2 (131 mg, 0.160 
mmol), and Et3N (1.1 mL, 7.9 mmol) in i-PrOH (130 mL) was heated to reflux for 16 
h. The mixture was cooled to room temperature and the solvent was removed in 
vacuo. The crude residue was dissolved CH2Cl2 (50 mL) and washed with H2O (40 
mL). The aqueous layer was separated and extracted with CH2Cl2 (2 × 50 mL) and 
the combined organic layers were washed with brine (100 mL), dried (MgSO4), 




chromatography (10%→20% EtOAc/iso-hexane) gave the vinylazaarene 175o (967 
mg, 66%) as a pale yellow crystalline solid. Rf 0.22 (20% EtOAc/petroleum ether); 
m.p 99-101 C (EtOAc/petroleum ether); IR (CHCl3) 3010, 1597, 1453, 1422, 1400, 
1267, 1055, 1008, 943, 851 cm‒1; 1H NMR (400 MHz, CDCl3)  8.12-8.08 (2H, m, 
ArH), 7.82 (1H, d, J = 8.9 Hz, ArH), 7.62 (1H, d, J = 8.9 Hz, ArH), 7.56-7.45 (3H, 
m, ArH), 7.09 (1H, dd, J = 17.8, 11.0 Hz, CH=CH2), 6.29 (1H, d, J = 17.8 Hz, 
CH=CH2), 5.69 (1H, d, J = 11.1 Hz, CH=CH2); 
13C NMR (100.6 MHz, CDCl3)  
157.8 (C), 156.5 (C), 136.1 (C), 134.3 (CH), 129.9 (CH), 128.9 (2 × CH), 126.9 (2 × 
CH), 123.79 (CH), 123.75 (CH), 120.2 (CH2); HRMS (ESI) Exact mass calcd for 
C12H11N2 [M+H]
+: 183.0917, found: 183.0918.  
 
2-Bromo-6-vinylpyridine (175p)  
 A solution of 2,6-dibromopyridine (215) (9.48 g, 40.0 mmol) and dry CH2Cl2 (125 
mL) was cooled to −78 °C. n-BuLi in hexane (17.8 mL, 44.0 mmol, 2.5 M) was 
added dropwise over a period of 15 minutes. After 1 h acetaldehyde (3.40 mL, 60.0 
mmol) was added over a period of 5 minutes and the reaction was allowed to stir for 
30 minutes at −78 °C before it was warmed to room temperature. Saturated NH4Cl 
(100 mL) was added and the reaction mixture was extracted with CH2Cl2 (3 × 50 
mL). The combined organic phases were washed with brine (2 × 50 mL), dried 
(MgSO4) and filtered before concentrating in vacuo. Purification of the residue by 
column chromatography (10% EtOAc/hexane) gave the alcohol 216 (4.97 g, 62%) as 
a brown syrup that displayed spectroscopic data consistent with those reported 
previously.66 1H NMR (500 MHz, CDCl3) δ 7.56 (1H, t, J = 7.7 Hz, ArH), 7.39 (1H, 
d, J = 7.8 Hz, ArH), 7.32-7.25 (1H, m, ArH), 4.88 (1H, q, J = 6.6 Hz, CH), 3.42 (1H, 
br, s, OH), 1.51 (3H, d, J = 6.6 Hz, CH3); 
13C NMR (126 MHz, CDCl3) δ 165.2 (C), 
141.1 (C), 139.1 (CH), 126.6 (CH), 118.5 (CH), 69.1 (CH), 24.1 (CH3). 
Alcohol 216 (3.16 g, 15.6 mmol) was cooled to 0 °C and concentrated H2SO4 (20.0 
mL, 35.0 mmol) was added slowly. The reaction was purged with N2 before heating 




until the solution was neutral. Solids were removed by filtration and the aqueous 
solution extracted with diethyl ether (3 × 50 mL) the combined organic extracts were 
washed with brine (2 × 50 mL), dried (MgSO4), filtered and concentrated in vacuo. 
Purification of the residue by column chromatography (5% EtOAc/iso-hexane) gave 
the vinylazaarene 175p (1.49 g, 52%) as a pale yellow oil. 1H NMR (400 MHz, 
CDCl3) δ 7.48 (1H, t, J  = 7.7 Hz, ArH), 7.32 (1H, dd, J = 7.8, 0.8 Hz, ArH), 7.25 
(1H, dd, J = 7.8, 0.8 Hz, ArH),  6.72 (1H, dd, J = 17.4, 10.8 Hz, CH=CH2), 6.23 (1H, 
dd, J = 17.4, 1.0 Hz, CH=CH2), 5.53 (1H, dd, J  = 10.8, 1.0 Hz, CH=CH2); 
13C NMR 
(100.6 MHz, CDCl3)  156.9 (C), 141.9 (C), 138.7 (CH), 135.3 (CH), 126.6 (2 × 
CH), 119.9 (CH2). 
1H NMR and 13C NMR data were consistent with those reported 
previously.66  
 
4.2.2 Preparation of β-Substituted Alkenylazaarenes 
 
2-[(1E)-Hex-1-en-1-yl]pyridine (179e)  
 
A solution of 2-bromopyridine (0.48 mL, 5.00 mmol), alkenylboronic ester 178c 
(1.16  g, 5.50 mmol), Pd(OAc)2 (56 mg, 0.25 mmol), PPh3 (262 mg, 1.00 mmol),  
and NaOH (0.6 g, 15.0 mmol) in THF (50 mL) was heated to reflux for 16 h. The 
mixture was cooled to room temperature, and partitioned between Et2O (100 mL) 
and H2O (50 mL). The aqueous layer was separated and extracted with Et2O (2 × 30 
mL) and the combined organic layers were washed with saturated aqueous NH4Cl 
solution (80 mL), dried (MgSO4), filtered and concentrate in vacuo. Purification of 
the residue by flash column chromatography (10% EtOAc/hexanes) gave the 
alkenylazaarene 179e (801 mg, 99%) as a pale yellow liquid. 1H NMR (400 MHz, 
CDCl3) δ 8.54-8.48 (1H, m, ArH), 7.60-7.53 (1H, m, ArH), 7.24-7.18 (1H, m, ArH), 
7.08-7.02 (1H, m, ArH), 6.78-6.68 (1H, m, CH=CH), 6.47 (1H, d, J = 15.6 Hz, 
CH=CH), 2.29-2.22 (2H, m, CH2), 1.53-1.43 (2H, m, CH2), 1.42-1.32 (2H, m, CH2), 
0.91 (3H, t, J = 7.3 Hz, CH3); 




136.3 (CH), 136.0 (CH), 129.7 (CH), 121.4 (CH), 120.8 (CH), 32.4 (CH2), 31.0 
(CH2), 22.2 (CH2), 13.9 (CH3); HRMS (ESI) Exact mass calcd for C11H16N [M+H]
+: 




A solution of 2-chloroquinoline (818 mg, 5.00 mmol), alkenylboronic ester 178c 
(1.16 g, 5.50 mmol), Pd(OAc)2 (56 mg, 0.25 mmol), PPh3 (262 mg, 1.00 mmol) and 
NaOH (0.6 g, 15.0 mmol) in THF (50 mL) was heated to reflux for 16 h. The mixture 
was cooled to room temperature, and partitioned between Et2O (100 mL) and H2O 
(50 mL). The aqueous layer was separated and extracted with Et2O (2 × 30 mL) and 
the combined organic layers were washed with saturated aqueous NH4Cl solution (80 
mL), dried (MgSO4), filtered and concentrate in vacuo. Purification of the residue by 
flash column chromatography (10% EtOAc/hexanes) gave the alkenylazaarene 179f 
(904 mg, 86%) as an orange liquid. 1H NMR (400 MHz, CDCl3) δ 8.04 (2H, dd, J = 
8.5, 4.2 Hz, ArH), 7.74 (1H, d, J = 8.1 Hz, ArH), 7.71-7.63 (1H, m, ArH), 7.52 (1H, 
d, J = 8.6 Hz, ArH), 7.48-7.42 (1H, m, ArH), 6.83 (1H, dt, J = 15.9, 6.7 Hz, 
ArCH=CH), 6.72 (1H, dt, J = 15.9, 1.1 Hz, ArCH=CH), 2.38-2.30 (2H, m, CH2), 
1.59-1.49 (2H, m, CH2), 1.48-1.35 (2H, m, CH2), 0.97 (3H, t, J = 7.3 Hz, CH3); 
13C 
NMR (100.6 MHz, CDCl3)  156.5 (C), 148.0 (C), 138.0 (CH), 136.1 (CH), 131.0 
(CH), 129.5 (CH), 129.1 (CH), 127.4 (CH), 127.1 (C), 125.8 (CH), 118.6 (CH), 32.7 
(CH2), 31.0 (CH2), 22.3 (CH2), 13.9 (CH3). 
1H NMR and 13C NMR data were 








A solution of 2-chlorobenzoxazole (0.65 mL, 5.00 mmol), alkenylboronic ester 178c 
(1.16 g, 5.50 mmol), Pd(OAc)2 (56 mg, 0.25 mmol), PPh3 (262 mg, 1.00 mmol) and 
NaOH (600 mg, 15.0 mmol) in THF (50 mL) was heated to reflux for 16 h. The 
mixture was cooled to room temperature, and partitioned between Et2O (100 mL) 
and H2O (50 mL). The aqueous layer was separated and extracted with Et2O (2 × 30 
mL) and the combined organic layers were washed with saturated aqueous NH4Cl 
solution (80 mL), dried (MgSO4), filtered and concentrate in vacuo. Purification of 
the residue by flash column chromatography (5% EtOAc/hexanes) gave the 
alkenylazaarene 179g (530 mg, 52%) as a pale yellow oil. 1H NMR (400 MHz, 
CDCl3) δ 7.74-7.64 (1H, m, ArH), 7.53-7.43 (1H, m, ArH), 7.35-7.30 (2H, m, ArH), 
7.06 (1H, dt, J = 15.9, 7.2 Hz, ArCH=CH), 6.45 (1H, dt, J = 15.9, 1.5 Hz, 
ArCH=CH), 2.35 (2H, qd, J = 7.2, 1.5 Hz, CH2), 1.59-1.48 (2H, m, CH2), 1.47-1.35 
(2H, m, CH2), 0.95 (3H, t, J = 7.3 Hz, CH3); 
13C NMR (100.6 MHz, CDCl3)  162.6 
(C), 150.3 (C), 144.4 (CH), 141.9 (C), 124.8 (CH), 124.3 (CH), 119.7 (CH), 116.7 
(CH), 110.2 (CH), 32.7 (CH2), 30.5 (CH2), 22.2 (CH2), 13.9 (CH3); HRMS (ESI) 
Exact mass calcd for C13H15NNaO [M+Na]
+: 224.1046, found: 224.1044. 
 
4.2.3 Preparation of N-Boc Imines 
 
tert-Butyl carbamate (218)  
 
To a solution of di-tert-butyl dicarbonate (50.9 g, 233 mmol) in EtOH (500 mL) at –
10 °C was added 35% NH3 (aq) (50 mL) over 5 min. The reaction mixture was 
stirred vigorously for a further 30 min at –10 °C to 0 °C, and then at room 
temperature for 18 h. The solvents were removed from the resulting thick suspension 
in vacuo at 50 °C to ensure decomposition of ammonium tert-butyl carbonate. The 
residue was suspended in hexane (500 mL), stirred at 60 °C for 1 h, and then 
recrystallized from refluxing hexane (total volume ~650 mL) to provide tert-butyl 
carbamate (218) (25.9 g, 95%) as a white crystalline solid. 1H NMR (400 MHz, 
CDCl3) δ 1.47 (9H, s, C(CH3)3); 
13C NMR (100.6 MHz, CDCl3) δ 156.5 (C), 79.5 





140.0682, found: 140.0683. 1H NMR and 13C NMR data were consistent with those 
reported previously.91  
 
 
4.2.3.1 tert-Butyl N-[(benzenesulfonyl)(phenyl)methyl]carbamates 
 
tert-Butyl N-[(benzenesulfonyl)(phenyl)methyl]carbamate (219a) 
 
Benzaldehyde (2.30 ml, 22.5 mmol) was suspended in 2:1:0.7 H2O:MeOH:HCO2H 
(40 ml). Sodium benzenesulfinate (4.93 g, 30.0 mmol) and tert-butyl carbamate 
(218) (1.76 g, 15.0 mmol) were added sequentially and the reaction mixture was 
stirred for 2 days. The solids were collected by filtration and triturated with H2O and 
then Et2O to yield title compound as a white solid (3.94 g, 76%). 
1H NMR (400 
MHz, CDCl3) δ 7.93 (2H, d, J = 9.5 Hz, ArH), 7.69-7.62 (1H, m, ArH), 7.58-751 
(2H, m, ArH), 7.50-7.39 (5H, m, ArH), 5.96 (1H, d, J = 10.7 Hz, NH), 5.85 (1H, d, J 
= 10.7 Hz, CH), 1.28 (9H, s, C(CH3)3); 
13C NMR (100.6 MHz, CDCl3) δ 153.3 (C), 
136.9 (C), 133.9 (CH), 129.9 (2 × CH), 129.8 (C), 129.4 (2 × CH), 129.0 (2 × CH), 
128.9 (CH), 128.7 (2 × CH), 81.2 (C), 73.9 (CH), 28.0 (3 × CH3); HRMS (ESI) 
Exact mass calcd for C18H21NO4SNa [M+Na]
+: 370.1083, found: 370.1072. 1H NMR 
and 13C NMR data were consistent with those reported previously.10e  
 
tert-Butyl N-[(benzenesulfonyl)(3-chlorophenyl)methyl]carbamate (219b) 
 
3-Chlorobenzaldehyde (3.1 mL, 15.0 mmol) was suspended in 2:1:0.7 
H2O/MeOH/HCO2H (40 mL). Sodium benzenesulfinate (4.92 g, 30.0 mmol) and 
tert-butyl carbamate (218) (1.76 g, 15.0 mmol) were added sequentially and the 
reaction mixture was stirred for 3 days. The solids were collected by filtration and 
triturated with H2O and then Et2O to yield the title compound as a white solid (4.64 




= 7.4 Hz, ArH), 7.60-7.50 (2H, m, ArH), 7.48-7.31 (4H, m, ArH), 5.92 (1H, d, J = 
10.6 Hz, NH), 5.81 (1H, d, J = 10.6 Hz, CH), 1.26 (9H, s, C(CH3)3); HRMS (ESI) 
Exact mass calcd for C18H20ClNO4SNa [M+Na]
+: 404.0703, found: 404.0694. 1H 
NMR and 13C NMR data were consistent with those reported previously.10e  
 
tert-Butyl N-[(benzenesulfonyl)(4-methylphenyl)methyl]carbamate (219c) 
 
4-Methylbenzaldehyde (1.8 mL, 15.0 mmol) was suspended in 2:1:0.7 
H2O/MeOH/HCO2H (40 mL). Sodium benzenesulfinate (3.28 g, 20.0 mmol) and 
tert-butyl carbamate (218) (1.17 g, 10.0 mmol) were added sequentially and the 
reaction mixture was stirred for 4 days. The solids were collected by filtration and 
triturated with H2O and then 5:3 hexane/toluene to yield the title compound as a 
white solid (3.28 g, 91%). 1H NMR (500 MHz, CDCl3) δ 7.93 (2H, d, J = 7.5 Hz, 
ArH), 7.65 (1H, t, J = 7.5 Hz, ArH), 7.55 (2H, t, J = 7.5 Hz, ArH), 7.34 (2H, d, J = 
8.1 Hz, ArH), 7.24 (2H, d, J = 8.1 Hz, ArH), 5.89 (1H, d, J = 10.6 Hz, NH), 5.69 
(1H, d, J = 10.6 Hz, CH), 2.38 (2H, s, ArCH3), 1.25 (9H, s, C(CH3)3); 
13C NMR 
(125.6 MHz, CDCl3) δ 153.4 (C), 139.9 (C), 137.0 (C), 133.8 (CH), 129.4 (4 × CH), 
129.0 (2 × CH), 128.8 (2 × CH), 126.7 (C), 81.0 (C), 73.7 (CH), 27.9 (3 × CH3), 21.3 
(CH3). 
1H NMR and 13C NMR data were consistent with those reported 
previously.10e  
 
tert-Butyl N-[(benzenesulfonyl)(naphthalen-2-yl)methyl]carbamate (219d) 
 
2-Naphthaldehyde (2.34 g, 15.0 mmol) was suspended in 2:1:0.7 
H2O/MeOH/HCO2H (40 ml). Sodium benzenesulfinate (3.28 g, 20.0 mmol) and tert-
butyl carbamate (218) (1.17 g, 10.0 mmol) were added sequentially and the reaction 
mixture was stirred for 2 days. The solids were collected by filtration and triturated 




1H NMR (400 MHz, CDCl3) δ 8.00-7.86 (6H, m, ArH), 7.68 (1H, t, J = 7.1 Hz, 
ArH), 7.61-7.55 (5H, m, ArH), 6.12 (1H, d, J = 10.5 Hz, NH), 5.88 (1H, d, J = 10.5 
Hz, CH), 1.31 (9H, s, C(CH3)3); 
13C NMR (100.6 MHz, CDCl3) δ 153.3 (C), 136.9 
(C), 134.0 (C), 133.7 (C), 132.9 (C), 129.5 (CH), 129.1 (CH), 129.0 (CH), 128.6 
(CH), 128.3 (2 × CH), 127.7 (2 × CH), 127.2 (CH), 127.1 (CH), 126.7 (CH), 125.5 
(CH), 81.3 (C), 74.1 (CH), 28.0 (3 × CH3). 
1H NMR and 13C NMR data were 
consistent with those reported previously.92  
 
tert-Butyl N-[(benzenesulfonyl)(naphthalen-1-yl)methyl]carbamate (219e) 
 
1-Naphthaldehyde (1.35 mL, 10.0 mmol) was suspended in 10:3.5:1.9 
H2O/THF/HCO2H (15.4 mL). Sodium benzenesulfinate (1.64 g, 10.0 mmol) and tert-
butyl carbamate (218) (1.17 g, 10.0 mmol) were added sequentially and the reaction 
mixture was stirred for 2 days. The solids were collected by filtration and triturated 
with H2O and then MTBE to yield the title compound as a white solid (1.83 g, 46%). 
1H NMR (400 MHz, CDCl3) δ 8.13 (1H, d, J = 8.4 Hz, ArH), 7.99 (2H, d, J = 8.2 
Hz, ArH),7.95 (1H, d, J = 8.2 Hz, ArH), 7.89 (1H, d , J = 7.9 Hz, ArH), 7.79 (1H, J 
= 7.3 Hz, ArH), 7.67-7.48 (6H, m, ArH), 6.87 (1H, d, J = 10.5 Hz, CH), 5.91 (1H, d, 
J = 10.5 Hz, NH), 1.28 (9H, s, C(CH3)3); 
13C NMR (100.6 MHz, CDCl3) δ 156.3 
(C), 137.3 (C), 133.9 (C), 133.6 (C), 131.7 (C), 130.5 (2 × CH), 129.4 (CH), 129.0 (2 
× CH), 128.9 (CH), 127.2 (CH), 127.0 (CH), 126.5 (CH), 126.2 (CH), 125.1 (CH), 
122.8 (CH), 81.2 (C), 69.0 (CH), 28.0 (3 × CH3); HRMS (ESI) Exact mass calcd for 
C22H23NO4SNa [M+Na]
+: 420.1240, found: 420.1226. 1H NMR and 13C NMR data 








2-Tolualdehyde (1.70 mL, 15.0 mmol) was suspended in 2:1:0.7 
H2O/MeOH/HCO2H (40 mL). Sodium p-toluenesulfinate (3.56 g, 20.0 mmol) and 
tert-butyl carbamate (218) (1.17 g, 15.0 mmol) were added sequentially and the 
reaction mixture was stirred for 3 days. The solids were collected by filtration and 
triturated with H2O then 1:5 MTBE/iso-hexane to yield the title compound as a white 
solid (3.23 g, 86%). 1H NMR (400 MHz, CDCl3) δ 7.80 (2H, d, J = 8.2 Hz, ArH), 
7.48-7.41 (1H, m, ArH), 7.36-7.28 (4H, m, ArH), 7.25-7.20 (1H, m, ArH), 6.22 (1H, 
d, J = 10.7 Hz, NH), 5.76 (1H, d, J = 10.7 Hz, CH), 2.46 (3H, s, ArCH3), 2.44 (3H, 
s, ArCH3), 1.27 (9H, s, C(CH3)3); HRMS (ESI) Exact mass calcd for C20H25NO4SNa 
[M+Na]+: 398.1397, found: 398.1400. 1H NMR data was consistent with those 





2-Chlorobenzaldehyde (1.70 mL, 15.0 mmol) was suspended in 2:1:0.7 
H2O/MeOH/HCO2H (40 mL). Sodium p-toluenesulfinate (3.56 g, 20.0 mmol) and 
tert-butyl carbamate (218) (1.17 g, 15.0 mmol) were added sequentially and the 
reaction mixture was stirred for 3 days. The solids were collected by filtration and 
triturated with H2O and then 1:5 MTBE/iso-hexane to yield the title compound as a 
white solid (2.65 g, 67%). 1H NMR (400 MHz, CDCl3) δ 7.81 (2H, d, J = 8.0 Hz, 
ArH), 7.60-7.53 (1H, m, ArH), 7.46-7.40 (1H, m, ArH), 7.39-7.29 (4H, m, ArH), 
6.58 (1H, d, J = 10.7 Hz, CH), 5.95-5.80 (1H, m, NH), 2.44 (3H, s, ArCH3), 1.30 
(9H, s, C(CH3)3); HRMS (ESI) Exact mass calcd for C19H22ClNO4SNa [M+H]
+: 













4-(Trifluoromethyl)benzaldehyde (3.10 mL, 22.5 mmol) was suspended  in 2:1:0.7 
H2O/MeOH/HCO2H (40 mL). Sodium benzenesulfinate (4.92 g, 30.0 mmol) and 
tert-butyl carbamate (218) (1.76 g, 15.0 mmol) were added sequentially and the 
reaction mixture was stirred for 3 days. The solids were collected by filtration and 
triturated with H2O and then Et2O to yield the title compound as a white solid (4.00 
g, 65%). 1H NMR (300 MHz, CDCl3) δ 7.95 (2H, d, J = 7.5 Hz, ArH), 7.73-7.64 
(3H, m, ArH), 7.64-7.53 (4H, m, ArH), 6.03 (1H, d, J = 10.6 Hz, NH), 5.92 (1H, d, J 
= 10.6 Hz, CH), 1.25 (9H, s, C(CH3)3); HRMS (ESI) Exact mass calcd for 
C19H20F3NO4SNa [M+Na]
+: 438.0957, found: 438.0970. 1H NMR data was 
consistent with those reported previously.94  
 
tert-Butyl N-[(benzenesulfonyl)(thiophen-2-yl)methyl]carbamate (219i) 
 
2-Thiophenecarbaldehyde (2.10 mL, 22.5 mmol) was suspended in 2:1:0.7 
H2O/MeOH/HCO2H (40 mL). Sodium benzenesulfinate (4.92 g, 30.0 mmol) and 
tert-butyl carbamate (218) (1.76 g, 15.0 mmol) were added sequentially and the 
reaction mixture was stirred for 3 days. The solids were collected by filtration and 
triturated with H2O and then hexane to yield the title compound as a white solid 
(2.52 g, 49%). 1H NMR (400 MHz, CDCl3) δ 7.95 (2H, d, J = 7.4 Hz, ArH), 7.67 
(1H, t, J = 7.4 Hz, ArH), 7.56 (2H, t, J = 7.7 Hz, ArH), 7.44 (1H, dd, J = 5.1, 1.2 Hz, 
thienyl H), 7.29 (1H, m, thienyl H), 7.09 (1H, dd, J  = 5.1, 1.2 Hz, thienyl H), 6.21 
(1H, d, J = 10.6 Hz, CH), 5.70 (1H, d, J = 10.6 Hz, NH), 1.28 (9H, s, C(CH3)3); 
HRMS (ESI): calcd for [M+H]+ C19H16NO4S2: 354.0833, found: 354.0855. 
1H NMR 








Piperonal (1.50 g, 10.0 mmol) was suspended in 10:3.5:1.9 H2O/THF/HCO2H (15.4 
mL). Sodium benzenesulfinate (1.64 g, 10.0 mmol) and tert-butyl-carbamate (218) 
(1.17 g, 10.0 mmol) were added sequentially and the reaction mixture was stirred for 
2 days. The reaction mixture was dissolved in CH2Cl2 (50 mL) and H2O (50 mL). 
The aqueous layer was extracted with CH2Cl2 (2 × 25 mL) then dried (MgSO4). The 
crude residue was triturated with 1:5 Et2O/iso-hexane to yield the title compound as a 
white solid (1.92 g, 49%). 1H NMR (400 MHz, CDCl3) δ 7.97-7.92 (2H, m, ArH), 
7.67 (1H, t, J = 7.4 Hz, ArH), 7.57 (2H, t, J = 7.6 Hz, ArH), 6.98 (1H, d, J = 1.6 Hz, 
ArH), 6.93 (1H, dd, J = 8.1, 1.6 Hz, ArH), 6.85 (1H, d, J = 8.1 Hz, ArH), 6.03 (2H, 
s, CH2), 5.84 (1H, d, J = 10.6 Hz, CH), 5.65 (1H, d, J = 10.6 Hz, NH), 1.27 (9H, s, 
C(CH3)3); HRMS (ESI): calcd for [M+H]
+ C19H21NO6S: 392.1168, found: 392.1192. 





4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-benzaldehyde (1.44 g, 6.20 mmol) was 
suspended in 6.2:2.1:1.2 H2O/THF/HCO2H (9.5 mL). Sodium benzenesulfinate (1.01 
g, 6.20 mmol) and tert-butyl-carbamate (218) (726 mg, 6.2 mmol) were added 
sequentially and the reaction mixture was stirred for 2 days. The reaction mixture 
was dissolved in CH2Cl2 (50 mL) and H2O (50 mL). The aqueous layer was extracted 
with CH2Cl2 (2 × 25 mL) then dried (MgSO4). The crude residue was triturated with 
MTBE to yield the title compound as a white solid (1.10 g, 38%). 1H NMR (400 




(2H, m, ArH), 7.46-7.41 (2H, m, ArH), 5.94 (1H, d, J = 10.6 Hz, NH), 5.87 (1H, d, J 
= 10.6 Hz, CH), 1.34 (12H, s, 2 × C(CH3)2), 1.25 (9H, s, C(CH3)3); HRMS (ESI) 
Exact mass calcd for [M+NH4]
+ C24H36BN2O6S: 491.2387, found: 491.2425. 
1H 
NMR data was consistent with those reported previously.95  
 
tert-Butyl N-[(benzenesulfonyl)(3-methoxyphenyl)methyl]carbamate (219l) 
 
m-Anisaldehyde (2.70 mL, 22.2 mmol) was suspended in 2:1:0.7 
H2O/MeOH/HCO2H (40 mL). Sodium benzenesulfinate (4.92 g, 30.0 mmol) and 
tert-butyl carbamate (218) (1.76 g, 15.0 mmol) were added sequentially and the 
reaction mixture was stirred for 3 days. The solids were collected by filtration and 
triturated with H2O then 1:1 hexane/Et2O to yield the title compound as a white solid 
(4.90 g, 87%). 1H NMR (400 MHz, CDCl3)  7.93 (2H, d, J = 7.6 Hz, ArH), 7.65 
(1H, t, J = 7.4 Hz, ArH), 7.58-7.48 (2H, m, ArH), 7.32 (1H, dd, J = 8.4, 7.8 Hz, 
ArH), 7.02 (1H, d, J = 7.6 Hz, ArH), 7.00-6.94 (2H, m, ArH), 5.91 (1H, d, J = 10.8 
Hz, CH), 5.82 (1H, d, J = 10.8 Hz, NH), 3.80 (3H, s, OCH3), 1.26 (9H, s, C(CH3)3); 
13C NMR (100.6 MHz, CDCl3)  159.7 (C), 153.5 (C), 136.9 (C), 133.9 (CH), 131.3 
(C), 129.8 (2 × CH), 129.4 (CH), 129.0 (2 × CH), 121.12 (CH), 115.6 (CH), 114.4 
(CH), 81.2 (C), 73.9 (CH), 55.3 (CH3), 28.0 (3 × CH3); HRMS (ESI) Exact mass 
calcd for C19H23NO5SNa [M+Na]
+: 400.1189, found: 400.1184. 1H NMR and 13C 
NMR data were consistent with those reported previously.10e  
 
tert-Butyl N-[(benzenesulfonyl)(cyclohexyl)methyl]carbamate (219m) 
 
Cyclohexanecarboxyaldehyde (1.80 mL, 14.9 mmol) was suspended in 2:1:0.7 
H2O/MeOH/HCO2H (30 mL). Sodium benzenesulfinate (4.27 g, 26.0 mmol) and 
tert-butyl carbamate (218) (1.17 g, 10.0 mmol) were added sequentially and the 




triturated with H2O and then hexane to yield the title compound as a white solid 
(3.48 g, 95%). 1H NMR (400 MHz, CDCl3)  7.93-7.85 (2H, m, ArH), 7.71-7.45 
(3H, m, ArH), 5.22 (1H, d, J = 11.2 Hz, NH), 4.71 (1H, dd, J = 11.2, 3.7 Hz, CH), 
2.51-2.39 (1H, m, CH), 2.13 (1H, d, J = 12.5 Hz, CH), 1.85-1.71 (3H, m, CH), 1.67 
(1H, d, J = 12.9 Hz, CH), 1.45-1.07 (14H, m, CH); 13C NMR (100.6 MHz, CDCl3)  
153.9 (C), 138.0 (C), 133.6 (CH), 128.91 (2 × CH), 128.87 (2 × CH), 80.6 (C), 74.3 
(CH), 36.2 (CH), 30.5 (CH2), 27.9 (3 × CH3) 27.3 (CH2), 25.9 (CH2), 25.8 (CH2), 
25.6 (CH2) ; HRMS (ESI) Exact mass calcd for C18H27NNaO4S [M+Na]
+: 376.1553, 
found: 376.1532. 1H NMR and 13C NMR data were consistent with those reported 
previously.94  
 
tert-Butyl N-[1-(benzenesulfonyl)butyl]carbamate (219n) 
 
Butylaldehyde (1.35 mL, 15.0 mmol) was suspended in 2:1:0.7 H2O/MeOH/HCO2H 
(30 mL). Sodium benzenesulfinate (4.27 g, 26.0 mmol) and tert-butyl carbamate 
(225) (1.17 g, 10.0 mmol) were added sequentially. The reaction mixture was stirred 
for 3 days, the solids collected by filtration and triturated with H2O and then hexane 
to yield the title compound as a white solid (2.60 g, 83%). IR (CHCl3) 3287 (NH), 
2960, 1691 (C=O), 1528, 1311, 1146, 1084 cm‒1; 1H NMR (400 MHz, CDCl3)  
7.92 (2H, d, J = 7.2 Hz, ArH), 7.66-7.59 (1H, m, ArH), 7.59-7.51 (2H, m, ArH), 
4.98 (1H, d, J = 10.8 Hz, NH), 4.86 (1H, td, J = 10.8, 3.3 Hz, CH), 2.28-2.16 (1H, 
m, CHXCHY), 1.81-1.65 (1H, m, CHXHY), 1.49-1.36 (1H, m, CH2), 1.21 (9H, s, 
C(CH3)3), 0.98 (3H, t, J = 7.4 Hz, CH3); 
13C NMR (100.6 MHz, CDCl3)  153.8 (C), 
137.0 (C), 133.8 (CH), 129.3 (2 × CH), 129.0 (2 × CH), 80.8 (C), 70.6 (CH), 28.3 (3 
× CH3), 28.2 (CH2), 27.7 (CH2), 13.5 (CH3); HRMS (ESI) Exact mass calcd for 
C15H23NNaO4S [M+Na]
+: 336.1240, found: 336.1228. 
 
4.2.3.2 N-Boc Imines 
 






A suspension of flame dried Cs2CO3 (3.90 g, 12.0 mmol) and NaSO4 (1.70 g, 12.0 
mmol) in a solution of sulfonylcarbamate 219a (1.39 g, 4.00 mmol) in anhydrous 
alcohol-free CH2Cl2 (80 mL) was heated at reflux. After 2 h, the reaction was cooled 
to room temperature, diluted with petroleum ether, stirred for 10 min and filtered. 
The filtrate was concentrated in vacuo to give imine 206a (814 mg, 99%) as 
colourless oil. 1H NMR (400 MHz, CDCl3)  8.88 (1H, s, CH), 7.93 (2H, d, J = 6.1 
Hz, ArH), 7.60-7.55 (1H, m, ArH), 7.48 (2H, t, J = 7.5 Hz, ArH), 1.60 (9H, s, 
C(CH3)3); 
13C NMR (126 MHz, CDCl3) δ 169.7 (CH), 162.6 (C), 134.1 (C) , 133.5 
(CH), 130.2 (2 × CH), 128.8 (2 × CH), 82.3 (C), 27.9 (3 × CH3). 
1H NMR and 13C 
NMR data were consistent with those reported previously.92  
 
tert-Butyl N-[(1E)-(3-chlorophenyl)methylidene]carbamate (206b). 
The title compound was prepared according to the Representative 
Procedure from sulfonylcarbamate 219b (760 mg, 2.00 mmol) to give 
imine 206b (468 mg, 97%) as a colourless oil. 1H NMR (300 MHz, 
CDCl3) δ 8.80 (1H, s, CH), 7.96 (1H, t, J = 1.8 Hz, ArH), 7.76 (1H, dt, J = 7.6, 1.3 
Hz, ArH), 7.53 (1H ddd, J = 8.0, 2.1, 1.2 Hz, ArH), 7.42 (1H, t, J = 7.8 Hz, ArH), 
1.60 (9H, s, C(CH3)3); 
13C NMR (100.6 MHz, CDCl3) δ 167.9 (CH), 162.1 (C), 
135.8 (C), 135.2 (C), 133.3 (CH), 130.1 (CH), 129.3 (CH), 128.5 (CH), 82.6 (C), 
27.9 (3 × CH3). 
1H NMR data was consistent with those reported previously.96  
 
tert-Butyl N-[(1E)-(4-methylphenyl)methylidene]carbamate (206c) 
 
Sulfonylcarbamate 219c (1.45 g, 4.00 mmol) was dissolved in CH2Cl2 (64 mL) and 
K2CO3 (1.4 M solution) and stirred for 16 h. The aqueous layer was extracted with 
CH2Cl2 (2 × 50 mL) and the combined organic layers were dried (NaSO4) and 




NMR (400 MHz, CDCl3)  8.88 (1H, s, CH), 7.82 (2H, d, J = 8.0 Hz, ArH), 7.28 
(2H, d, J = 8.0 Hz, ArH), 2.42 (3H, s, ArCH3), 1.59 (9H, s, C(CH3)3); 
13C NMR 
(100.6 MHz, CDCl3)  168.4 (CH), 162.5 (C), 143.7 (C), 132.1 (C), 130.2 (2 × CH), 
129.7 (2 × CH), 81.0 (C), 27.9 (3 × CH3), 21.4 (CH3). 
1H NMR and 13C NMR data 
were consistent with those reported previously.92  
 
tert-Butyl N-[(1E)-naphthalen-2-ylmethylidene]carbamate 
(206d). The title compound was prepared according to the 
Representative Procedure from sulfonylcarbamate 219d (795 mg, 
2.00 mmol) to give imine 206d (418 mg, 82%) as a white solid. 1H NMR (400 MHz, 
CDCl3)  9.06 (1H, s, CH), 8.30 (1H, s, ArH), 8.10 (1H, dd, J = 8.6, 1.6 Hz, ArH), 
8.00-7.85 (3H, m, ArH), 7.68-7.52 (2H, m, ArH), 1.63 (9H, s, C(CH3)3); 
13C NMR 
(125.8 MHz, CDCl3)  169.9 (CH), 162.7 (C), 136.0 (C), 134.2 (CH), 132.8 (C), 
129.2 (CH), 128.9 (CH), 128.6 (CH), 128.0 (CH), 126.9 (CH), 124.0 (CH), 82.3 (C), 
28.0 (3 × CH3). 
1H NMR and 13C NMR data were consistent with those reported 
previously.92  
 
tert-Butyl N-[(1E)-naphthalen-1-ylmethylidene]carbamate (206e). 
The title compound was prepared according to the Representative 
Procedure from sulfonylcarbamate 219e (795 mg, 2.00 mmol) to give 
imine 206e (498 mg, 97%) as a white solid. 1H NMR (400 MHz, CDCl3)  9.55 (1H, 
s, CH), 8.93 (1H, d, J = 8.6 Hz, ArH), 8.19 (1H, dd, J = 7.2, 1.1 Hz, ArH), 8.05 (1H, 
d, J = 8.2 Hz, ArH), 7.93-7.89 (1H, m, ArH), 7.66 (1H, ddd, J = 8.5, 6.9, 1.4 Hz, 
ArH), 7.62-7.50 (2H, m, ArH), 1.64 (9H, s, C(CH3)3);
13C NMR (100.6 MHz, CDCl3) 
 168.9 (CH), 162.8 (C), 134.3 (C), 133.7 (C), 131.92 (CH), 131.86 (CH), 129.3 (C), 
128.8 (CH), 128.0 (CH), 126.5 (CH), 125.0 (CH), 123.9 (CH), 82.2 (C), 27.9 (3 × 
CH3). 










tert-Butyl N-[(1E)-(2-methylphenyl)methylidene]carbamate (206f). 
The title compound was prepared according to the Representative 
Procedure from sulfonylcarbamate 219f (1.50 g, 4.00 mmol) to give 
imine 206f (850 mg, 97%) as a pale yellow oil. 1H NMR (400 MHz, 
CDCl3)  9.22  (1H, s, CH), 8.08 (1H, dd, J = 7.8, 1.1 Hz, ArH), 7.42 (1H, td, J = 
7.5, 1.4 Hz, ArH), 7.27 (1H, t, J = 7.6 Hz, ArH), 7.23 (1H, d, J = 7.6 Hz, ArH), 2.64 
(3H, s, ArCH3), 1.60 (9H, s, C(CH3)3); 
13C NMR (100.6 MHz, CDCl3)  168.0 (CH), 
163.0 (C), 140.8 (C), 133.2 (CH), 131.9 (CH), 131.1 (C), 128.7 (CH), 126.3 (CH), 
82.1 (C), 27.9 (3 × CH3), 19.2 (CH3). 
1H NMR and 13C NMR data were consistent 
with those reported previously. 94  
 
tert-Butyl N-[(1E)-(2-chlorophenyl)methylidene]carbamate (206g). 
The title compound was prepared according to the Representative 
Procedure from sulfonylcarbamate 219g (792 mg, 2.00 mmol) to give 
imine 206g (462 mg, 96%) as a white solid. 1H NMR (400 MHz, 
CDCl3)  9.27 (1H, s, CH), 8.18 (1H, dd, J = 7.9, 1.6 Hz, ArH), 7.49-7.40 (2H, m, 
ArH), 7.35-7.30 (1H, m, ArH), 1.59 (9H, s, C(CH3)3); 
13C NMR (100.6 MHz, 
CDCl3)  165.7 (CH), 162.4 (C), 137.8 (C), 134.2 (CH), 131.3 (C), 130.2 (CH), 
129.1 (CH), 127.2 (CH), 82.6 (C), 27.9 (3 × CH3). 
1H NMR and 13C NMR data were 
consistent with those reported previously.97  
 
tert-Butyl N-[(1E)-[4-
(trifluoromethyl)phenyl]methylidene]carbamate (206h). The title 
compound was prepared according to the Representative Procedure 
from sulfonylcarbamate 219h (831 mg, 2.00 mmol) to give imine 
206h (530 mg, 97%). 1H NMR (400 MHz, CDCl3)  8.86 (1H, s, CH), 7.80 (2H, d, J 
= 8.0 Hz, ArH), 7.27 (2H, d, J = 8.0 Hz, ArH), 1.59 (9H, s, C(CH3)3). 
1H NMR data 







tert-Butyl N-[(1E)-thiophen-2-ylmethylidene]carbamate (206i). 
The title compound was prepared according to the Representative 
Procedure from sulfonylcarbamate 219i (353 mg, 1.00 mmol) to give 
imine 206i (209 mg, 98%) as a colourless oil. 1H NMR (400 MHz, 
CDCl3)  9.07 (1H, s, CHN), 7.68-7.63 (2H, m, thienylH), 7.1-7.14 
(1H, m, thienylH), 1.57 (9H, s, C(CH3)3); 
13C NMR (100.6 MHz, CDCl3)  163.4 
(CH), 162.1 (C), 140.2 (C), 137.0 (CH), 134.1 (CH), 128.3 (CH), 82.0 (C), 27.8 (3 × 
CH3). 
1H NMR and 13C NMR data were consistent with those reported previously.92  
 
tert-Butyl N-[(1E)-2H-1,3-benzodioxol-5-
ylmethylidene]carbamate (206j). The title compound was 
prepared according to the Representative Procedure from 
sulfonylcarbamate 219j (784 mg, 2.00 mmol) give imine 206j (475 
mg, 97%) as a white solid. m.p 53-55 C (not recrystallized); IR (CHCl3) 3010, 1707 
(C=O), 1621, 1597, 1505, 1492, 1452, 1243, 1154, 1103 cm‒1; 1H NMR (400 MHz, 
CDCl3)  8.82 (1H, s, CH), 7.53 (1H, d, J = 1.2 Hz, ArH), 7.36 (1H, dd, J = 8.0, 1.2 
Hz, ArH), 6.89 (1H, d, J = 8.0 Hz, ArH), 6.07 (2H, s, CH2), 1.57 (9H, s, C(CH3)3); 
13C NMR (100.6 MHz, CDCl3)  169.5 (CH), 162.7 (C), 152.6 (C), 148.6 (C), 128.9 
(CH), 128.8 (C), 108.3 (CH), 107.6 (CH), 102.0 (CH2), 82.0 (C), 27.9 (3 × CH3); 
HRMS (ESI) Exact mass calcd for C13H15NO4Na [M+Na]




yl)phenyl]methylidene]carbamate (206k). The title compound 
was prepared according to the Representative Procedure from 
sulfonylcarbamate 219k (947 mg, 2.00 mmol) to give imine 206k 
(601 mg, 91%) as a white solid. m.p. 103-105 C (not recrystallized); IR (CHCl3) 
2984, 1711 (C=O), 1623, 1395, 1360, 1272, 1144, 1088, 856 cm‒1; 1H NMR (400 
MHz, CDCl3)  8.88 (1H, s, CH), 7.91 (4H, s, ArH), 1.60 (9H, s, C(CH3)3), 1.37 
(12H, s, 2 × C(CH3)2); 
13C NMR (100.6 MHz, CDCl3)  169.7 (CH), 162.6 (C), 
136.2 (C), 135.1 (2 × CH), 129.2 (2 × CH), 84.2 (2 x × C), 82.4 (C), 27.9 (3 × CH3), 




relaxation effects of 11B; HRMS (ESI) Exact mass calcd for C18H26BNO4Na 
[M+Na]+: 354.1850, found: 354.1847. 
 
tert-Butyl N-[(1E)-(3-methoxyphenyl)methylidene]carbamate 
(206l). The title compound was prepared according to the 
Representative Procedure from sulfonylcarbamate 219l (755 mg, 
2.00 mmol) to give imine 206l (464 mg, 98%) as a pale yellow oil. -
1H NMR (400 MHz, CDCl3)  8.82 (1H, s, CH), 7.49 (1H, dd, J = 2.4, 1.3 Hz, ArH), 
7.45-7.33 (2H, m, ArH), 7.10 (1H, ddd, J = 8.0, 2.7, 1.2 Hz, ArH), 3.84 (3H, s, 
OCH3), 1.59 (9H, s, C(CH3)3); 
13C NMR (400 MHz, CDCl3)  169.5 (CH), 162.5 
(C), 159.9 (C), 135.4 (C), 129.8 (CH), 124.1 (CH), 120.7 (CH), 112.3 (CH), 82.3 
(C), 55.4 (CH3), 28.2 (3 × CH3). 
1H NMR and 13C NMR data were consistent with 
those reported previously.98  
 
tert-Butyl N-[(1E)-cyclohexylmethylidene]carbamate (206m). 
The title compound was prepared according to the Representative 
Procedure from sulfonylcarbamate 219m (707 mg, 2.00 mmol) to give 
imine 206m (415 mg, 98%) as a colourless oil. 1H NMR (400 MHz, 
CDCl3)  8.17 (1H, br, s, CHN), 2.35-2.25 (1H, m, CH), 1.95-1.85 
(2H, m, CH2), 1.84-1.75 (2H, m, CH2), 1.73-1.65 (1H, m, CHXHY), 1.53 (9H, s, 
C(CH3)3), 1.38-1.30 (5H, m, 2 × CH2, CHXHY); 
13C NMR (100.6 MHz, CDCl3)  
178.1 (CH), 162.3 (C), 81.7 (C), 43.4 (CH), 29.5 (CH2), 28.4 (2 × CH2), 27.7 (3 × 
CH3), 25.7 (CH2), 25.1 (CH2). 
1H NMR and 13C NMR data were consistent with 
those reported previously.94  
 
tert-Butyl N-[(1E)-butylidene]carbamate (206n)  
The title compound was prepared according to the Representative 
Procedure from sulfonylcarbamate 219n (1.17 g, 3.70 mmol) to give 
imine 206n (340 mg, 99%) as a pale yellow oil. IR (film) 2966, 2937, 
2876, 1720.7 (C=O), 1367, 1251, 1158 cm‒1; 1H NMR (400 MHz, CDCl3)  8.33 
(1H, br, s, CH), 2.46-2.35 (2H, m, CHCH2), 1.73-1.62 (2H, m, CH2CH3), 1.56 (9H, 
s, C(CH3)3), 1.02 (3H, t, J = 7.4 Hz, CH2CH3); 




(CH), 167.8 (C), 82.1 (C), 28.4 (CH2), 28.3 (CH2), 27.9 (3 × CH3), 13.7 (CH3); 
HRMS (ESI) Exact mass calculated for C9H17NNaO2 [M+Na]




4.2.4 Enantioselective Copper-Catalysed Reductive Coupling 
Reactions 
 
General Procedure A: Reductive Coupling of Vinylazaarenes with Imine 215a 
Using Ligand L15  
 
A solution of the appropriate vinylazaarene (0.30 mmol), Cu(OAc)2·H2O (3.0 mg, 
0.01 mmol), (S)-DTBM-SEGPHOS® (L15) (17.7 mg, 0.015 mmol), and imine 215a 
(68 mg, 0.33 mmol) in THF (1.5 mL) was stirred at 0 °C for 15 min. TMDS (64 μL, 
0.36 mmol) was then added dropwise over 1 min. The mixture was stirred at 0 °C for 
1 h, then at room temperature for 15 h. The reaction was quenched carefully with 
SiO2, and the resulting suspension was stirred for 15 min before being filtered 
through a short plug of SiO2, using EtOAc as eluent and concentrated in vacuo. 




propyl]carbamate (212a). The title compound was prepared 
according to General Procedure A from 2-vinylquinoline (175b) 
(47 mg, 0.30 mmol) and purified by column chromatography (5% EtOAc/hexane) to 




131 C (EtOAc/petroleum ether); [α] 24D  +98.6 (c 1.10, CHCl3); IR (film) 2970, 2934, 
1709 (C=O), 1503, 1390, 1289, 827, 756, 700 cm−1; 1H NMR (500 MHz, (CD3)2CO) 
 8.14 (1H, d, J = 8.4 Hz, ArH), 8.05 (1H, d, J = 8.3 Hz, ArH), 7.88 (1H, d, J = 8.0 
Hz, ArH), 7.75 (1H, ddd, J = 8.4, 6.9, 1.4 Hz, ArH), 7.57-7.51 (1H, m, ArH), 7.33 
(2H, d, J = 7.3 Hz, ArH), 7.24 (3H, t, J = 8.0 Hz, ArH), 7.16 (2H, t, J = 7.0 Hz, ArH 
and NH), 5.09 (1H, t, J = 7.7 Hz, CHN), 3.63-3.54 (1H, m, CHCH3), 1.35 (3H, d, J 
= 6.9 Hz, CHCH3), 1.27 (9H, s, C(CH3)3); 
13C NMR (125.8 MHz, (CD3)2CO)  
165.1 (C), 156.0 (C), 148.5 (C), 144.1 (C), 137.0 (CH), 130.2 (CH), 129.7 (CH), 
128.9 (2 × CH), 128.6 (CH), 128.0 (C), 127.7 (2 × CH), 127.5 (CH), 126.8 (CH), 
122.8 (CH), 78.5 (C), 60.2 (CH), 48.1 (CH), 28.5 (3 × CH3), 19.6 (CH3); HRMS 
(ESI) Exact mass calcd for C23H27N2O2 [M+H]
+: 363.2067, found: 363.2067. 
Enantiomeric excess was determined by HPLC with a Chiralcel OD-H column 
(90:10 iso-hexane:i-PrOH, 1.0 mL/min, 254 nm, 25 °C); tr (major) = 4.6 min, tr 
(minor) = 5.9 min; 85% ee.  
 
tert-Butyl N-[(1R,2S)-1-phenyl-2-(quinoxalin-2-
yl)propyl]carbamate (212b). The title compound was prepared 
according to General Procedure A from 2-vinylquinoxaline 
(175d) (47 mg, 0.30 mmol) and purified by by column chromatography (10% 
EtOAc/hexane) to give a white solid (75 mg, 69%). Rf 0.43 (30% EtOAc/petroleum 
ether); m.p. 160-162 C (EtOAc/petroleum ether); [α] 24D  +118.6 (c 1.05, CHCl3); IR 
(film) 2970, 2939, 1697 (C=O), 1493, 1454, 1365, 1249, 1168, 760, 700 cm−1; 1H 
NMR (500 MHz, (CD3)2CO)  8.76 (1H, s, ArH), 8.09 (1H, d, J = 8.1 Hz, ArH), 
8.04 (1H, d, J = 7.9 Hz, ArH), 7.83 (1H, t, J = 7.7 Hz, ArH), 7.79 (1H, t, J = 7.1 Hz, 
ArH), 7.45 (2H, d, J = 7.5 Hz, ArH), 7.33 (2H, t, J = 7.5 Hz, ArH), 7.25 (1H, t, J = 
7.3 Hz, ArH), 6.74 (1H, d, J = 8.0 Hz, NH), 5.10 (1H, t, J = 8.9 Hz, CHN), 3.79-3.66 
(1H, m, CHCH3), 1.31 (3H, d, J = 6.9 Hz, CHCH3), 1.15 (9H, s, C(CH3)3); 
13C NMR 
(125.8 MHz, (CD3)2CO)  160.0 (C), 155.7 (C), 147.3 (CH), 143.4 (C), 142.8 (C), 
142.5 (C), 130.7 (CH), 130.04 (CH), 129.99 (CH), 129.89 (2 × CH), 129.2 (2 × CH), 
128.02 (CH), 127.96 (CH), 78.7 (C), 60.3 (CH), 46.1 (CH), 28.4 (3 × CH3), 18.6 
(CH3); HRMS (ESI) Exact mass calcd for C22H26N3O2 [M+H]
+: 364.2020, found: 




column (98:2 hexane:i-PrOH, 0.8 mL/min, 230 nm, 25 °C); tr (minor) = 11.3 min, tr 
(major) = 14.6 min; 92% ee.  
 
tert-Butyl N-[2-(6-bromopyridin-2-yl)-1-
phenylpropyl]carbamate (212c). The title compound was 
prepared according to General Procedure A from 6-bromo-2-
vinylpyridine (175p) (55 mg, 0.30 mmol) and purified by column chromatography 
(10% EtOAc/iso-hexane) to give a 4.3:1 mixture of diastereomers as a white solid 
(80 mg, 68%). Rf 0.24 (20% EtOAc/petroleum ether); [α]
22
D  +121.2 (c 0.66, CHCl3); 
IR (CHCl3) 3009, 2934, 1709 (C=O), 1584, 1499, 1456, 1435, 1367, 1163, 842 cm
‒1; 
Enantiomeric excess was determined by HPLC with a Chiralpak AD-H column (99:1 
iso-hexane:EtOH, 0.3 mL/min, 254 nm, 25 °C); major diastereomer: tr (major) = 
30.2, tr (minor) = 34.5 min, 80% ee; minor diastereomer: tr (major) = 46.3, tr (minor) 
= 55.0 min, 20% ee. 
Major diastereomer: 1H NMR (400 MHz, (CD3)2CO)  7.59 (1H, t, J = 7.7 Hz, ArH), 
7.41 (1H, d, J = 2.4 Hz, ArH), 7.37 (2H, d, J = 7.2 Hz, ArH), 7.31 (2H, d, J = 7.6 
Hz, ArH), 7.23 (2H, d, J = 6.5 Hz, ArH), 6.61 (1H, d, J = 7.8 Hz, NH), 4.92 (1H, t, J 
= 7.8 Hz, CHN), 3.37-3.30 (1H, m, CHCH3), 1.27 (9H, s, C(CH3)3), 1.13 (3H, d, J = 
6.8 Hz, CHCH3); 
13C NMR (125.8 MHz, (CD3)2CO)  166.3 (C), 155.7 (C), 143.6 
(C), 141.8 (C), 140.1 (CH), 129.0 (2 × CH), 128.0 (2 × CH), 127.8 (CH), 126.7 
(CH), 123.2 (CH), 78.6 (C), 60.1 (CH), 47.6 (CH), 28.5 (3 × CH3), 19.1 (CH3). 
Diagnostic peaks for minor diastereomer: 1H NMR (400 MHz, (CD3)2CO)  8.05 
(1H, d, J = 7.3 Hz, ArH), 7.52 (1H, t, J = 7.6 Hz, ArH), 7.46-7.40 (1H, m, ArH), 
7.34-7.28 (1H, t, J = 7.6 Hz, ArH), 7.17 (2H, t, J = 7.5 Hz, ArH), 7.10 (1H, d, J = 7.1 
Hz, ArH), 7.01 (1H, d, J = 7.5 Hz, ArH), 5.05 (1H, t, J = 9.3 Hz, CHN), 3.45-3.42 
(1H, m, CHCH3), 1.38-1.33 (12H, m, CHCH3 and C(CH3)3); 
13C NMR (125.8 MHz, 
(CD3)2CO)  165.9 (C), 156.1 (C), 143.4 (C), 141.7 (C), 139.9 (CH), 128.7 (2 × CH), 
128.1 (2 × CH), 127.5 (CH), 126.5 (CH), 123.1 (CH), 78.7 (C), 60.0 (CH), 48.1 
(CH), 28.6 (3 × CH3), 17.5 (CH3); HRMS (ESI) Exact mass calcd for C19H24BrN2O2 







yl)propyl]carbamate (212d). The title compound was prepared 
according to General Procedure A from 3-phenyl-6-
vinylpyridazine (175o) (55 mg, 0.30 mmol) and purified by column chromatography 
(0.5% Et3N in 25% EtOAc/hexane) to give a white solid (68 mg, 58%). Rf 0.14 (20% 
EtOAc/petroleum ether); m.p. 181-182 C (EtOAc/petroleum ether); [α] 24D  +68.0 (c 
1.00, CHCl3); IR (film) 2976, 1690 (C=O), 1504, 1497, 1454, 1426, 1365, 1170, 753, 
699 cm‒1; 1H NMR (400 MHz, (CD3)2CO)  8.20-8.14 (2H, m, ArH), 8.01 (1H, d, J 
= 8.8 Hz, ArH), 7.58-7.48 (4H, m, ArH), 7.44-7.40 (2H, m, ArH), 7.32 (2H, t, J = 
7.5 Hz, ArH), 7.23 (1H, t, J = 7.2 Hz, ArH), 6.81 (1H, d, J = 8.6 Hz, NH), 5.06 (1H, 
t, J = 8.7 Hz, CHN), 3.71-3.56 (1H, m, CHCH3), 1.32 (3H, d, J = 6.9 Hz, CHCH3), 
1.26 (9H, s, C(CH3)3); 
13C NMR (125.8 MHz, (CD3)2CO)  165.0 (C), 158.3 (C), 
155.9 (C), 143.5 (C), 137.6 (C), 130.6 (CH), 129.8 (2 x CH), 129.1 (2 × CH), 127.93 
(2 × CH), 127.90 (CH), 127.86 (2 × CH), 127.7 (CH), 124.6 (CH), 78.8 (C), 60.1 
(CH), 46.6 (CH), 28.5 (3 × CH3), 19.2 (CH3); HRMS (ESI) Exact mass calcd for 
C24H28N3O2 [M+H]
+: 390.2176, found: 390.2176. Enantiomeric excess was 
determined by HPLC with a Chiralcel OD-H column (95:5 hexane:i-PrOH, 
0.8 mL/min, 230 nm, 25 °C); tr (minor) = 10.6 min, tr (major) = 12.0 min; 82% ee.  
 
tert-Butyl N-[(1S,2R)-2-(1,3-benzoxazol-2-yl)-1-
phenylpropyl]carbamate (212e). The title compound was 
prepared according to General Procedure A from 2-
vinylbenzoxazole (175l) (44 mg, 0.30 mmol) and purified by column 
chromatography (5% EtOAc/hexane) to give a white solid (78 mg, 74%). Rf 0.38 
(20% EtOAc/petroleum ether); m.p. 93-95 C (EtOAc/petroleum ether); [α] 24D  +26.6 
(c 1.02, CHCl3); IR (film) 2976, 1715 (C=O), 1567, 1497, 1365, 1288, 1171, 1002, 
748, 701 cm‒1; 1H NMR (400 MHz, (CD3)2CO)  7.69-7.65 (1H, m, ArH), 7.57-7.53 
(1H, m, ArH), 7.47-7.42 (2H, m, ArH), 7.37-7.29 (4H, m, ArH), 7.25 (1H, t, J = 7.2 
Hz, ArH), 6.75 (1H, d, J = 8.2 Hz, NH), 5.11 (1H, t, J = 8.2 Hz, CHN), 3.70-3.59 
(1H, m, CHCH3), 1.33 (3H, d, J = 7.7 Hz, CHCH3), 1.25 (9H, s, C(CH3)3); 
13C NMR 
(125.8 MHz, (CD3)2CO)  168.9 (C), 155.8 (C), 151.4 (C), 142.3 (C), 142.2 (C), 




111.3 (CH), 79.0 (C), 59.0 (CH), 41.0 (CH), 28.4 (3 × CH3), 17.0 (CH3); HRMS 
(ESI) Exact mass calcd for C21H25N2O3 [M+H]
+: 353.1860, found: 353.1863. 
Enantiomeric excess was determined by HPLC with a Chiralpak AS-H column (98:2 
hexane:i-PrOH, 0.8 mL/min, 280 nm, 25 °C); tr (major) = 15.2 min, tr (minor) = 19.3 
min; 75% ee.  
 
tert-Butyl N-[(1R,2S)-2-(1,3-benzothiazol-2-yl)-1-
phenylpropyl]carbamate (212f). The title compound was 
prepared according to General Procedure A from 2-
vinylbenzothiazole (175k) (47 mg, 0.30 mmol) and purified by column 
chromatography (5% EtOAc/hexane) to give a white solid (72 mg, 65%). Rf 0.32 
(20% EtOAc/petroleum ether); m.p. 142-145 C (EtOAc/petroleum ether); [α] 24D  
+55.0 (c 1.00, CHCl3); IR (film) 2979, 2928, 1713 (C=O), 1498, 1390, 1365, 1170, 
1022, 759, 700 cm‒1;  1H NMR (400 MHz, (CD3)2CO)  7.98 (2H, t, J = 8.9 Hz, 
ArH), 7.54-7.45 (1H, m, ArH), 7.45-7.35 (3H, m, ArH), 7.30 (2H, t, J = 7.4 Hz, 
ArH), 7.23 (1H, t, J = 7.5 Hz, ArH), 6.80 (1H, d, J = 7.5 Hz, NH), 5.15-4.90 (1H, m, 
CHN), 3.88-3.65 (1H, m, CHCH3), 1.37 (3H, d, J = 6.8 Hz, CHCH3), 1.28 (9H, s, 
C(CH3)3); 
13C NMR (125.8 MHz, (CD3)2CO)  174.7 (C), 155.9 (C), 154.1 (C), 
142.9 (C), 135.6 (C), 129.1 (2 × CH), 128.0 (CH), 127.8 (2 × CH), 126.8 (CH), 
125.7 (CH), 123.4 (CH), 122.6 (CH), 78.9 (C), 60.3 (CH), 45.1 (CH), 28.5 (3 × 
CH3), 19.5 (CH3); HRMS (ESI) Exact mass calcd for C21H25N2O2S [M+H]
+: 
369.1631, found: 369.1634. Enantiomeric excess was determined by HPLC with a 
Chiralpak IC column (98:2 hexane:i-PrOH, 0.8 mL/min, 280 nm, 25 °C); tr (major) = 
18.9 min, tr (minor) = 27.9 min; 88% ee.  
Slow diffusion of hexane into a solution of 212f in EtOAc provided single crystals 




   
 
General Procedure B: Reductive Coupling of Vinylazaarenes with Various N-
Boc Imines Using Ligand L15  
 
A solution of the appropriate vinylazaarene (0.30 mmol), Cu(OAc)2·H2O (3.0 mg, 
0.015 mmol), (S)-DTBM-SEGPHOS® (L15) (17.7 mg, 0.015 mmol), and the 
appropriate imine (0.33 mmol) in THF (1.5 mL) was stirred at 0 °C for 15 min. 
TMDS (64 μL, 0.36 mmol) was then added dropwise over 1 min. The mixture was 
stirred at 0 °C for 1 h, then at room temperature for 16 h. The reaction was quenched 
carefully with SiO2, and the resulting suspension was stirred for 15 min before being 
filtered through a short plug of SiO2, using EtOAc as eluent and concentrated in 




2-yl)propyl]carbamate (221a). The title compound was 
prepared according to General Procedure B from 2-




mmol) and purified by column chromatography (5-10% EtOAc/iso-hexane) to give a 
white solid (73 mg, 58%). Rf 0.33 (20% EtOAc/petroleum ether); m.p. 156-158 C 
(EtOAc/petroleum ether); [α] 24D  +144.8 (c 1.02, CHCl3); IR (film) 2973, 2928, 1707 
(C=O), 1503, 1365, 1169, 1048, 858, 818, 755 cm‒1; 1H NMR (400 MHz, (CD3)2CO) 
 8.11 (1H, d, J = 8.4 Hz, ArH), 8.08 (1H, d, J = 8.4 Hz, ArH), 7.91-7.72 (6H, m, 
ArH), 7.58-7.52 (2H, m, ArH), 7.48-7.40 (2H, m, ArH), 7.27 (1H, d, J = 8.4 Hz, 
ArH), 7.23 (1H, d, J = 7.2 Hz, NH), 5.35-5.11 (1H, m, CHN), 3.79-3.58 (1H, m, 
CHCH3), 1.38 (3H, d, J = 7.0 Hz, CHCH3), 1.27 (9H, s, C(CH3)3); 
13C NMR 
(125.8 MHz, (CD3)2CO)  165.1 (C), 156.1 (C), 148.5 (C), 141.6 (C), 137.1 (CH), 
134.2 (C), 133.6 (C), 130.2 (CH), 129.8 (CH), 128.65 (CH), 128.62 (CH), 128.61 
(CH), 128.4 (CH), 128.0 (C), 126.8 (2 × CH), 126.5 (CH), 126.4 (CH), 126.0 (CH), 
122.8 (CH), 78.6 (C), 60.4 (CH), 48.0 (CH), 28.5 (3 × CH3), 19.7 (CH3); HRMS 
(ESI) Exact mass calcd for C27H29N2O2 [M+H]
+: 413.2224, found: 413.2226. 
Enantiomeric excess was determined by HPLC with a Chiralcel OD-H column (98:2 
hexane:i-PrOH, 0.8 mL/min, 230 nm, 25 °C); tr (major) = 18.1 min, tr (minor) = 21.9 
min; 86% ee.  
 
tert-Butyl N-[(1R,2S)-1-(4-methylphenyl)-2-(quinolin-2-
yl)propyl]carbamate (221b). The title compound was 
prepared according to General Procedure B from 2-
vinylquinoline (175b) (47 mg, 0.30 mmol) and N-Boc imine 206c (72 mg, 0.33 
mmol and purified by column chromatography (5% EtOAc/hexane) to give a white 
solid (68 mg, 61%). Rf 0.60 (30% EtOAc/petroleum ether); m.p. 142-144 C 
(EtOAc/petroleum ether); [α] 24D  +94.5 (c 0.55, CHCl3); IR (film) 2974, 2930, 1711 
(C=O), 1600, 1504, 1365, 1248, 1170, 1047, 830 cm‒1; 1H NMR (500 MHz, 
(CD3)2CO)  8.15 (1H, d, J = 8.4 Hz, ArH), 8.03 (1H, d, J = 8.4 Hz, ArH), 7.88 (1H, 
d, J = 8.0 Hz, ArH), 7.78-7.73 (1H, m, ArH), 7.57-7.52 (1H, m, ArH), 7.26 (1H, d, 
ArH), 7.20 (2H, t, J = 8.0 Hz, ArH), 7.13-7.01 (3H, m, ArH and NH), 5.10-4.90 
(1H, m, CHN), 3.61-3.46 (1H, m, CHCH3), 2.24 (3H, s, ArCH3), 1.33 (3H, d, J = 6.8 
Hz, CHCH3), 1.27 (9H, s, C(CH3)3); 
13C NMR (125.8 MHz, (CD3)2CO)  165.3 (C), 




129.5 (2 × CH), 128.6 (CH), 128.0 (C), 127.6 (2 × CH), 126.8 (CH), 122.8 (CH), 
78.5 (C), 59.9 (CH), 48.2 (CH), 28.5 (3 × CH3), 21.0 (CH3), 19.6 (CH3); HRMS 
(ESI) Exact mass calcd for C24H29N2O2 [M+H]
+: 377.2229, found: 377.2228. 
Enantiomeric excess was determined by HPLC with a Chiralcel OD-H column (98:2 
hexane:i-PrOH, 0.8 mL/min, 230 nm, 25 °C); tr (major) = 10.6, tr (minor) = 15.9 min; 
82% ee.  
 
 tert-Butyl N-[(1R,2S)-1-(2-chlorophenyl)-2-(quinolin-2-
yl)propyl]carbamate (221c). The title compound was 
prepared according to General Procedure B from 2-
vinylquinoline (175b) (47 mg, 0.30 mmol) and N-Boc imine 206g (79 mg, 0.33 
mmol) and purified by column chromatography (0-10% EtOAc/petroleum ether) to 
give an orange oil (50 mg, 42%). Rf 0.65 (30% EtOAc/petroleum ether); [α]
22
D +189.1 
(c 1.10, CHCl3); IR (CHCl3) 3062, 2930, 1709 (C=O), 1502, 1367, 1282, 1170, 
1049, 881, 864 cm‒1; 1H NMR (400 MHz, (CD3)2CO)  8.13 (1H, d, J = 8.4 Hz, 
ArH), 8.08 (1H, d, J = 8.5 Hz, ArH), 7.90 (1H, d, J = 8.1 Hz, ArH), 7.84-7.74 (1H, 
m, ArH), 7.58 (1H, t, J = 7.1 Hz, ArH), 7.50 (1H, d, J = 7.6 Hz, NH), 7.40 (1H, d, J 
= 7.9 Hz, ArH), 7.27-6.97 (4H, m, ArH), 5.56-5.44 (1H, m, CHN), 3.69-3.47 (1H, 
m, CHCH3), 1.46 (3H, d, J = 6.9 Hz, CHCH3), 1.32 (9H, s, C(CH3)3); 
13C NMR 
(125.8 MHz, (CD3)2CO)  164.4 (C), 156.0 (C), 148.3 (C), 141.6 (C), 137.3 (CH), 
133.3 (C), 130.4 (CH), 130.1 (CH), 129.7 (CH), 129.1 (CH), 128.9 (CH), 128.7 
(CH), 128.0 (C), 127.6 (CH), 127.0 (CH), 123.1 (CH), 78.9 (C), 57.0 (CH), 46.0 
(CH), 28.5 (3 × CH3), 19.4 (CH3); HRMS (ESI) Exact mass calcd for C23H26ClN2O2 
[M+H]+: 397.1677, found: 397.1645. Enantiomeric excess was determined by HPLC 
with a Chiralpak  IA-3 column (90:10 hexane:i-PrOH, 1.5 mL/min, 230 nm, 25 °C); 




(trifluoromethyl)phenyl]propyl]carbamate (221d). The 
title compound was prepared according to General 




206h (90 mg, 0.33 mmol) and purified by column chromatography (5% 
EtOAc/hexane) to give a white solid (59 mg, 46%). Rf 0.21 (20% EtOAc/petroleum 
ether); m.p. 167-169 C (EtOAc/petroleum ether); [α] 24D  +103.7 (c 1.06, CHCl3); IR 
(film) 2979, 2938, 1701 (C=O), 1493, 1367, 1326, 1165, 1125, 1067, 848 cm‒1; 1H 
NMR (500 MHz, (CD3)2CO)  8.78 (1H, s, ArH), 8.10 (1H, d, J = 8.1 Hz, ArH), 
8.05 (1H, d, J = 7.8 Hz, ArH), 7.85 (1H, t, J = 7.0 Hz, ArH), 7.83-7.77 (1H, m, 
ArH), 7.69 (4H, s, ArH), 6.91 (1H, d, J = 8.2 Hz, NH), 5.23-5.14 (1H, m, CHN), 
3.85-3.72 (1H, m, CHCH3), 1.33 (3H, d, J = 6.8 Hz, CHCH3), 1.17 (9H, s, C(CH3)3); 
13C NMR (125.8 MHz, (CD3)2CO)  159.6 (C), 155.8 (C), 148.2 (C), 147.2 (CH), 
142.8 (C), 142.6 (C), 130.8 (CH), 130.2 (CH), 130.1 (CH), 129.9 (CH), 129.6 (C, q, 
J = 32.5 Hz), 128.8 (2 × CH), 126.1 (2 × CH, q, J = 3.9 Hz), 125.4 (C, q, J = 270.6 
Hz), 79.0 (C), 60.0 (CH), 45.6 (CH), 28.3 (3 × CH3), 18.7 (CH3); 
19F NMR (377 
MHz, (CD3)2CO)  −62.9; HRMS (ESI) Exact mass calcd for C23H25F3N3O2 
[M+H]+: 432.1898, found: 432.1897. Enantiomeric excess was determined by HPLC 
with a Chiralcel OD-H column (98:2 hexane:i-PrOH, 0.8 mL/min, 230 nm, 25 °C); tr 
(minor) = 11.7, tr (major) = 14.6 min; 93% ee.  
Slow diffusion of hexane into a solution of 221d in EtOAc provided single crystals 





(quinoxalin-2-yl)propyl]carbamate (221e). The title 
compound was prepared according to General Procedure 




mg, 0.33 mmol) and purified by column chromatography (5% EtOAc/hexane) to give 
a white solid (69 mg, 59%). Rf 0.52 (20% EtOAc/petroleum ether); m.p. 134-136 C 
(EtOAc/petroleum ether); [α] 24D  +115.7 (c 1.14, CHCl3); IR (film) 2975, 2930, 1699 
(C=O), 1601, 1492, 1366, 1253, 1045, 762, 699 cm‒1; 1H NMR (500 MHz, 
(CD3)2CO)  8.77 (1H, s, ArH), 8.09 (1H, d, J = 8.1 Hz, ArH), 8.04 (1H, d, J = 8.1 
Hz, ArH), 7.83 (1H, t, J = 7.1 Hz, ArH), 7.80-7.75 (1H, m, ArH), 7.24 (1H, t, J = 7.9 
Hz, ArH), 7.06 (1H, s, ArH), 7.01 (1H, d, J = 7.5 Hz, ArH), 6.83-6.79 (1H, m, ArH), 
6.73 (1H, d, J = 8.4 Hz, NH), 5.15-4.91 (1H, m, CHN), 3.76 (3H, s, OCH3), 3.75-
3.67 (1H, m, CHCH3), 1.32 (3H, d, J = 7.0 Hz, CHCH3), 1.16 (9H, s, C(CH3)3); 
13C 
NMR (125.8 MHz, (CD3)2CO)  160.8 (C), 160.0 (C), 155.7 (C), 147.3 (CH), 145.0 
(C), 142.8 (C), 142.5 (C), 130.7 (CH), 130.2 (CH), 130.02 (CH), 129.96 (CH), 
129.86 (CH), 120.3 (CH), 113.5 (2 × CH), 78.7 (C), 60.3 (CH), 55.4 (CH3), 46.1 
(CH), 28.4 (3 × CH3), 18.5 (CH3); HRMS (ESI) Exact mass calcd for C23H28N3O3 
[M+H]+: 394.2125, found: 394.2146. Enantiomeric excess was determined by HPLC 
with a Chiralpak IC column (70:30 hexane:i-PrOH, 0.8 mL/min, 230 nm, 25 °C); tr 
(minor) = 8.8, tr (major) = 15.6 min; 79% ee.  
   
tert-Butyl N-[(1R,2S)-1-(2-methylphenyl)-2-(quinoxalin-2-
yl)propyl]carbamate (221f). The title compound was 
prepared according to General Procedure B from 2-
vinylquinoxaline (175d) (47 mg, 0.30 mmol) and N-Boc imine 206f (72 mg, 0.33 
mmol) and purified by column chromatography (10% EtOAc/iso-hexane) to give a 
pale yellow oil (63 mg, 56%). Rf 0.26 (20% EtOAc/petroleum ether); [α]
24
D  +181.8 
(c 0.66, CHCl3); IR (CHCl3) 3010, 2981, 1708 (C=O), 1494, 1455, 1367, 1289, 
1250, 1168, 924 cm‒1; 1H NMR (500 MHz, (CD3)2CO)  8.78 (1H, s, ArH), 8.11 
(1H, d, J = 8.0 Hz, ArH), 8.05 (1H, d, J = 8.1 Hz, ArH), 7.84 (1H, t, J = 7.3 Hz, 
ArH), 7.79 (1H, t, J = 7.3 Hz, ArH), 7.41-7.35 (1H, m, ArH), 7.24-7.18 (1H, m, 
ArH), 7.18-7.10 (2H, m, ArH), 6.67 (1H, d, J = 8.2 Hz, NH), 5.52-5.28 (1H, m, 
CHN), 3.80-3.65 (1H, m, CHCH3), 2.57 (3H, s, ArCH3), 1.30 (3H, d, J = 7.0 Hz, 
CHCH3), 1.12 (9H, s, C(CH3)3); 
13C NMR (125.8 MHz, (CD3)2CO)  160.1 (C), 
155.7 (C), 147.4 (CH), 142.9 (C), 142.6 (C), 142.0 (C), 136.7 (C), 131.1 (CH), 130.7 




78.6 (C), 55.8 (CH), 45.8 (CH), 28.3 (3 × CH3), 19.9 (CH3), 17.9 (CH3); HRMS 
(ESI) Exact mass calcd for C23H28N3O2 [M+H]
+: 378.2176, found: 378.2168. 
Enantiomeric excess was determined by HPLC with a Chiralpak IA-3 column (80:20 
iso-hexane:i-PrOH, 1.5 mL/min, 230 nm, 25 °C); tr (major) = 7.4, tr (minor) = 18.4 
min; 80% ee.  
 
tert-Butyl N-[(1R,2S)-2-(1,3-benzothiazol-2-yl)-1-(thiophen-
2-yl)propyl]carbamate (221g). The title compound was 
prepared according to General Procedure B from 2-
vinylbenzoxazole (175l) (44 mg, 0.30 mmol) and N-Boc imine 206i (70 mg, 0.33 
mmol) and purified by column chromatography (10% EtOAc/hexane) to give a 
yellow foam (77 mg, 71%). Rf 0.52 (20% EtOAc/petroleum ether); [α]
24
D  +11.6 (c 
1.03, CHCl3); IR (film) 2974, 2925, 1710 (C=O), 1616, 1567, 1533, 1456, 1241, 
1183, 700, cm‒1; 1H NMR (500 MHz, (CD3)2CO)  7.71-7.65 (1H, m, ArH), 7.60-
7.55 (1H, m, ArH), 7.39-7.31 (2H, m, ArH), 7.28 (1H, d, J = 4.9 Hz, ArH), 7.07 
(1H, d, J = 3.5 Hz, ArH), 6.98-6.89 (1H, m, ArH), 6.87-6.75 (1H, m, NH), 5.50-5.28 
(1H, m, CHN), 3.86-3.66 (1H, m, CHCH3), 1.44 (3H, d, J = 7.0 Hz, CHCH3), 1.33 
(9H, s, C(CH3)3); 
13C NMR (125.8 MHz, (CD3)2CO)  168.6 (C), 155.9 (C), 151.4 
(C), 145.9 (C), 142.1 (C), 127.6 (CH), 125.7 (CH), 125.6 (CH), 125.2 (CH), 125.1 
(CH), 120.4 (CH), 111.3 (CH), 79.4 (C), 54.6 (CH), 41.1 (CH), 28.5 (3 × CH3), 16.7 
(CH3); HRMS (ESI) Exact mass calcd for C19H23N2O3S [M+H]
+: 359.1424, found: 
359.1426. Enantiomeric excess was determined by HPLC with a Chiralpak AS-H 
column (98:2 hexane:i-PrOH, 0.8 mL/min, 230 nm, 25 °C); tr (major) = 17.1, tr 
(minor) = 27.1 min; 69% ee.  
 
tert-Butyl N-[(1R,2S)-2-(1,3-benzoxazol-2-yl)-1-
(naphthalen-2-yl)propyl]carbamate (221h). The title 
compound was prepared according to General Procedure B 
from 2-vinylbenzoxazole (175l) (44 mg, 0.30 mmol) and N-Boc imine 206d (84 mg, 
0.33 mmol) and purified by column chromatography (10% EtOAc/hexane) to give a 
white solid (76 mg, 63%). Rf 0.59 (20% EtOAc/petroleum ether); m.p. 142-144 C 




(C=O), 1500, 1456, 1392, 1243, 1166, 927, 891 cm‒1; 1H NMR (400 MHz, 
(CD3)2CO)  7.93 (1H, s, ArH), 7.91-7.82 (3H, m, ArH), 7.71-7.66 (1H, m, ArH), 
7.64 (1H, dd, J = 8.5, 1.7 Hz, ArH), 7.59-7.52 (1H, m, ArH), 7.51-7.43 (2H, m, 
ArH), 7.38-7.29 (2H, m, ArH), 6.86 (1H, d, J = 8.1 Hz, NH), 5.28 (1H, t, J = 8.3 Hz, 
CHN), 3.85-3.68 (1H, m, CHCH3), 1.37 (3H, s, CHCH3), 1.25 (9H, s, C(CH3)3); 
13C 
NMR (128.5 MHz, (CD3)2CO)  168.9 (C), 155.8 (C), 151.5 (C), 142.3 (C), 139.8 
(C), 134.3 (C), 133.8 (C), 129.1 (CH), 128.7 (CH), 128.5 (CH), 127.1 (CH), 127.0 
(CH), 126.8 (CH), 125.8 (CH), 125.6 (CH), 125.0 (CH), 120.4 (CH), 111.3 (CH), 
79.1 (C), 59.2 (CH), 40.9 (CH), 28.4 (3 × CH3), 17.2 (CH3); HRMS (ESI) Exact 
mass calcd for C25H26N2O3Na [M+Na]
+: 425.1835, found: 425.1836. Enantiomeric 
excess was determined by HPLC with a Chiralpak AS-H column (95:5 hexane:i-
PrOH, 0.8 mL/min, 230 nm, 25 °C); tr (major) = 13.5, tr (minor) = 22.6 min; 81% ee.  
 
tert-Butyl N-[(1R,2S)-1-(2H-1,3-benzodioxol-5-yl)-2-(1,3-
benzoxazol-2-yl)propyl]carbamate (221i). The title 
compound was prepared according to General Procedure B 
from 2-vinylbenzoxazole (175l) (44 mg, 0.30 mmol) and N-Boc imine 206j (82 mg, 
0.33 mmol) and purified by column chromatography (0-25% EtOAc/petroleum 
ether) to give a colorless foam (93 mg, 78%). Rf 0.49 (30% EtOAc/petroleum ether); 
[α] 22D  +68.4 (c 1.05, CHCl3); IR (CHCl3) 3008, 2982, 1710 (C=O), 1504, 1489, 
1368, 1243, 1164, 1042, 933 cm‒1; 1H NMR (400 MHz, (CD3)2CO)  7.71-7.64 (1H, 
m, ArH), 7.60-7.53 (1H, m, ArH), 7.38-7.29 (2H, m, ArH), 7.04 (1H, d, J = 1.7 Hz, 
ArH), 6.90 (1H, dd, J = 8.0, 1.5 Hz, ArH), 6.78 (1H, d, J = 8.0 Hz, ArH), 6.69 (1H, 
d, J = 8.0 Hz, NH), 5.97 (2H, s, CH2), 5.01 (1H, t, J = 8.7 Hz, CHN), 3.59 (1H, app 
quin, J = 7.1 Hz, CHCH3), 1.31 (3H, d, J = 7.0 Hz, CHCH3), 1.23 (9H, s, C(CH3)3); 
13C NMR (100.6 MHz, (CD3)2CO)  169.0 (C), 155.7 (C), 151.5 (C), 148.8 (C), 
147.8 (C), 142.3 (C), 136.4 (C), 125.5 (CH), 125.0 (CH), 121.5 (CH), 120.4 (CH), 
111.3 (CH), 108.7 (CH), 108.0 (CH), 102.0 (CH2), 79.0 (C), 58.8 (CH), 41.1 (CH), 
28.4 (3 × CH3), 17.0 (CH3); HRMS (ESI) Exact mass calcd for C22H25N2O5 [M+H]
+: 
397.1758, found: 397.1756. Enantiomeric excess was determined by HPLC with a 
Chiralpak IC column (95:5 hexane:i-PrOH, 1.5 mL/min, 230 nm, 25 °C); tr (major) = 






chlorophenyl)propyl]carbamate (221j). The title 
compound was prepared according to General Procedure B 
from 2-vinylbenzothiazole (175k) (47 mg, 0.30 mmol) and N-Boc imine 206b (79 
mg, 0.33 mmol) and purified by column chromatography (5% EtOAc/hexane) to give 
a white solid (51 mg, 42%). Rf 0.45 (20% EtOAc/petroleum ether); m.p. 102-104 C 
(EtOAc/petroleum ether); [α] 24D  +83.7 (c 0.86, CHCl3); IR (film) 2977, 1711 (C=O), 
1498, 1453, 1369, 1284, 1253, 1167, 767 cm‒1; 1H NMR (500 MHz, (CD3)2CO)  
8.02-7.96 (2H, m, ArH), 7.54-7.48 (2H, m, ArH), 7.43-7.39 (1H, m, ArH), 7.38-7.36 
(1H, m, ArH), 7.33 (1H, t, J = 7.7 Hz, ArH), 7.30-7.25 (1H, m, ArH), 6.87 (1H, d, J 
= 7.1 Hz, NH), 5.14-4.90 (1H, m, CHN), 3.95-3.67 (1H, m, CHCH3), 1.39 (3H, d, J 
= 6.8 Hz, CHCH3), 1.29 (9H, s, C(CH3)3); 
13C NMR (125.8 MHz, (CD3)2CO)  
174.2 (C), 155.9 (C), 154.1 (C), 145.5 (CH), 135.6 (C), 134.6 (C), 130.8 (CH), 128.1 
(CH), 127.9 (CH), 126.9 (CH), 126.5 (CH), 125.8 (CH), 123.5 (CH), 122.6 (CH), 
79.2 (C), 59.9 (CH), 44.8 (CH), 28.5 (3 × CH3), 19.5 (CH3); HRMS (ESI) Exact 
mass calcd for C21H24ClN2O2S [M+H]
+: 403.1242, found: 403.1242. Enantiomeric 
excess was determined by HPLC with a Chiralpak IC column (98:2 hexane:i-PrOH, 
0.8 mL/min, 230 nm, 25 °C); tr (major) = 12.8, tr (minor) = 16.9 min; 75% ee.  
 
tert-Butyl N-[(1R,2S)-2-(1,3-benzothiazol-2-yl)-1-(2-
methylphenyl)propyl]carbamate (221k). The title compound 
was prepared according to General Procedure B from 2-
vinylbenzothiazole (175k) (48 mg, 0.30 mmol) and N-Boc imine 206f (72 mg, 0.33 
mmol) and purified by column chromatography (5% EtOAc/hexane) to give a white 
solid (62 mg, 54%). Rf 0.59 (20% EtOAc/petroleum ether); m.p. 124-126 C 
(EtOAc/petroleum ether); [α] 24D  +98.4 (c 0.97, CHCl3); IR (film) 2974, 1712 (C=O), 
1500, 1456, 1365, 1245, 1170, 1013, 759, 729 cm‒1; 1H NMR (400 MHz, (CD3)2CO) 
 8.00 (2H, t, J = 8.8 Hz, ArH), 7.55-7.48 (1H, m, ArH), 7.43-7.34 (2H, m, ArH), 
7.23-7.15 (1H, m, ArH), 7.15-7.08 (2H, m, ArH), 6.79 (1H, d, J = 7.1 Hz, NH), 5.33 
(1H, t, J = 8.3 Hz, CHN), 3.82-3.76 (1H, m, CHCH3), 2.53 (3H, s, ArCH3), 1.33 
(3H, d, J = 7.0 Hz, CHCH3), 1.23 (9H, s, C(CH3)3); 




(CD3)2CO)  174.9 (C), 155.9 (C), 154.1 (CH), 141.6 (C), 136.4 (C), 135.7 (C), 
131.0 (CH), 127.8 (C), 127.1 (CH), 126.84 (CH), 126.77 (CH), 125.7 (CH), 123.5 
(CH), 122.6 (CH), 78.9 (C), 56.0 (CH), 44.9 (CH), 28.4 (3 × CH3), 19.8 (CH3), 19.2 
(CH3); HRMS (ESI) Exact mass calcd for C22H27N2O2S [M+H]
+: 383.1788, found: 
383.1790. Enantiomeric excess was determined by HPLC with a Chiralpak IC 
column (98:2 hexane:i-PrOH, 0.8 mL/min, 230 nm, 25 °C); tr (major) = 11.5, tr 
(minor) = 16.2 min; 94% ee.  
Slow diffusion of petroleum ether into a solution of 221k in EtOAc provided single 
crystals that were suitable for X-ray crystallography:  
   
 
tert-Butyl N-[(1R,2S)-2-(1,3-benzothiazol-2-yl)-1-
(naphthalen-1-yl)propyl]carbamate (221l). The title 
compound was prepared according to General Procedure B 
from 2-vinylbenzothiazole (175k) (55 mg, 0.30 mmol) and N-
Boc imine 206e (78 mg, 0.33 mmol) and purified by column chromatography (20-
30% Et2O/petroleum ether) to give a glassy foam (89 mg, 71%). Rf 0.71 (30% 
EtOAc/petroleum ether); [α] 22D  +143.4 (c 1.06, CHCl3); IR (CHCl3) 3066, 3011, 
1709 (C=O), 1501, 1456, 1393, 1253, 1168, 1049, 952 cm‒1; 1H NMR (400 MHz, 
(CD3)2CO)  8.41 (1H, d, J = 8.6 Hz, ArH), 8.04 (1H, d, J = 8.1 Hz, ArH), 7.94 (2H, 
t, J = 7.8 Hz, ArH), 7.81 (1H, d, J = 8.1 Hz, ArH), 7.68-7.61 (1H, m, ArH), 7.61-
7.47 (3H, m, ArH), 7.46-7.32 (2H, m, ArH), 7.03 (1H, d, J = 8.0 Hz, NH), 6.05-5.85 
(1H, m, CHN), 4.07-3.90 (1H, m, CHCH3), 1.48 (3H, d, J = 6.5 Hz, CHCH3), 1.29 
(9H, s, C(CH3)3); 
13C NMR (125.8 MHz, (CD3)2CO)  174.4 (C), 156.0 (C), 154.2 




126.8 (CH), 126.5 (CH), 126.2 (CH), 125.8 (CH), 124.6 (CH), 124.0 (CH), 123.5 
(CH), 122.5 (CH), 79.1 (C), 55.6 (CH),  44.8 (CH), 28.5 (3 × CH3), 19.6 (CH3); 
HRMS (ESI) Exact mass calcd for C25H27N2O2S [M+H]
+: 419.1788, found: 
419.1791. Enantiomeric excess was determined by HPLC with a Chiralpak IA-3 
column (90:10 hexane:i-PrOH, 1.5 mL/min, 230 nm, 25 °C); tr (minor) = 7.2,  tr 




yl)phenyl]propyl]carbamate (221m). The title compound 
was prepared according to General Procedure B from 2-vinylbenzothiazole (175k) 
(48 mg, 0.30 mmol) and N-Boc imine 206k (109 mg, 0.33 mmol) and purified by 
column chromatography (0-15% EtOAc/petroleum ether) to give a colorless foam 
(59 mg, 40%). Rf 0.50 (30% EtOAc/petroleum ether); [α]
22
D  +97.4 (c 1.15, CHCl3); 
IR (CHCl3) 2982, 2932, 1710 (C=O), 1612, 1500, 1362, 1258, 1167, 980, 858 cm
‒1; 
1H NMR (400 MHz, (CD3)2CO)  7.99 (1H, d, J = 8.2 Hz, ArH), 7.96 (1H, d, J = 8.0 
Hz, ArH), 7.68 (2H, d, J = 7.8 Hz, ArH), 7.53-7.46 (1H, m, ArH), 7.44-7.36 (3H, m, 
ArH), 6.84 (1H, d, J = 8.5 Hz, NH), 5.16-4.97 (1H, m, CHN), 3.88-3.70 (1H, m, 
CHCH3), 1.39 (3H, d, J = 6.9 Hz, CHCH3), 1.32 (12H, s, 2 x C(CH3)2), 1.29 (9H, s, 
C(CH3)3); 
13C NMR (125.8 MHz, (CD3)2CO)  174.5 (C), 155.9 (C), 154.1 (C), 
146.1 (C), 135.5 (2 × CH), 127.2 (2 x CH), 126.8 (CH), 125.8 (CH), 123.4 (CH), 
122.6 (CH), 115.9 (C), 84.5 (2 × C), 79.0 (C), 60.3 (CH), 45.0 (CH), 28.5 (3 × CH3), 
25.2 (4 x CH3), 19.6 (CH3), the carbon next to boron was not observed due to 
quadrupolar relaxation effects of 11B; HRMS (ESI) Exact mass calcd for 
C27H36BN2O4S [M+H]
+: 495.2483, found: 495.2499. Enantiomeric excess was 
determined by HPLC with a Chiralpak IA-3 column (95:5 hexane:i-PrOH, 
1.5 mL/min, 254 nm, 25 °C); tr (minor) = 18.3, tr (major) = 40.1 min, 86% ee.  
 
tert-Butyl N-[(1R,2S)-2-(6-bromopyridin-2-yl)-1-
phenylpropyl]carbamate (221n). The title compound was 
prepared according to General Procedure B from 6-bromo-




mmol) and purified by column chromatography (20-30% Et2O/petroleum ether) to 
give a 4.7:1 mixture of diastereomers as a white solid (89 mg, 71%). Rf 0.39 (30% 
EtOAc/petroleum ether); m.p. 138-142 C (EtOAc/petroleum ether); [α] 24D  +88.5 (c 
1.04, CHCl3); IR (CHCl3) 3008, 2981, 1709 (C=O), 1602, 1498, 1367, 1259, 1164, 
1045, 858 cm‒1; HRMS (ESI) Exact mass calcd for C20H26BrN2O5 [M+COOH]
-: 
465.1032, found: 465.1031. Enantiomeric excess was determined by HPLC with a 
Chiralpak IA-3 column (90:10 hexane:i-PrOH, 0.8 mL/min, 230 nm, 25 °C); major 
diastereomer: tr (major) = 5.9, tr (minor) = 19.6 min, 80% ee; minor diastereomer:  tr 
(minor) = 8.8, tr (major) = 13.3 min, 5% ee. 
Major diastereomer: 1H NMR (400 MHz, (CD3)2CO)  7.60 (1H, t, J = 7.7 Hz, ArH), 
7.42 (1H, d, J = 8.0 Hz, ArH), 7.27-7.20 (2H, m, ArH), 7.01-6.97 (1H, m, ArH), 
6.96-6.91 (1H, m, ArH), 6.83-6.76 (1H, m, ArH), 6.60 (1H, d, J = 8.2 Hz, NH), 4.89 
(1H, t, J = 8.9 Hz, CHN), 3.78 (3H, s, OCH3), 3.41-3.27 (1H, m, CHCH3), 1.27 (9H, 
s, C(CH3)3), 1.14 (3H, d, J = 6.8 Hz, CHCH3); 
13C NMR (125.6 MHz, (CD3)2CO)  
166.3 (C), 160.7 (C), 155.7 (C), 145.1 (C), 141.8 (C), 140.1 (CH), 130.0 (CH), 126.7 
(CH), 123.2 (CH), 120.2 (CH), 113.4 (CH), 113.3 (CH), 78.6 (C), 60.1 (CH), 55.4 
(CH3), 47.6 (CH), 28.5 (3 × CH3), 19.0 (CH3). 
Diagnostic peaks for minor diastereomer: 1H NMR (400 MHz, (CD3)2CO)  7.46 
(1H, d, J = 7.7, ArH), 7.31 (1H, d, J = 7.3 Hz, ArH), 7.08 (1H, t, J = 7.8 Hz, ArH), 
7.02 (1H, d, J = 7.4 Hz, ArH), 6.66 (1H, dd, J = 8.2, 1.7 Hz, ArH), 5.03 (1H, t, J = 
9.3 Hz, CHN), 3.70 (3H, s, OCH3), 1.39-1.32 (12H, m, CH3 and C(CH3)3); 
13C NMR 
(125.6 MHz, (CD3)2CO)  165.9 (C), 160.4 (C), 156.1 (C), 145.0 (C), 141.7 (C), 
139.9 (CH), 130.2 (CH), 129.7 (CH), 126.5 (CH), 123.1 (CH), 113.6 (CH), 113.2 




methylphenyl)propyl]carbamate (221o). The title compound 
was prepared according to General Procedure C from 6-bromo-
2-vinylpyridine (175p) (55 mg, 0.30 mmol) and N-Boc imine 206f (72 mg, 0.33 
mmol) and purified by column chromatography (0-10% EtOAc/ petroleum  ether) to 




(30% EtOAc/petroleum ether); [α] 22D  +59.1 (c 1.32, CHCl3); IR (CHCl3) 3009, 2979, 
2931, 1709 (C=O), 1500, 1367, 1253, 1164, 1044, 919 cm‒1; HRMS (ESI) Exact 
mass calcd for C20H25BrN2O2 [M+H]
+: 405.1172, found: 405.1155. Enantiomeric 
excess was determined by HPLC with a Chiralpak IC column (98:2 hexane:i-PrOH, 
0.8 mL/min, 210 nm, 25 °C); major diastereomer: tr (major) = 11.6, tr (minor) =19.5 
min, 79% ee; minor diastereomer: tr (minor) = 14.7, tr (major) =21.1 min, 57% ee. 
Major diastereomer: 1H NMR (400 MHz, (CD3)2CO)  7.61 (1H, t, J = 7.7 Hz, ArH), 
7.45 (1H, t, J = 8.4 Hz, ArH), 7.35-7.31 (1H, m, ArH), 7.26 (1H, d, J = 7.6 Hz, 
ArH), 7.21-7.12 (2H, m, ArH), 7.00-6.90 (1H, m, ArH), 6.55 (1H, d, J = 7.3 Hz, 
NH), 5.24 (1H, t, J = 9.1 Hz, CHN), 3.41-3.23 (1H, m, CHCH3), 2.51 (3H, s, 
ArCH3), 1.24 (9H, s, C(CH3)3), 1.12 (3H, d, J = 6.9 Hz, CHCH3); 
13C NMR 
(125.8 MHz, (CD3)2CO)  166.3 (C), 155.7 (C), 142.2 (C), 141.9 (C), 140.0 (CH), 
139.8 (CH), 136.5 (C), 130.9 (CH), 127.5 (CH), 127.0 (CH), 126.7 (CH), 123.2 
(CH), 78.6 (C), 55.5 (CH), 47.8 (CH), 28.5 (3 × CH3), 19.9 (CH3), 18.4 (CH3). 
Minor diastereomer: 1H NMR (400 MHz, (CD3)2CO)  7.31 (1H, t, J = 7.7 Hz, 
ArH), 7.10-7.04 (1H, m, ArH), 6.49-6.42 (1H, m, NH), 5.36 (1H, t, J = 9.5 Hz, HN), 
3.49-3.40 (1H, m, CHCH3), 2.34 (3H, s, ArCH3), 1.39-1.34 (12H, m, CHCH3 and 
C(CH3)3 (assignments made where possible); 
13C NMR (125.8 MHz, (CD3)2CO)  
165.9 (C), 156.3 (C), 141.8 (C), 130.7 (CH), 127.4 (CH), 127.3 (CH), 126.9 (CH), 
126.8 (CH), 126.5 (CH), 123.3 (CH), 78.7 (C), 55.2 (CH), 47.5 (CH), 28.6 (3 × 




yl)phenyl]propyl]carbamate (221p). The title compound 
was prepared according to General Procedure C from 6-bromo-2-vinylpyridine 
(175p) (55 mg, 0.30 mmol) and N-Boc imine 206k (109 mg, 0.33 mmol) and 
purified by column chromatography (0-22% EtOAc/petroleum ether) to give a 1.6:1 
mixture of diastereomers as a colorless foam (86 mg, 56%). Rf 0.29 (20% 
EtOAc/petroleum ether); [α] 22D  +55.2 (c 1.015, CHCl3); IR (CHCl3) 3049, 3008, 
1701 (C=O), 1612, 1583, 1499, 1362, 1163, 1143, 858 cm‒1; HRMS (ESI) Exact 
mass calcd for C25H35BBrN2O4 [M+H]




excess was determined by HPLC with a Chiralpak AD-H column (98:2 hexane:i-
PrOH, 0.8 mL/min, 230 nm, 25 °C); major diastereomer: tr (major) = 25.9, tr (major) 
= 48.7 min, 85% ee; minor diastereomer: tr (major) =29.8 min, tr (minor) = 38.6 min, 
0% ee. 
Major diastereomer:  1H NMR (400 MHz, (CD3)2CO)  7.69 (2H, d, J = 7.6 Hz, 
ArH), 7.57 (2H, d, J = 7.9 Hz, ArH), 7.43 (1H, dd, J = 12.6, 7.8 Hz, ArH), 7.38 (1H, 
d, J = 7.9 Hz, ArH), 7.23 (1H, d, J = 8.0 Hz, ArH), 6.65 (1H, d, J = 4.7 Hz, NH), 
4.94 (1H, t, J = 8.7 Hz, CHN), 3.45-3.30 (1H, m, CHCH3), 1.39-1.38 (3H, m, 
CHCH3), 1.33 (12H, s, 2 × C(CH3)2), 1.30 (9H, s, C(CH3)3); 
13C NMR (125.8 MHz, 
(CD3)2CO)  166.1 (C), 155.7 (C), 146.8 (C), 141.8 (C), 140.1 (CH), 135.5 (2 × CH), 
127.4 (2 × CH), 126.7 (CH), 123.2 (CH), 84.4 (2 × C), 78.7 (C), 60.2 (CH), 47.3 
(CH), 28.5 (3 × CH3), 25.2 (4 × CH3), 19.1 (CH3), the carbon next to boron was not 
observed due to quadrupolar relaxation effects of 11B. 
Minor diastereomer:  1H NMR (400 MHz, (CD3)2CO)  7.69 (1H, d, J = 7.6 Hz, 
ArH), 7.57 (1H, d, J = 7.9 Hz, ArH), 7.43 (1H, dd, J = 12.6, 7.8 Hz, ArH), 7.38 (1H, 
d, J = 7.9 Hz, ArH), 7.31 (1H, J = 7.6 Hz, ArH), 7.24 (1H, d, J = 8.0 Hz, ArH), 7.03 
(1H, 7.5 Hz, ArH), 6.65 (1H, d, J = 4.7 Hz, CNH), 5.08 (1H, t, J = 9.3 Hz, CHN), 
3.45-3.30 (1H, m, CHCH3), 1.38-1.33 (12H, m, CHCH3 and C(CH3)3), 1.28 (12H, s, 
2 x C(CH3)2; (CD3)2CO)  165.7 (C), 156.1 (C), 146.7 (C), 141.7 (C), 139.9 (CH), 
135.2 (2 × CH), 127.5 (2 × CH), 126.5 (CH), 123.1 (CH), 84.4 (2 × C), 78.8 (C), 
60.0 (CH), 47.8 (CH), 28.6 (3 × CH3), 25.2 (4 × CH3), 17.5 (CH3), the carbon next to 
boron was not observed due to quadrupolar relaxation effects of 11B.   
 
tert-Butyl N-[(1R,2S)-1-(2-methylphenyl)-2-(6-
phenylpyridazin-3-yl)propyl]carbamate (221q). The title 
compound was prepared according to General Procedure B 
from 3-phenyl-6-vinylpyridazine (175o) (55 mg, 0.30 mmol) and N-Boc imine 206f 
(72 mg, 0.33 mmol) and purified by column chromatography (0-20% 
EtOAc/petroleum ether) to give a white solid (62 mg, 51%). Rf 0.23 (20% 
EtOAc/petroleum ether); m.p. 168-170 C (EtOAc/petroleum ether); [α] 22D  +85.2 (c 
0.92, CHCl3); IR (film) 2972, 1700 (C=O), 1495, 1424, 1291, 1249, 1171, 753, 694 




Hz, ArH), 7.66-7.49 (4H, m, ArH), 7.42-7.32 (1H, m, ArH), 7.25-7.10 (3H, m, 
ArH), 6.77 (1H, d,  J = 8.4 Hz, NH), 5.40 (1H, t, J = 8.7 Hz, CHN), 3.74-3.53 (1H, 
m, CHCH3), 2.57 (3H, s, ArCH3), 1.32 (3H, d, J = 7.0 Hz, CHCH3), 1.24 (9H, s, 
C(CH3)3); 
13C NMR (125.8 MHz, (CD3)2CO)  165.0 (C), 158.3 (C), 155.8 (C), 
142.0 (C), 137.7 (C), 136.5 (C), 131.0 (CH), 130.6 (CH), 129.8 (2 × CH), 128.0 
(CH), 127.6 (2 × CH), 127.1 (CH), 126.9 (CH), 124.5 (CH), 78.7 (C), 55.6 (CH), 
55.5 (CH), 46.2 (CH), 28.5 (3 × CH3), 19.9 (CH3), 18.6 (CH3); HRMS (ESI) Exact 
mass calcd for C25H30N3O2 [M+H]
+: 377.2229, found: 377.2228. Enantiomeric 
excess was determined by HPLC with a Chiralcel OD-H column (95:5 hexane:i-
PrOH, 0.8 mL/min, 230 nm, 25 °C); tr (major) = 12.4, tr (minor) = 14.3 min; 74% ee.  
 
tert-Butyl N-[(1R,2S)-1-(naphthalen-1-yl)-2-(6-
phenylpyridazin-3-yl)propyl]carbamate (221r). The title 
compound was prepared according to General Procedure B 
from 3-phenyl-6-vinylpyridazine (175o) (55 mg, 0.30 mmol) 
and N-Boc imine 206e (84 mg, 0.33 mmol) and purified by column chromatography 
(0-18% EtOAc/petroleum ether) to give a white solid (46 mg, 35%). Rf 0.37 (30% 
EtOAc/petroleum ether); m.p. 182-184 C (EtOAc/petroleum ether); [α] 22D  +213.9 (c 
1.01, CHCl3); IR (CHCl3) 3008, 2982, 1709 (C=O), 1499, 1428, 1168, 861, 851 cm
‒
1; 1H NMR (400 MHz, (CD3)2CO)  8.49 (1H, d, J = 8.5 Hz, ArH), 8.18 (2H, d, J = 
6.9 Hz, ArH), 7.95 (2H, d, J = 7.7 Hz, ArH), 7.80 (1H, d, J = 8.0 Hz, ArH), 7.64 
(1H, ddd, J = 8.4, 6.8, 1.3 Hz, ArH), 7.59-7.46 (5H, m, ArH), 7.45-7.33 (2H, m, 
ArH), 7.04 (1H, d, J = 8.4 Hz, NH), 6.00 (1H, t, J = 8.2 Hz, CHN), 3.95-3.69 (1H, 
m, CHCH3), 1.43 (3H, d, J = 6.7 Hz, CHCH3), 1.26 (9H, s, C(CH3)3); 
13C NMR 
(125.8 MHz, (CD3)2CO)  164.9 (C), 158.3 (C), 155.9 (C), 139.6 (C), 137.6 (C), 
134.8 (C), 132.3 (C), 130.6 (CH), 129.8 (2 × CH), 129.7 (CH), 128.4 (CH), 128.3 
(CH), 127.7 (2 × CH), 127.1 (CH), 126.5 (CH), 126.2 (CH), 124.7 (CH), 124.5 (CH), 
124.2 (CH), 78.9 (C), 55.3 (CH), 46.2 (CH), 28.5 (3 × CH3), 19.1 (CH3); HRMS 
(ESI) Exact mass calcd for C28H30N3O2 [M+H]
+: 440.2333, found: 440.2319. 
Enantiomeric excess was determined by HPLC with a Chiralpak IC column (95:5 





Slow diffusion of petroleum ether into a solution of 221r in EtOAc provided single 
crystals that were suitable for X-ray crystallography:  
   
 
tert-Butyl N-[(1R,2S)-1-(2H-1,3-benzodioxol-5-yl)-2-(6-
phenylpyridazin-3-yl)propyl]carbamate (221s). The title 
compound was prepared according to General Procedure B 
from 3-phenyl-6-vinylpyridazine (175o) (55 mg, 0.30 mmol) and N-Boc imine 206j 
(82 mg, 0.33 mmol) and purified by column chromatography (0-25% 
EtOAc/petroleum ether) to give a white solid (65 mg, 50%). Rf 0.29 (30% 
EtOAc/petroleum ether); m.p. 216-218 C (EtOAc/petroleum ether); [α] 22D  +116.8 (c 
1.01, CHCl3); IR (CHCl3) 3008, 2982, 1708 (C=O), 1504, 1490, 1368, 1249, 1169, 
1042, 937 cm‒1; 1H NMR (400 MHz, (CD3)2CO)  8.21-8.14 (2H, m, ArH), 8.04 
(1H, d, J = 8.8 Hz, ArH), 7.66-7.44 (4H, m, ArH), 7.01 (1H, d, J = 1.5 Hz, ArH), 
6.88 (1H, dd, J = 8.0, 1.4 Hz, ArH), 6.78 (1H, d, J = 8.0 Hz, ArH), 6.75 (1H, d, J = 
9.3 Hz, NH), 5.97 (2H, s, CH2), 4.97 (1H, t, J = 9.0 Hz, CHN), 3.70-3.48 (1H, m, 
CHCH3), 1.30 (3H, d, J = 7.0 Hz, CHCH3), 1.24 (9H, s, C(CH3)3); 
13C NMR 
(125.8 MHz, (CD3)2CO)  165.1 (C), 158.2 (C), 155.8 (C), 148.7 (C), 147.5 (C), 
137.6 (C), 137.5 (C), 130.6 (CH), 129.8 (2 × CH), 127.8 (CH), 127.6 (2 × CH), 
124.6 (CH), 121.4 (CH), 108.6 (CH), 108.1 (CH), 101.9 (CH2), 78.7 (C), 59.9 (CH), 
46.7 (CH), 28.5 (3 × CH3), 19.2 (CH3); HRMS (ESI) Exact mass calcd for 
C25H28N3O4 [M+H]
+: 434.2074, found: 434.2068. Enantiomeric excess was 
determined by HPLC with a Chiralpak IB-3 column (98:2 hexane:i-PrOH, 






General Procedure C: Reductive Coupling of Vinylazaarene 184j with N-Boc 
Imines Using Ligand L13 
 
A solution of the appropriate vinylazaarene (0.30 mmol), Cu(OAc)2·H2O (3.0 mg, 
0.015 mmol), (R,R)-Ph-BPE (L13) (7.5 mg, 0.015 mmol), and the appropriate imine 
(0.33 mmol) in THF (1.5 mL) was stirred at 0 °C for 15 min. TMDS (64 μL, 0.36 
mmol) was then added dropwise over 1 min. The mixture was stirred at 0 °C for 1 h, 
then at room temperature for 15 h. The reaction was quenched carefully with SiO2, 
and the resulting suspension was stirred for 15 min before being filtered through a 
short plug of SiO2 using EtOAc as eluent and concentrated in vacuo. Purification of 
the residue by flash column chromatography gave the reductive coupling product. 
 
 tert-Butyl N-[(1S,2R)-1-phenyl-2-(4-phenyl-1,3-thiazol-2-
yl)propyl]carbamate (221t). The title compound was prepared 
according to General Procedure C from 4-phenyl-2-vinylthiazole 
(175j) (56 mg, 0.30 mmol) and N-Boc imine 206a (68 mg, 0.33 mmol) and purified 
by column chromatography (1% Et3N, 9.9% EtOAc, 89.1% hexane) to give a white 
solid (104 mg, 88%). Rf 0.40 (20% EtOAc/petroleum ether); m.p. 119-121 C 
(EtOAc/petroleum ether); [α] 24D  −66.6 (c 0.47, CHCl3); IR (film) 2973, 1712 (C=O), 
1494, 1454, 1366, 1220, 1169, 1030, 772, 699 cm‒1; 1H NMR (500 MHz, (CD3)2CO) 
 8.06-8.02 (2H, m, ArH), 7.74 (1H, s, SCH), 7.50-7.44 (2H, m, ArH), 7.40-7.35 
(3H, m, ArH), 7.32 (2H, t, J = 7.2 Hz, ArH), 7.25-7.22 (1H, m, ArH), 7.00-6.85 (1H, 
m, NH), 5.10-5.00 (1H, m, CHN), 3.82-3.70 (1H, m, CHCH3), 1.40 (3H, d, J = 7.0 
Hz, CHCH3), 1.35 (9H, s, C(CH3)3); 
13C NMR (125.8 MHz, (CD3)2CO)  173.3 (C), 
156.0 (C), 155.5 (C), 143.2 (C), 135.7 (C), 129.6 (2 × CH), 129.1 (2 × CH), 128.8 
(CH), 127.9 (CH), 127.8 (2 × CH), 127.1 (2 × CH), 113.3 (CH), 78.9 (C), 60.4 (CH), 
44.5 (CH), 28.6 (3 × CH3), 19.8 (CH3); HRMS (ESI) Exact mass calcd for 
C23H27N2O2S [M+H]




determined by HPLC with a Chiralpak IC column (98:2 hexane:i-PrOH, 0.8 mL/min, 
254 nm, 25 °C); tr (minor) = 14.7 min, tr (major) = 21.7 min; 87% ee.  
Slow diffusion of petroleum ether into a solution of 221t in EtOAc provided single 
crystals that were suitable for X-ray crystallography:  
   
 
tert-Butyl N-[(1S,2R)-1-(3-methoxyphenyl)-2-(4-phenyl-
1,3-thiazol-2-yl)propyl]carbamate (221u). The title 
compound was prepared according to General Procedure C 
from 4-phenyl-2-vinylthiazole (175j) (56 mg, 0.30 mmol) and N-Boc imine 206l (78 
mg, 0.33 mmol) and purified by column chromatography (1% Et3N in 10% 
EtOAc/hexane) to give a white solid (106 mg, 83%). Rf 0.62 (30% EtOAc/petroleum 
ether); m.p. 132-136 C (EtOAc/petroleum ether); [α] 24D  −59.4 (c 1.01, CHCl3); IR 
(film) 2975, 2931, 1710 (C=O), 1601, 1490, 1365, 1263, 1167, 1041, 693 cm‒1; 1H 
NMR (400 MHz, (CD3)2CO)  8.04-8.00 (2H, m, ArH), 7.73 (1H, s, ArH), 7.49-7.41 
(2H, m, ArH), 7.38-7.32 (1H, m, ArH), 7.21 (1H, t, J = 7.9 Hz, ArH), 7.00-6.83 (3H, 
m, ArH), 6.79 (1H, dd, J = 8.2, 2.0 Hz, NH), 5.05-4.80 (1H, m, CHN), 3.78-3.70 
(1H, m, CHCH3), 3.76 (3H, s, OCH3), 1.38 (3H, d, J = 7.0 Hz, CHCH3), 1.33 (9H, s, 
C(CH3)3); 
13C NMR (125.8 MHz, (CD3)2CO)  173.4 (C), 160.8 (C), 156.0 (C), 
155.5 (C), 144.7 (C), 135.7 (C), 130.1 (CH), 129.6 (2 × CH), 128.8 (CH), 127.1 (2 × 
CH), 120.0 (CH), 113.5 (CH), 113.34 (CH), 113.29 (CH), 78.9 (C), 60.3 (CH), 55.4 
(CH3), 44.4 (CH), 28.6 (3 × CH3), 19.7 (CH3); HRMS (ESI) Exact mass calcd for 
C24H29N2O3S [M+H]
+: 425.1892, found: 425.1890. Enantiomeric excess was 
determined by HPLC with a Chiralpak AS-H column (95:5 hexane:i-PrOH, 




Slow diffusion of hexane into a solution of 221u in EtOAc provided single crystals 
that were suitable for X-ray crystallography:  
 
   
 
tert-Butyl N-[2-(1,3-benzothiazol-2-yl)-1-cyclohexylpropyl]carbamate (221v)  
 
A solution of 2-vinylbenzothiazole (184k) (48 mg, 0.30 mmol), Cu(OAc)2·H2O (3.0 
mg, 0.015 mmol), SL-J006-1 (L3) (13 mg, 0.015 mmol), and N-Boc imine 215m 
(127 mg, 0.60 mmol) in THF (1.5 mL) was stirred at 0 °C for 15 min. TMDS (64 μL, 
0.36 mmol) was then added dropwise over 1 min. The mixture was stirred at 0 °C for 
1 h, then at room temperature for 15 h. The reaction was quenched carefully with 
SiO2, and the resulting suspension was stirred for 15 min before being filtered 
through a short plug of SiO2, using EtOAc as eluent and concentrated in vacuo and 
purified by column chromatography (0-10% EtOAc/petroleum ether) to give the 
major diastereomer of 5u as a yellow oil (81 mg, 73%) followed by the minor 




Major diastereomer: Rf 0.40 (20% EtOAc/petroleum ether); [α]
22
D  +22.9 (c 0.87, 
CHCl3); IR (CHCl3) 2931, 2855, 1708 (C=O), 1504, 1451, 1438, 1367, 1242, 1170, 
978 cm‒1; 1H NMR (500 MHz, (CD3)2CO)  8.01 (1H, d, J = 8.0 Hz, ArH), 7.96 (1H, 
d, J = 7.8 Hz, ArH), 7.50 (1H, ddd, J = 8.3, 7.3, 1.2 Hz, ArH), 7.41 (1H, td, J = 7.8, 
1.1 Hz, ArH), 5.99 (1H, d, J = 9.6 Hz, NH), 3.75-.3.66 (2H, m, CHN and CHCH3), 
1.90 (1H, d, J = 11.7 Hz, CH2), 1.81 (1H, d, J = 12.2Hz, CH2), 1.74-1.66 (3H, m, 
CH2), 1.62-1.56 (1H, m, CH2), 1.43 (3H, d, J = 6.8 Hz, CHCH3), 1.40-1.37 (10H, m, 
CHCH2 and C(CH3)3), 1.21-1.06 (4H, m, CH2); 
13C NMR (125.8 MHz, (CD3)2CO)  
174.9 (C), 157.0 (C), 154.1 (C), 135.4 (C), 126.8 (CH), 125.7 (CH), 123.4 (CH), 
122.6 (CH), 78.5 (C), 60.3 (CH), 41.4 (CH), 40.3 (CH), 31.3 (CH2), 29.8 (CH2), 28.6 
(3 × CH3), 27.10 (CH2), 26.71 (CH2), 26.69 (CH2), 19.9 (CH3). HRMS (ESI) Exact 
mass calcd for C21H31N2O2S [M+H]
+: 375.2101, found: 375.2100. Enantiomeric 
excess was determined by HPLC with a Chiralpak OD-H column (98:2 hexane:i-
PrOH, 1.5 mL/min, 254 nm, 25 °C); tr (minor) = 3.0, tr (minor) = 3.3 min, 82% ee.  
Minor diastereomer: Rf 0.20 (20% EtOAc/petroleum ether); [α]
22
D  +25.6 (c 0.78, 
CHCl3); IR (CHCl3) 2932, 2856, 1712 (C=O), 1501, 1453, 1439, 1368, 1242, 1168, 
882 cm-1; 1H NMR (500 MHz, (CD3)2CO)  8.00 (1H, d, J = 7.9 Hz, ArH), 7.93 (1H, 
d, J = 8.1 Hz, ArH), 7.51-7.46 (1H, m, ArH), 7.42-7.36 (1H, m, ArH), 5.91 (1H, d, J 
= 10.2 Hz, NH), 3.92 (1H, dtt, J = 16.0, 13.1, 8.0 Hz, CHN),  3.60 (1H, app quin, J = 
7.0 Hz, CHCH3), 1.93-1.84 (1H, m CH2), 1.72-1.63 (3H, m, CH2), 1.60-1.56 (1H, m, 
CH2), 1.41-1.39 (4H, m, CH and CHCH3), 1.36 (9H, s, C(CH3)3), 1.19-1.04 (5H, m, 
CH2); 
13C NMR (125.8 MHz, (CD3)2CO)  175.9 (C), 157.0 (C), 154.1 (C), 135.9 
(C), 126.6 (CH), 125.6 (CH), 123.5 (CH), 122.6 (CH), 78.5 (C), 60.3 (CH), 41.7 
(CH), 40.8 (CH), 31.5 (CH2), 28.6 (3 x CH3), 28.1 (CH2), 27.1 (CH2), 26.9 (CH2), 
26.8 (CH2), 17.5 (CH3). HRMS (ESI) Exact mass calcd for C21H31N2O2S [M+H]
+: 
375.2101, found: 375.2099.  
Enantiomeric excess was determined by HPLC with a Chiralpak AD-H column (98:2 
hexane:i-PrOH, 1.5 mL/min, 254 nm, 25 °C: tr (major) = 17.4 min, tr (minor) = 28.6 











TMSCl (0.14 mL, 1.12 mmol) was added carefully to MeOH (1.1 mL) and the 
resulting solution was stirred for 10 min before N-Boc-protected amine 221a (46 mg, 
0.11 mmol) was added. The solution was heated at 50 °C for 30 min and cooled to 
room temperature. The mixture was diluted with EtOAc (5 mL), washed with 1:1 
saturated aqueous NaHCO3 solution/brine (2 × 5 mL) and brine (5 mL), dried 
(MgSO4), and concentrated in vacuo to give the amine 222 (31 mg, 90%) as a white 
solid. Rf 0.50 (30% acetone/petroleum ether with 1% Et3N); m.p. 134-136 C 
(EtOAc/petroleum ether); [α] 19D  +14.0 (c 0.72, CHCl3); IR (CHCl3) 3060 (NH), 2969, 
2934, 1620, 1601, 1562, 1505, 1428, 1374, 831 cm‒1; 1H NMR (400 MHz, CD3OD) 
δ 8.29 (1H, d, J = 8.4 Hz, ArH), 8.10 (1H, d, J = 8.4 Hz, ArH), 7.95-7.83 (5H, m, 
ArH), 7.77 (1H, t, J = 7.6 Hz, ArH), 7.64-7.55 (2H, m, ArH), 7.56-7.44 (3H, m, 
ArH), 4.55 (1H, br s, CHN), 3.56-3.43 (1H, m, CHCH3), 1.16 (3H, d, J = 6.8 Hz, 
CHCH3); 
13C NMR (125.8 MHz, CD3OD)  166.1 (C), 148.9 (C), 142.1 (C), 138.6 
(CH), 134.9 (C), 134.5 (C), 130.9 (CH), 129.4 (CH), 129.2 (CH), 129.0 (CH), 128.9 
(CH), 128.7 (CH), 127.7 (CH), 127.4 (CH), 127.2 (CH), 126.9 (CH), 126.1 (CH), 
122.5 (CH), 62.1 (CH), 51.0 (CH), 19.3 (CH3), peak for one carbon could not be 
determined unambiguously due to possible overlapping signals; HRMS (ESI) Exact 
mass calculated for C22H21N2 [M+H]
+: 313.1699, found: 313.1698. Enantiomeric 
excess was determined by HPLC with a Chiralpak AD-H column (90:10 hexane:i-









4.3   X-Ray Crystallography Data  
 
The X-ray crystallography data can be obtained free of charge from The Cambridge 
Crystallographic Data Centre (CCDC) via www.ccdc.cam.ac.uk/data_request/cif.  
 
Table 4.01: X-Ray Crystallography Data 
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